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 Abstract 
 
Abstract 
Current in vitro cellular methods utilised in drug metabolism and pharmacokinetic 
(DMPK) studies during drug development do not provide the 3D structure and functions 
of organs found in vivo, such that resulting in vitro-in vivo extrapolation (IVIVE) may not 
always accurately reflect clinical outcome.  This highlights the need for the development 
of new dynamic in vitro cell models to aid improvement of IVIVE. The aim of this project 
was to incorporate characterised primary renal cells within a hollow fibre bioreactor for 
use in DMPK studies investigating renal clearance.  
Fluorescence based assays were developed to assess the functionality of three drug 
transporters involved in the renal transport of pharmaceutical compounds: P-gp, BCRP 
and OCT2. The developed assays were then applied alongside transporter visualisation 
and genetic expression assays to characterise primary human proximal tubule cells over 
a series of population doublings. Cells at a population doubling of 5 demonstrated the 
best transporter activity whilst allowing cells to be expanded in vitro.  
Polysulfone (PSF) based membranes, which are widely used in dialysis components were 
developed by blending additives to improve renal cell attachment and culture. The 
membranes exhibited a characteristic porous internal structure with smooth skin layers 
on the surface, and were able to be sterilised via autoclaving due to their high thermal 
stability. PSF blended with polyvinylpyrrolidone (PVP) was the most hydrophilic with cell 
metabolic activity similar to standard tissue culture plastic. 
The production of hollow fibres of varying thicknesses and properties from the PSF and 
PVP blend yielded a marked difference in renal cell attachment and long term viability. 
Fibres incorporated into glass casings to produce the single hollow fibre bioreactors 
(HFBs) were able to be sterilised by autoclaving whilst remaining intact. Due to the 
variation of fibre integrity within the batch, many fibres exhibited tears within the HFBs. 
This ultimately led to cell depletion within the fibre over the culture period; however, 
intact fibres demonstrated an increase in cell growth towards the end of the culture 
period under flow conditions. These results demonstrate the progress made towards a 
small scale in vitro renal model incorporating characterised primary renal cells to aid the 
improvement of IVIVE in DMPK research.    
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1.1. General Background 
The kidneys are primarily responsible for the excretion of waste products such as urea 
and ammonia from the body through the urine. Alongside this the kidneys also provide a 
variety of significant secondary functions including homeostatic, endocrine, immune and 
metabolic processes. The proximal tubule is the main site of action within the kidney in 
terms of reabsorption of nutrients back into the blood and the secretion of metabolites 
into the urine, as well as being the main site of drug metabolism within the kidney. Its 
architecture is distinct, and whilst it is not as complex as the liver, which is the main site 
of drug metabolism within the body, it does rely on the extensive interconnectivity of 
parenchymal cells, non-parenchymal cells, extracellular matrix (ECM) proteins and 
vascular supply. The proximal tubule epithelial cells form the tubule, with the apical side 
exposed to the tubular lumen and the basolateral side anchored to the non-
parenchymal cells and ECM proteins. These proteins also act as a size selective filter for 
substances and a support network for the closely associated vascular supply. Interaction 
with these cells results in many of the functions that are associated with the kidney, and 
in many disease states, the proximal tubule is the main site of injury.  In the UK, 
approximately 5% of all deaths are caused or contributed to by renal diseases. Acute 
renal failure (ARF) affects approximately 58,000 people with a mortality rate of 7% 
which is steadily increasing [1]. Approximately 200,000 people are affected annually in 
the US [2]. ARF is predominantly caused by renal proximal tubule cell injury and necrosis 
from ischemic or toxic insult [2][3]. Death usually occurs after the development of 
systemic inflammatory response syndrome or sepsis [3], causing ischemic damage to 
vital organs and cardiovascular collapse and eventually culminating in Multiple Organ 
Failure [2]. If a patient survives an episode of ARF, the kidney can regenerate to restore 
90-95% of its functional capacity. However, with a non-reversible disease such as chronic 
kidney disease (CKD), renal function is progressively lost alongside the development of 
comorbidities such as congestive heart failure, coronary artery disease, hypertension, 
diabetes and anaemia [4]. Once the patient loses 90% of their renal function, they 
require transplantation or renal replacement therapies such as chronic dialysis [3]. 
Although kidney transplantation has significantly decreased mortality and morbidity, the 
demand for organs outweighs the number available. Only a third of patients on the 
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waiting list actually received a transplant in the UK [5] whilst in the US less than a fifth of 
patients received a kidney transplant in 2013 [6]. For many patients, dialysis is the only 
option of renal replacement therapy (RRT), with the population prevalence for adults of 
746 per million population, and an annual increase of approximately 5% per annum 
since 2007 [7]. However, dialysis only provides a basic and usually intermittent filtration 
function, and does not provide the homeostatic, metabolic, endocrine and regulatory 
functions of the native kidney. The number of patients treated for renal diseases 
alongside the treatments of comorbidities highlights both the need for the more 
efficient drugs to treat renal diseases, and the development of RRTs with enhanced 
function compared to conventional dialysis.   
Current forms of RRT consist of haemofiltration and haemo or peritoneal dialysis. 
Haemofiltration utilises an extracorporeal system that filters blood through a semi-
permeable membrane using convective forces to remove water and small solutes from 
the blood. A haemofilter is also used in haemodialysis to produce the dialysate which 
flows counter current to the blood. Solutes diffuse through the membrane along their 
concentration gradients, allowing some replacement of electrolytes back into the blood. 
Peritoneal dialysis uses the peritoneal membrane as the semipermeable membrane for 
the removal of waste from the body. However all forms of RRT lack many functions of 
the native kidney including drug metabolism and clearance, which may lead to the 
development of comorbidities in CKD. Examples of drugs that are not removed by RRT 
include digoxin, tri-cyclics and beta-blockers [8]. Alternative methods of RRT to address 
these issues have included the development of bioartificial kidney (BAK) devices. These 
devices utilise renal cells within the device to provide some reabsorption, metabolism 
and clearance functions of the kidney. From the initial conception of the device by 
Aebischer et al in the 1980’s [9], the devices have progressed into various forms of BAK 
devices that are seen today (see Figure 1). Many of them focus on the need for RRTs, 
and have subsequently incorporated cell lines [10] or human [11][12] proximal tubule 
cells within a hollow fibre bioreactor (usually consisiting of a haemofilration cartridge). 
Although these have been relatively successful, with the model by Humes et al 
progressing onto phase I/IIa clinical trials [11], there are many areas of improvement to 
be addressed before these devices can be utilised in the clinical setting. In recent years, 
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with the emergence of ‘organ-on-a-chip’ technologies and microfluidics, there has been 
emphasis on creating smaller scale BAKs for use as in vitro models. Whilst demonstrating 
promising results such as the ability to recapitulate the in vivo toxicity after exposure to 
nephrotoxic compounds, the devices need further development and validation [13][14]. 
Other devices that stray away from the conventional compartmentalisation by renal 
cells mimicking the in vivo architecture include the bioartificial renal epithelial cell 
system (BRECS) [15]. This device, also created by the Humes group incorporate renal 
cells on coated discs within a perfusion bioreactor, allowing the culture and 
cryopreservation of cells within the device. Although the device has also shown 
promising results, it requires further validation and testing before utilisation as an RRT. 
Overall, the emergence of BAK devices has seen many forms of device design to address 
the need for better RRTs, and more recently, the need for in vitro models as both a 
replacement to animal models and as an improvement on the current methods of 
testing within the pharmaceutical industry. However, there are still many aspects to be 
addressed an improved on in the development of devices to mimic the native kidney.    
The current economic climate is seeing an increase in the demand for cost effective, safe 
and efficacious new chemical and biological entities (NCE/NBEs) developed over short 
periods of time, to the detriment of many companies within the pharmaceutical industry. 
Presently, the process of bringing a new drug to market consumes an average of $1.3 
billion over 12 years [16] [17]. This process spans the identification of the compound and 
characterisation in pre-clinical testing using in vitro methods and in vivo animal models, 
to phase I/II/III clinical trials and regulatory approval to bring the drug to market [17]. 
There is evidence that many NCE/NBEs which fail late stage human testing do not 
produce in vitro pharmacological and toxicity data predictive of the clinical situation 
through pre-clinical testing stages. In light of this evidence alongside financial and time 
costs, there is great interest in in the development of newer and more reliable in vitro 
methods for compound investigation [18]. Current cellular models and cell based assays 
utilise 2D systems to assess drug transport, metabolism, excretion and the effects of 
drug-drug interactions (DDIs). However, in the case of renal cells the presence of shear 
via the fluid flow has shown to be important in the reorganisation of the cytoskeleton 
and junction complexes of the epithelium, and may improve transport 
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Figure 1: The development of BAKs for clinical and research uses: (a) RAD, (b) Kidney on 
a chip, (c) BRECS. Modified from [14] [15][11]  
(b) 
(a) 
(c) 
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the transport capacities of the cells [19]. Therefore, the development of 3D dynamic 
systems will provide an increased similarity to the native architecture of the proximal 
tubule, which is the main site of activity but also injury in the kidney. 3D in vitro models 
may improve the assessments of drugs before progressing to later stages of testing, 
thereby reducing the time and monetary investments currently utilised in the clinical 
testing of drugs that will not be brought to market.     
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1.2. Thesis objectives 
To generate in vitro models of the kidney to aid pre-clinical testing, many aspects must 
be addressed.  Device functionality is important to ensure cells express the desired 
transporters for drug screening. As the intention of the model is incorporation into 
pharmaceutical research the device must be easy to assemble and use, reproducible, 
cost effective and easy to validate. Existing BAKs are being developed for both clinical 
and research uses, but have major limitations in the source of cells used and 
maintenance of cell phenotype over the culture period. This work aims to address these 
issues by developing a proof of concept model of the proximal tubule. The aim of this 
work can be defined in four parts, which are summarised in Figure 2. 
The first aim of the project is to develop a panel of fluorescence based assays to assess 
the functionality of the transporters of interest in DMPK studies. These assays provide 
an easier and more cost effective method of transporter analysis over current assays 
using radioligands. By employing cell lines overexpressing the transporter of interest, 
functionality assays were developed for 3 transporters important to renal substrate 
transport. The application of these assays in multi-transporter systems was also 
addressed and is detailed in Chapter 2.  
The second aim of the project is to determine the transporter capabilities on primary 
cells over time in in vitro culture. The need to ascertain transporter functionality and 
expression is due to the tendency of primary cells loosing functional transporter 
expression over time. Consequently they have not been widely applied in BAKs. To 
achieve this aim the fluorescence assays developed previously in cell lines, alongside 
visualisation and genetic expression were applied to ascertain the preferential doubling 
of cells to apply within the bioreactor (Chapter 3). 
The third aim of the project is to develop porous membranes as an improved renal cell 
culture substrate without the need for protein coatings and is addressed in Chapter 4. 
Tailoring polymer blends is beneficial in terms of reducing costs and also increasing the 
reproducibility of the models. Using polysulfone as a polymer backbone, additives were 
incorporated to generate flat sheet membranes. These membranes were physically 
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characterised before renal cell culture to ascertain the appropriate blend for hollow 
fibre production.  
The final aim of the project is to produce hollow fibres, incorporate them into the device 
and assess cells within the hollow fibre bioreactor. To achieve this aim, fibres of varying 
thicknesses were produced and assessed both physically and in terms of renal cell 
performance. Seeded bioreactors were then run under flow conditions for 7 days and 
cell performance was assessed (Chapter 5).   
Page | 8  
 
Introduction Chapter 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Project methodology representation
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2.1. Introduction 
Cellular experimental models are regularly employed in the pharmaceutical industry to 
assess the impact of potential compounds on cells and organ systems in vivo. Cellular 
models enable the screening of compounds for certain properties and characteristics in 
the earlier stages of drug development, before progressing successful candidates into 
the clinic.  
However, due the difficulties of culturing primary cells in vitro whilst retaining their 
native functionality [20], genetically modified or immortalised cell lines are employed as 
an easier and more cost effective alternative. Cell lines like MDCK-MDR1 are used to 
overexpress a specific drug transporter for drug interaction studies, whilst the Caco-2 
cell line is employed to act as a multifunctional model system when cultured under 
specific conditions. These cell lines are used throughout the drug metabolic and 
pharmacokinetic (DMPK) process to screen and eliminate ~99% of compounds initially 
generated, so it is of great importance that they are representative of cellular 
functionality in vivo [21].   
Cells can be cultured as polarised or non-polarised monolayers when modelling epithelia. 
Polarised monolayers are usually cultured on inserts, exposing both sides of the 
monolayer to medium and allowing cells to develop apical and basolateral permeability 
barriers with specialised functions (Figure 2). Polarised cell monolayers also contain tight 
junction complexes between cells, which restrict the transport of large molecules and 
allows small (<250 Da) positively charged molecules through the cell barrier via 
paracellular diffusion. The selective permeability of these cells also allows the transport 
of compounds to be assessed, whether they cross by passive diffusion (paracellular or 
transcellular movement) or active transport (dependent on transporter activity within 
the cell [22]). Non-polarised cells adhere to the bottom of tissue culture plates and flasks 
with only one side of the monolayer exposed to medium. Although these monolayers 
express functional transporters they lack the apical/ basolateral surfaces found in vivo 
and in polarised cell monolayers [23]. Transport into these cells can only be measured 
indirectly due to the accumulation of compounds within the cells. Polarised cell 
monolayers are a preferable epithelial model due to the ability to measure the direct 
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vectorial transport of compounds, and are routinely cultured when using cell lines due 
to the ease of maintenance on porous inserts. However, for the extrapolation of 
absorption, distribution, metabolism, excretion-toxicology (ADME-Tox) data 
representing the effects of compounds in vivo, robust assays to initially assess 
transporter functionality are also required. Therefore both types of models are utilised 
in the pre-clinical screening of compounds.         
Radioligands are widely used to measure the transport of labelled substrates across cell 
monolayers in the presence and absence of transporter inhibitors. Radiolabelled 
compounds have the advantage of being directly quantifiable in high throughput 
screening techniques (such as scintillation proximity assays) as opposed to methods such 
as liquid chromatography-mass spectrometry which require additional bioanalytical 
work up. However, they are costly and require special handling and disposal procedures 
within a controlled laboratory environment. Fluorescence assays are comparably 
cheaper, safer and do not generally require extensive training or costly disposal 
procedures. When assessing non-specific compounds via radio or fluorescent labelling, a 
caveat arises when developing assays for cell models expressing multiple transporters 
with overlapping substrate specificities. However, this caveat is usually addressed by 
utilising transporter inhibitors to analyse the specific transporter activity of a fluorescent 
substrate [24][25].    
This Chapter describes the development of fluorescence assays for the efflux 
transporters P-glycoprotein (P-gp/MDR1) and Breast cancer resistance protein (BCRP), 
and the uptake organic cation transporter (OCT2) in specific cell lines. These assays will 
then be used to later characterise primary human proximal tubule cell transporter 
function (Chapter 3).  
Page | 12  
 
Fluorescence assay development for transporter characterisation Chapter 2 
 
2.2. Review of the literature 
2.2.1. Drug screening processes within the pharmaceutical industry 
At present, there is a balance within the pharmaceutical industry between the stringent 
testing of drugs and products against increasing costs and return on investment risks. On 
average, bringing a new drug to market costs US $1.3 billion over 12 years with pre-
clinical in vitro testing consuming approximately half of the total development time [26]. 
This emphasises the need to improve current screening methods of NCEs/NBEs, many of 
which fail late stage human testing. The DMPK process encompasses many models and 
techniques to assess NBEs and NCEs before Phase I clinical trials, which can be split up 
into 6 waves of testing [21].  
2.2.1.1. Wave 0: In silico prediction for compound design 
In silico pharmacology, also known as computation therapeutics or computational 
pharmacology uses software to capture, analyse and integrate biological and medical 
data from a variety of sources. The development of computational models and 
simulations from this data can then be used to predict compounds and entities for 
specific target sites. The earliest in silico methods used quantitative structure-activity 
relationships (QSARs) to mathematically model biological effects relating to a molecular 
structure using statistical techniques. Incorporating descriptor-based and rule-based 
methods alongside knowledge-based approaches have enabled these models to address 
many biological effects of potential compounds, such as ligand-protein complex 
formation and ligand metabolism. With the inclusion of virtual ligand screening and 
affinity profiling to the QSAR models the pharmacological profile of molecules on 
multiple targets can be predicted [27]. In silico predictive methods are therefore 
valuable in lead molecule selection and optimisation in terms of selectivity, potency and 
pharmacokinetics i.e. ADME-Tox [28]. The molecules generated in this wave are filtered 
through the screening cascade (the subsequent waves) to generate lead compounds to 
submit to clinical trials.         
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2.2.1.2. Wave 1: High throughput assays  
From wave 0, thousands of compounds can be generated as candidates for a specific 
target. It is therefore necessary to identify hit molecules (compounds which exhibit 
specific activity at the target protein) as efficiently as possible. High throughput 
screening (HTS) assays are fully automated high volume short delivery time assays which 
have a throughput of at least 10,000 samples per day and have an approximate hit rate 
of between one in two hundred and one in a thousand compounds [29]. Through this 
wave 20-60% of compounds generated from in silico predictions can be eliminated. 
These assays are designed to represent a cost effective screen for a broad range of 
ADME-Tox properties. Examples of these assays include rat hepatocyte and human 
microsome assays to assess intrinsic clearance and metabolism, aqueous solubility at 
physiological pH (7.4), plasma protein binding and lipophilicty via LogD measurements 
[21]. Numerous HTS assays have been developed for different targets, and the appeal of 
these rapid screening methods is also translating into academia [30]. Through wave 1 
most of the chemistry output for the compounds will be evaluated and metabolic 
stability and key project specific issues will be addressed. Positive hit molecules are then 
assessed further in terms interactions with more complete biological systems in wave 2.  
2.2.1.3. Wave 2: High-use project specific assays 
High-use project specific assays involve the increased assessment of hit molecules in 
terms of intrinsic clearance, oral absorption and bioavailability, which further eliminates 
30-55% of compounds from the previous wave. Human hepatocytes are a valuable tool 
for assessing compound pharmacokinetic (PK) properties as they possess a wide range 
of phase I and phase II metabolising enzymes found within intact cells [31]. The ability to 
use them readily from a cryopreserved source provides some high throughput 
capabilities, although not as much so as the liver microsomes employed in the previous 
wave. Human oral absorption and bioavailability can be initially assessed using the Caco-
2 cell line, which when polarised expresses similar morphological and functional 
characteristics to the intestinal barrier [32]. To investigate in vivo clearance, 
bioavailability and to allow robust in vitro/in vivo extrapolations (IVIVE) to be developed 
compounds are also administered orally and intravenously to small animal models such 
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as rats and mice. Acquiring acceptable PK data requires many cycles of wave 1 and wave 
2 testing, with the integration of DMPK and pharmcodynamic (PD) data allowing the 
refinement of human dose predictions of the remaining hit molecules [21].    
2.2.1.4. Wave 3: Low-use project specific assays  
Wave 3 is used for PD testing on approximately 5% of compounds to build confidence in 
the data acquired in the previous waves. Typically, IVIVE across species and further oral 
bioavailability assessments are strengthened by conducting canine PK. Reactive 
metabolite assessments are also carried out to determine the potential toxicities of 
compound intermediates through metabolism, either by direct modification of cellular 
proteins or DNA, or adduct formation with proteins critical to cell viability. Liver 
microsomes or murine models are commonly used to assess adduct formation and 
generate covalent binding data for compounds in vitro and in vivo [33][34]. It is 
important within the drug screening and selection process to address all methods of 
drug interactions and clearance. As such, individualised models and further assays may 
be required, especially if metabolism is not the primary route of clearance [21]. 
2.2.1.5. Wave 4: Profiling assays   
Drug-drug interactions (DDIs) are also an important factor to investigate through the 
DMPK process and approximately 1% of lead compounds are assessed in this wave with 
the potential to become candidate drugs (CDs).  CDs should possess a low PK-based DDI 
potential to minimise the risks associated with comedication including the effect on the 
efficacy and/or toxicity of each drug administered compared to when dosed alone. 
Profiling assays are carried out to address the four most common forms of clinical PK-
based DDIs: 1) competitive (reversible) CYP inhibition; 2) mechanism-based/ time 
dependent CYP inhibition; 3) uptake and efflux transporter inhibition; and 4) CYP 
induction. A broad range of assays are employed to assess the DDIs of CDs (see Table 1), 
with data from in silico models (lipophilicity, aromaticity, charge type) aiding in the 
prediction of DDI potential for CDs [35]. Renal clearance (as the secondary site of drug 
metabolism within the body) is also addressed in this wave through murine and canine 
clearance studies. Clearance in these models can be predicted by in silico analysis as it is 
most commonly a feature of polar, low LogD compounds due to their low plasma 
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protein binding and lack of passive permeability. However, although in vitro assays for 
human and animal transporters have been developed, their application for human PK 
prediction is yet to be fully understood [21].     
2.2.1.6. Wave 5: Problem-solving assays 
Problem solving assays are employed on approximately 1% of compounds, and in this 
wave issues such as biotransformation, biliary clearance and the assessment of CD 
transport by specific drug transporters are addressed. It is essential to understand the 
biotransformation of compounds and the interactions of their reactive metabolites, 
especially in the case of pro-drugs, where the metabolite is the active form of the drug. 
Time-response studies can indicate the presence of these metabolites in circulation 
assuming an appropriate PD model is available. The biliary clearance of compounds can 
be a major issue in drug discovery due to the low systemic exposure of CDs from high 
drug clearance and low bioavailability. Although biliary clearance across species can be 
difficult to predict, biliary clearance assessment in in vitro systems or rat models is 
recommended before CD nomination. Extensive evaluation of clearance has suggested 
molecular weight to be a good predictor of biliary clearance in anionic compounds [36]. 
Biliary clearance involves active secretion from hepatocytes by the adenosine 
triphosphate (ATP) transporter proteins P-gp, Multidrug resistance protein 2 (MRP2) and 
BCRP into the biliary canaliculus. However, these transporters are widely distributed 
throughout the body performing active transport of a wide range of compounds. They 
are abundant through epithelial systems such as the renal tubules and the CNS as well as 
the liver, and are therefore useful in the characterisation of CD transport. Cell lines such 
as MDCK-MDR1 which overexpress P-gp are therefore used to perform permeability 
studies using the bidirectional transport assay. Efflux ratios (ERs) are used to indicate the 
active transport of compounds through the cell monolayer, and can be used in earlier 
phases for risk assessment alongside later phases after validation in vivo [21].     
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Table 1: Profiling assays employed to investigate DDI potential of CDs
Clinical DDI  Test systems  Profiling assay utilised Reference  
Competitive 
(reversible) 
CYP 
inhibition 
Enzymes, 
Microsomes, 
Hepatocytes   
Fluorescence: Pro-fluorescent 
substrate is metabolised to give 
fluorescent product (High 
throughput) 
Luminescence: Pro-luminescent 
substrate is metabolised to give 
luminescent product (High 
throughput) 
Radiometric: Release of 
radiolabel on the metabolism of 
the substrate (Medium 
throughput) 
LC-MS/MS: Substrate and 
metabolites are sorted and 
quantified. Industry standard 
(Medium throughput) 
[21][35][37] 
Mechanism-
based/ time 
dependent 
CYP 
inhibition 
Enzymes, 
Microsomes, 
Hepatocytes 
Radiometric: Metabolism of 
labelled substrate analysed by 
HPLC based fraction 
collection/scintillation counting 
technologies (Low throughput) 
LC-MS/MS: Substrate and 
metabolites are sorted and 
quantified. Industry standard 
(Medium throughput) 
[21][35][37] 
Uptake and 
efflux 
transporter 
inhibition 
Caco-2 and cell 
lines 
overexpressing 
transporters  
Fluorescence and radiometric: 
Bidirectional transport assay 
using fluorescent substrates to 
measure active transport 
(efflux). Uptake of fluorescent 
substrate and quantification of 
intracellular concentration 
(uptake) (Medium throughput). 
[21][35] 
CYP 
induction 
Microsomes, 
Cell lines, 
Human 
hepatocytes 
Fluorescence and radiometric: 
The displacement of labelled 
high affinity nuclear receptor 
ligands by test compound 
(Medium throughput)   
[21][35][38] 
Page | 17  
 
Fluorescence assay development for transporter characterisation Chapter 2 
 
2.2.2. Renal transporter mechanisms of action 
There are four fundamentally different membrane-bound transporter proteins in 
existence: ion channels, transporters, aquaporins and ATP-powered pumps [39]. The 
ATP pumps: P-gp and BCRP, and the transporters: OCT2, OAT1 + OAT3, and MATE1 + 
MATE2K are of interest when modelling drug transport in vivo. To understand the 
importance of these transporters in renal function, the mechanisms of action and 
transporter properties should be understood, and are summarised in Table 3.  
2.2.2.1. ABC transporters 
ATP binding cassette (ABC) transporters are a family of ATP-powered pumps which use 
the energy from ATP hydrolysis to transport substances across the membranes against 
their electrochemical gradient (i.e. active transport). Both ABC importers (transport of 
substrate into the cell) and exporters (transport of substrate from the cytoplasm) exist. 
However, ABC importers have only been found to exist in prokaryotes, whereas ABC 
exporters are expressed in all kingdoms of life [40]. The structure and mechanism of ABC 
transporter function are detailed in Figure 3a. The core unit of functional ABC 
transporters consist of a pair of cytoplasmic ATP-binding cassettes also known as the 
nucleotide binding domain (NBDs) and a pair of transmembrane domains (TMDs).  
The NBDs are involved in providing the energy required for substrate transport whilst 
the TMDs are involved in substrate recognition and translocation across the membrane 
[41]. The NBD is the conserved domain of these proteins attached to a variety of TMDs 
which in part make up the subfamilies and variants of the ABC transporters. There are 
several conserved sequences in this domain, most importantly the P-loops (Walker A 
motifs) and the LSGGQ motifs located in the RecA-like and helical subdomains 
respectively (Figure 3c). These motifs are in a head-to-tail arrangement (opposite to 
each other) leaving the shared interface exposed and available for ATP binding.  
The wide substrate specificity of ABC transporters is provided by the TMDs, although 
they all share a common core architecture of 12 transmembrane helices. These helices 
are intricately woven together rather than being independently aligned and are fused 
with the NBDs. Coupling proteins connect the separate helices of each monomer in the 
cytoplasm as is shown in Figure 4d. The cavity between the two monomers of the ABC 
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transporter is the site of substrate recognition, and is predominantly hydrophilic with 
little affinity to hydrophobic molecules. Upon binding with ATP, the energy from 
hydrolysis within the NBDs cause a conformation change of the TMDs in the form of an 
‘inversion’. The substrate within the TMD cavity is extruded out of the cell, where after 
the products of ATP hydrolyses are removed and the transporter reverts back to the pre-
ATP bound state completing the cycle. It is thought that two molecules of ATP are 
required for the transport cycle except in cases where the ATP binding site contains 
mutations which prevent hydrolysis, as is seen in some disease states [40].       
There are seven subfamilies of the ABC genes, of which P-gp and BCRP belong to the 
ABCB and ABCG2 subfamilies respectively. The transporters have some overlapping 
substrate specificities (see Table 2), but they are different in their dimer structure. P-gp 
is one of the four full transporters in the ABCB sub-family [39], meaning that the 2 NBD 
and TMD domains are within a single polypeptide. The hydrophobic nature of the cavity 
within the TMD gives rise to the alternative name for P-gp, MDR1. In contrast to P-gp, 
BCRP is one of six reverse half transporters in the ABCG subfamily, with the NBD on the 
N-terminus and the TMD on the C-terminus of each monomer, functioning as a 
homodimer [42].    
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Table 2: Properties of renal transporters clinically relevant in in vivo drug interactions 
[43] 
 
Abbreviations: BBM (AP); Brush border membrane (apical), OC; Organic cation, BLM; 
Basolateral membrane, DC; Dicarboxylate, OA; Organic anion, PMEG; 9-(2-
phosphonylmethoxyethyl)guanine, PMEDAP; 9-(2-phosphonylmethoxyethyl)-2,6-
diaminopurine 
Transporter Gene Mechanism Tissue  
distribution 
Function Membrane 
localisation in 
the kidney 
P-gp ABCB1 Primary 
active 
Intestinal enterocyte, 
kidney proximal 
tubule, hepatocyte 
(canalicular), brain 
endothelia 
Efflux BBM (AP) 
OCT2 SLC22A2 OC uniporter Kidney proximal 
tubule 
Uptake BLM 
OAT1 SLC22A6 DC/OA 
antiporter 
Kidney proximal 
tubule, placenta 
Uptake BLM 
OAT3 SLC22A8 DC/OA 
antiporter 
Kidney proximal 
tubule, choroid plexus, 
brain endothelia 
Uptake BLM 
BCRP ABCG2 Primary 
active 
Intestinal enterocyte, 
kidney proximal 
tubule, hepatocyte 
(canalicular), brain 
endothelia, placenta, 
stem cells, mammary 
gland (lactating) 
Efflux BBM (AP) 
MATE1 SLC47A1 H+/OC 
antiporter 
Liver, kidney proximal 
and distal tubules 
Efflux BBM (AP) 
MATE2 SLC47A H+/OC 
antiporter 
Kidney proximal 
tubule 
Efflux BBM (AP) 
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(d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic of ABC transporter structure and functions: (a) overview of 
substrate transport through the homodimeric ABC transporter (b) with ribbon 
representation of the conformation change of the monomers shown in light and dark 
grey (side view) (c) the NBD structure in more detail showing ATP binding sites and 
conserved protein sequences (d) The arrangement of the helices through the membrane 
(TMD) and in the cytoplasm (NBD) of P-gp (ABCB1). Modified from [40][44] 
(a) 
(c) (b) 
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2.2.2.2. SLC gene superfamily transporters  
Transporters facilitate the movement of specific substrates across the membrane with 
or against their concentration gradient. The transport of substrates is considered 
relatively slow compared to ion channels (102 to 104 s-1 compared to 108 s-1), with the 
conformational change of the transporters being fundamental to their function. Many of 
these transporters belong to the SLC gene superfamily and consist of passive (uniporters 
or facilitative transporters) and active transporters.  
Passive facilitative transporters, as the name implies move the substrate down its 
concentration gradient one molecule at a time [45][46]. As listed in Table 3, OCT2 is a 
passive uptake transporter although it has been shown to be sensitive but not 
dependent on membrane potential and extracellular pH [46]. OCT2 is made up of 12 α-
helices spanning the membrane with intracellular C and N termini and a large 
extracellular loop at transmembrane-spanning helices (TMH) 1 and 2 and a large 
intracellular loop at TMHs 6 and 7 (see Figure 4a and b). The precise mechanism of 
uptake by OCT2 however is not fully understood as there are multiple amino acid 
residue sites proposed for substrate binding [47][48][49].  
Active transporters such as the OAT and MATE transporters couple the movement of the 
substrate against its concentration gradient with another molecule down its 
concentration gradient. The renal active transporters listed above are antiporters, where 
the coupled transport of the substrate and molecule are in opposing directions. MATE1 
and its interplay with OCT2 is thought to be critical in the vectorial movement of shared 
substrates (see Table 3) across renal cells [50]. MATE1 is accordingly located on the 
apical membrane of renal tubular cells and performs efflux of organic cations into the 
lumen. It is argued whether MATE1 is made up of 12 or 13 helices, of which 12 are 
functional. The 12 TMHs are arranged in 2 bundles of 6 helices connected by a short 
cytoplasmic loop between TMH 6 and 7, which form a cavity exposed to the extracellular 
space [51]. Like OCT2 there are multiple amino acid residues important in MATE1 
function distributed throughout the TMHs (Figure 4c and d).        
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Figure 4: Schematic of OCT2 and MATE1 transporter structure and functions: (a) the 
arrangement of TMHs of the OCT2 uptake transporter with (b) ribbon representation of 
amino acid residues important to function (red, yellow, orange) and the extracellular 
and intracellular loops in pink (extracellular loop on top)(side view). Hydrophobic (blue) 
and hydrophilic (green) TMHs contribute to the structure and function of OCT2 (c) the 
arrangement of TMHs of the MATE1 efflux transporter with (d) ribbon representation of 
the 12 functional TMHs. The 6 N-termini TMHs are coloured light blue and the 6 C-
termini TMHs are coloured light green. The 13th TMH has not been included in the model. 
Modified from [51][52] 
(b) 
(d) 
(a) 
Uptake of substrate 
Cell membrane 
Cytoplasm 
(c) 
Cell membrane 
Cytoplasm 
Efflux of substrate 
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2.2.3. Methods for renal drug transporter functionality assessment in vitro 
As outlined in the previous section, transporter functionality is addressed in the profiling 
and problem solving assays in the DMPK process (waves 4 and 5). The most common 
methods employed use cell lines overexpressing the drug transporter of choice (such as 
MDCK-MDR1 cells), single or double knockout cell lines  (such as Caco-2/ MDR1 cells) or 
more physiologically relevant cells expressing multiple transporters (Caco-2 cells). These 
cells, various culture methods and assays can be employed depending on the 
transporter type and substrate properties. 
2.2.3.1. Polarised monolayer culture 
Epithelial cells cultured as non-polarised monolayers on conventional tissue culture 
plastic exhibit losses of structured polarity, differentiated function and lateral junctions 
(e.g. tight junction proteins) [23]. However, when cultured on porous inserts the 
retention of these features enables a physical and biochemical cell barrier to be cultured 
with the retention of specific functions. In the case of Caco-2 which is widely used for 
the prediction of the in vivo absorption of drugs across the gut wall, polarised 
monolayers exhibit a well-defined brush border on the apical surface and intercellular 
proteins [53]. By culturing wild-type and modified epithelial cell lines, efflux transporter 
functionality such as P-gp and BCRP can be assessed using bidirectional transport assays. 
These assays use transporter substrates to assess the apparent permeability (Papp) of the 
substrate through the monolayer in both apical to basolateral (A-B) and basolateral to 
apical (B-A) directions (Figure 5). From these permeabilities ERs can be calculated, 
indicating the transport of the substrate either by active transport or passive diffusion. 
By using transporter specific inhibitors, the specificity of the substrate can also be 
investigated.  
2.2.3.2. Flat plate culture  
For investigating transporter functionality, cell lines can also be cultured on conventional 
tissue culture plastic as non-polarised monolayers, although the drawbacks for this type 
of culture are mentioned above. When assessing uptake transporter functionality, lysis 
assays are performed and the intracellular concentration of the substrate is directly 
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measured (Figure 6). As with the bidirectional transport assay, in the presence of 
inhibitors the specificity of the substrate can be established in multi-transporter systems 
[54].  
2.2.3.3. Substrates and inhibitors for renal transporters  
In terms of renal transport studies P-gp, BCRP, OCT2, Organic anion transporter 1 and 3 
(OAT1 + OAT3), and Multidrug and toxin extrusion proteins 1 and 2 (MATE1 + MATE2K) 
have all been identified as clinically relevant in in vivo drug interactions [43][55]. For 
most profiling and problem solving assays involving transporter assessment 
radiolabelled substrates are used and analysed via scintillation counting and LC-MS as 
the industry standard. However as mentioned previously the risks and costs associated 
with radiolabelled substrates and their safe disposal are high. Fluorescent substrates are 
currently only utilised in high throughput assays, although they are being developed for 
incorporation into the testing in the later waves. Due to the wide range of substrate 
specificities by the multidrug transporters (P-gp and BCRP) it is necessary to apply 
transporter specific inhibitors to the assays where enhanced transporter expression or 
multi-transporter cell lines are used. A list of commonly used fluorescent and probe 
substrates and transporter specific inhibitors are listed in Table 3.  
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Figure 5: Bidirectional transport assay schematic to assess the transport of P-gp 
substrates through cell monolayers expressing/ overexpressing efflux transporters (P-gp) 
using the transwell system. Cells are cultured on a porous membrane and exposed to 
medium on both sides as a polarised monolayer. Substrates are incubated in either the 
insert (apical) or well (basolateral) chamber as the donor solution. Samples are taken 
from the receiver chamber (opposing the donor chamber where the test 
substrate/inhibitor is applied) over time and from this the Papp and Efflux ratio can be 
calculated. In the presence of inhibitors, efflux of the substrate is reduced resulting in 
less substrate in the receiver chamber 
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Figure 6: Schematic of uptake assays to assess the transport of substrates (blue) on non-
polarised cell monolayers expressing/ overexpressing uptake transporters (e.g. OCT2, 
green). In the presence of an inhibitor uptake of the substrate is reduced resulting in less 
substrate in the supernatant after washing, lysing and centrifugation    
Cells incubated with pre-incubation 
(inhibitor) and incubation 
(substrate/ substrate + inhibitor) 
 
1 
Cells washed to remove substrate 
and cells lysed to release 
  
2 
Cells pelleted and supernatant 
sampled and analysed 
3 
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2.2.4. Conclusion 
A substantial amount of time and a vast array of techniques are implemented in the pre-
clinical phases of drug development to minimize CD failure during clinical trials. However, 
fluorescent substrates are mainly utilised in the earlier waves of testing in high 
throughput assays, whilst radioligands are widely used throughout the preclinical drug 
testing process. As such, there is currently no complete panel of fluorescence assays for 
the assessment of renal specific transporter functionality that can be utilised for 
profiling and problem solving assays. This chapter aims to address this need by 
developing assays to assess the functionality of transporters using fluorescent substrates, 
in the development of a panel of fluorescence assays for the characterisation of renal 
specific transporter capabilities.  
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Table 3: Selected probe substrates and inhibitors for renal drug transporters  
Transporter Fluorescent probe 
substrates 
Probe substrates Inhibitors References 
P-gp Calcein-AM, Rhodamine 
123, Hoechst 33342, 
Daunorubicin 
Digoxin, Quindine, Vinblastine, 
Loperamide 
Elacridar (GF120918),  Quinidine,  
Verapamil,  Ketoconazole,  
Cyclosprine A 
[55][56][57][58][59][60] 
[25] 
[61][62][63][64][65][66] 
[67][68][69][70][71][72] 
OCT2 ASP+, NBD-TMA MPP, Amantadine, Cimetidine, 
Memantine, Metformin 
Ipratropium, Imipramine, TEA [55][73][74][75][76][77] 
[78][79][80][81][82][83] 
OAT1 5-carboxyfluorescein, 6-
carboxyfluorescein 
Acyclovir, Adefovir, 
Methotrexate, Zidovudine, PAH 
Probenecid, Cefradroxil, 
Cefamandole, Cefazolin 
[55][84][85][86][87][88] 
[89][90][91][92] 
OAT3 5-carboxyfluorescein, 6-
carboxyfluorescein 
Cimitidine, Methotrexate, 
Zidovudine, Estrone sulphate 
Probenecid, Cefadroxil, 
Cefamandole, Cefazolin, Eosin-Y 
[55][84][85][92][93][94] 
[95] 
[96][97][98] 
BCRP Daunorubicin, Hoechst 
33342, Doxorubicin, 
Mitoxantrone 
Topotecan, Rosuvastatin, 
Methotrexate 
Elacridar (GF120918), Ritonavir, 
Saquinavir, Fumitremorgin C 
[55][99][100][101][102][103
][104] 
[105][106][107][108][109][1
10] 
MATE1 DAPi, ASP+, NBD-TMA MPP, TEMA, Meformin, TEA, 
Cisplatin, Cephlaxin, Cephradine 
Cimitedine, Imipramine, Ritanovir, 
Levoflaxin, Ciproflaxin, 
Mitoxantrone, Topetecan, 
Mitoxantrone, PYR 
[111][112][113][114][115][5
0][116] 
[117][118] 
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Table 3 continued: 
 
Abbreviations: ASP+;  4-(4-(dimethylamino)styryl)-N-methylpyridinium, NBD-TMA; N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-
4-yl)amino]ethanaminium, MPP; 1-methyl-4-phenylpyridinium, TEA; tetraethylammonium, DAPi; 4′,6-Diamidino-2-phenylindole, PAH; p-
Aminohippuric acid, TEMA; triethylmethylammonium, PYR; Pyridostigmine bromide 
Transporter Fluorescent probe 
substrates 
Probe substrates Inhibitors References 
MATE2-K DAPi, ASP+, NBD-TMA MPP, Metformin, TEA, 
Cisplatin, Oxaliplatin 
Cimitedine, Imipramine, Ritanovir, 
Levoflaxin, Ciproflaxin, Ondansetron, 
PYR, Mitoxantrone, Nifekalant 
[111][112][113][114][115] 
[50][116][117][118] 
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2.3. Materials and methods 
2.3.1. Chemicals, reagents, consumables and equipment 
A list of equipment used is provided in Appendices 1. Water used for the preparation of 
aqueous solutions was filtered using the MilliQ ultrafiltration unit (Millipore, UK). 
Sterilisation of solutions and suitable materials was performed either by autoclaving at 
121 °C for 15 min using a Systec VX-95 autoclave (Systec, Germany), or by filtering 
through a 0.22 μm filter (Millipore, UK). 
2.3.2. Cell lines 
MDCKII (Manin-Darby Canine Kidney wild type; CRL-2936) cells for 12-well transwell 
experiments were purchased from the ATCC at Passage (P.) 80. 
MDCK-MDR1, MDCK-BCRP and HEK-OCT2 cell lines for 96-well plate experiments were 
all produced in house at AstraZeneca and were used between P.3-5 post transfection.  
2.3.3. Cryopreservation and cell resuscitation 
MDCKII cells were cryopreserved at a density of 1 x 106 cells/ml in a freezing medium of 
90% FBS (fetal bovine serum; Fisher Scientific, UK) and 10% (v/v) DMSO (dimethyl 
sulfoxide; Sigma Aldrich, UK).  
All cell lines were resuscitated by removal from liquid nitrogen storage and rapidly 
thawed in a 37°C water bath. Vials were half submerged and gently agitated until a sliver 
of ice remained. The vial was then transferred to the biosafety cabinet (BSC) and cell 
suspension removed and quenched in 9ml of pre-warmed DMEM in a 15ml centrifuge 
tube. The vial was rinsed with medium and the cell suspension and the tube centrifuged 
at 1200 rpm for 5 minutes. After centrifugation, the supernatant was removed and the 
cell pellet resuspended in 5ml of medium before seeding into a T-flask.    
2.3.4. Medium formulation 
DMEM (500mL) with phenol red, 4500 mg/L D-glucose, 110 mg/L sodium pyruvate 
supplemented with 2mM L-glutamine, and DMEM (500mL) with L-glutamine, 4500 mg/L 
D-glucose, 25mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) without 
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sodium pyruvate and phenol red (Fisher Scientific, UK) supplemented with 50mL fetal 
bovine serum (FBS) (Sigma Aldrich, UK) were used in the culture and initial transport 
assays of the MDCKII cells respectively. The medium was stored at 2 – 8 °C and used 
within one month of preparation. 
DMEM (500mL) with phenol red, D-glucose and GlutaMAX supplemented with 500mg 
geniticin (Life technologies, UK) and 50mL FBS were used in culture of the MDCK-MDR1 
and MDCK-BCRP cell lines and in the initial stages of culture of HEK-OCT2 cells. Later 
culture of HEK-OCT2 cells was performed with the basal medium mentioned above 
supplemented with 10mM sodium butyrate (Alfa Aesar, USA) to enhance transporter 
expression.  
2.3.5. Monolayer Culture  
2.3.5.1. T-flask culture 
 MDCKII cells were cultured for 4-6 with medium changes every 2 days until cells 
reached >80% confluency. On the day of passage, medium was aspirated and cells were 
washed with phosphate buffered saline without Ca2+ and Mg2+ (PBS; Lonza, UK). After 
the aspiration of PBS, pre-warmed 0.25% tryspin- EDTA (Life Technologies, UK) was 
added to the flask and incubated at 37°C for 8-15 MDCKII minutes for enzymatic 
digestion of the cell adherence proteins to the tissue culture plastic. After incubation the 
trypsin digestion was quenched with approximately double the amount of pre-warmed 
culture medium and the cell suspension was centrifuged for 5 minutes at 1200rpm. The 
supernatant was removed after centrifugation and the cell pellet was resuspended in 
the appropriate volume of culture medium. Cells were counted using a haemocytometer 
and the NC-100 (refer to Section 2.3.6.2.) for the calculation of desired seeding densities, 
with the flask seeding density at 1 x 106 cells/mL.  
2.3.5.2. Transwell culture  
Transwell types and seeding densities were established experimentally and details can 
be found in Appendices- Figure 51, but final methods for transwell culture of MDCKII 
and MDCK-MDR1 cells are as follows and summarized in Table 4. 
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For MDCKII cells cultured on Corning 12-well polyester transwell inserts (0.4µm pore size, 
1.12cm² surface area; Sigma Aldrich, UK) transwell plates were incubated with culture 
medium for 1 hour at 37°C to equilibrate before seeding. Culture medium was then 
aspirated and fresh medium was added to the wells. Cell suspension from tissue culture 
flask passages was added to the inserts at 1.3 x 105 cells/cm2. The plates were then 
incubated at 37°C and cultured for 5 days with medium changes on the 3rd and 4th day.    
MDCKII and MDCK-MDR1 cells were cultured on Millipore 96-well polyester transwell 
inserts (0.4µm pore size, 1.11cm² surface area; Merc-Millipore, UK). Transwell plates 
were incubated with culture medium for 1 hour at 37°C to equilibrate before seeding. 
Culture medium was then aspirated and fresh medium was added to the wells. Cell 
suspension was then added to the inserts at 2.7 x 105 cells/cm2. The plates were then 
incubated at 37°C and cultured for 3-4 days with no medium changes.        
2.3.5.3. Plate culture 
MDCK-MDR1 and MDCK-BCRP cells were cultured on Costar black clear bottom 96 well 
plates (0.32 cm2 surface area, Sigma Aldrich, UK) and HEK-OCT2 cells were cultured on 
Costar clear 96 well plates (0.32cm2 surface area, Sigma Aldrich, UK).  Seeding densities 
in 96-well plates of the respective cell lines are summarized in Table 4. No medium 
changes were performed for the MDCK-MDR1 or MDCK-BCRP cells which were cultured 
for 3-4 days and 2-3 days respectively. HEK-OCT2 cells were cultured for 2-3 days In 
normal medium before replacing with medium containing 10mM sodium butyrate (Alfa 
Aesar, USA) and culturing for a further 24 hours to enhance transporter expression. 
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Table 4: Culture conditions for the various cell types used on different plates  
  
Cell line Plate type Seeding 
density 
(cells/cm2) 
Culture 
period 
Medium changes 
MDCKII 12-well 
Transwell plate 
1.3 x 105 5 days On days 3 and 4 
MDCKII 96-well 
multiwell insert 
plate 
3.6 x 105   
MDCK-
MDR1 
96-well  
multiwell insert 
plate 
3.6 x 105 3-4 days N/A 
MDCK-
MDR1 
96-well plate 1.2 x 105 3-4 days N/A 
MDCK-
BCRP 
96-well plate 1.3 x 105 2-3 days N/A 
HEK-OCT2 96-well plate 6.3 x 105 2-3 days 24 hours before assay (with 
10mM sodium butyrate 
supplemented medium) 
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2.3.6. Cell counting 
2.3.6.1. Trypan blue exclusion (manual cell counts) 
Initial flask and transwell experiment cell counts were carried out using the Trypan blue 
exclusion method. From samples taken after trypsinisation of cells, an equal amount 
(usually 50µl) of Trypan blue (Life Technologies, UK) was added. The sample was then 
pipetted onto a haemocytometer with a cover slip and counted under a light microscope. 
Live cells with intact membranes are impermeable to Trypan Blue, whereas dead cells or 
those exhibiting membrane damage would allow Trypan blue absorption, and therefore 
be counted as non-viable. Viable cell numbers (per mL) were then ascertained from the 
haemocytometer and multiplied by sample volume to calculate the number of cells per 
sample. Cell counting calculations using a haemocytometer can be found in Appendices 
2.1. 
2.3.6.2. Propidium iodide exclusion (semi-automated cell counts) 
Semi-automated cell counts via propidium iodide (PI) exclusion were carried out on the 
NucleoCounter NC-100 automatic mammalian cell counter using two NucleoCassettes 
(Chemometec, Denmark) per sample. Viable cell counts (cells/mL) were performed by 
subtracting the non-viable cell count from the total cell count. Non-viable cell counts 
were performed by aspirating sample into the cassette and reading on the counter. 
Dead or damaged cells with compromised cell and nuclear membranes would allow the 
absorption of PI into the cell. Upon DNA binding within the nucleus the dye fluorescence 
is enhanced, therefore indicating these cells to be non-viable. Total cell counts were 
performed by the addition of 50µl NucleoCounter lysis buffer A and NucleoCounter 
stabilizing buffer B to 50µl of sample. After mixing the sample was aspirated into a 
second cassette and read. This step would allow all cells to be permeabilised therefore 
producing a total cell count. The total cell count would then be multiplied by 3 before 
subtraction of the non-viable count to take into account dilution factor.          
2.3.7. Monolayer integrity assessment 
The Lucifer yellow permeation assay was used to assess monolayer integrity by using 
threshold values to distinguish leaky and intact monolayers. Lucifer yellow (LY; Sigma 
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Aldrich, UK) was diluted in deionized water to make a stock solution of 1mM. This 
solution was stored out of light. After the bidirectional transport assay or on the day of 
integrity assessment the inserts were washed with pre-warmed Hanks balanced salt 
solution (HBSS; Sigma Aldrich, UK) containing 25mmol/L HEPES (Sigma Aldrich, UK), 0.1% 
(w/v) Bovine serum albumin (BSA; Sigma Aldrich, UK) at pH 7.4. 100µM LY was then 
incubated in the insert and fresh HBSS was placed in the well. The plate was then 
incubated for 30 mins on the shaking platform at 75rpm at 37°C with 100µl samples 
taken from the well before and after incubation and read on the fluorescence plate 
reader (FluoStar Omega) at Ex: 355nm and Em: 590nm.  Monolayers with an LY amount 
permeation of 1% or below were deemed to be acceptable.  
Transepithelial electrical resistance (TEER) measurements were taken using the REMS 
autosampler (World precision instruments, US) for MDCKII and MDCK-MDR1 cultured on 
96-well multiwell insert plates. TEERs above 500Ω/cm² indicated acceptable monolayer 
integrity of the cells. The LY and TEER thresholds were used to quality control the 
monolayer integrity assays used at AstraZeneca for cell lines cultured on porous inserts. 
2.3.8. Bidirectional Transport Assay- P-gp Assessment 
The bidirectional transport assay was used to determine the functional activity of P-gp in 
MDCKII (see Figure 5) by calculating the apparent permeabilites in both directions 
through the cell monolayer and generating the efflux ratio. Rhodamine 123 (Rho123; 
Sigma Aldrich, UK) was used as the fluorescent substrate for P-gp in the transport assay. 
Two solutions were generated for use in the assay, the donor solution containing 
Rho123 in transport buffer, and the receiver solution containing Dimethyl sulfoxide 
(DMSO) and transport buffer. Rho123 stock solutions were made at 100x their final 
concentration in DMSO to keep the DMSO amounts at 1% (v/v) and from these, final 
concentrations of Rho123 were achieved by a 1:100 dilution of 100x solution in 
transport buffer with receiver solution containing DMSO at 100x in transport buffer. 
Rho123 dilutions in DMSO for varying concentrations can be found in Table 5.   
Concentrations of Rho123 ranging from 0.1µM to 200µM were determined initially from 
concentrations used in literature [119][120] and then from experimental procedure (see 
Section 2.4.1.). On the day of the experiment culture medium was removed and the 
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wells were washed with pre-warmed HBSS. The donor and receiver solutions were 
added according to the concentration and direction of the assay: analysis of the 
transport of Rho123 from the apical to basolateral (A-B) side of the membrane would 
utilize donor solution in the insert and receiver solution in the well, while looking at the 
basolateral to apical transport would use donor solution in the well and receiver solution 
in the insert (B-A). Twelve well transwell plates (MDCKII) were then incubated on the 
shaking platform at 75rpm at 37°C for 120mins away from light, whilst 96-well multiwell 
insert plates (MDCKII, MDCK-MDR1) were statically incubated. Samples (100µl) were 
taken from the receiver compartment at 30 minute intervals. After sampling, receiver 
compartments were replaced with 100µl of fresh receiver solution and samples were 
read on the fluorescence plate reader at 485nm excitation and 520nm emission. The 
apparent permeabilities were then calculated using these fluorescence measurements 
(see Appendices 2.4. and 2.5. for equations). Finally, the efflux ratios from monolayers 
exhibiting acceptable LY permeation percentage and TEER values in MDCKII and MDCK-
MDR1 cells were then compared. 
 
Table 5: Rho123 dilutions in DMSO to get 100x solutions for the production of varying 
concentrations of Rho123 with DMSO at 1% (v/v) 
 
 
Final Rho123 
Concentration 
100x concentration Stock solution 
1µM 100µM 1mM 
5µM 500µM 5mM 
10µM 1mM 2mM 
20µM 2mM 4mM 
50µM 5mM 10mM 
100µM 10mM 20mM 
200µM 20mM 20mM 
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2.3.9. Fluorescence assays to assess transporter functionality  
Functional assays were performed after cell culture (see Section 2.3.5.3.). The IC50 
concentrations for each of the inhibitors used for the transporters: P-gp (Section 2.3.9.1), 
OCT2 (Section 2.3.9.2) and BCRP (Section 2.3.9.3) and concentrations used are 
summarised in Table 6. For all cell line fluorescence assays the transport buffer used was 
HBSS containing HEPES (Sigma Aldrich, UK) and balanced to pH 7.4.  
2.3.9.1. Fluorescence assay to assess P-gp functionality  
Calcein-Acetoxymethyl (Calcein-AM) (Invitrogen; Life technologies, UK) was used as the 
probe substrate for P-gp on non-polarised monolayers of cells. Fluorescence is primarily 
achieved by energy independent esterases inside the cell cleaving the non-fluorescent 
Calcein-AM to produce fluorescent Calcein. By looking at cells incubated with Calcein-
AM alone compared to cells with Calcein-AM and a P-gp specific inhibitor, P-gp efflux 
functionality in the cells can be assessed.  As P-gp is an efflux transporter, intracellular 
fluorescence would increase in the presence of a P-gp inhibitor due to the accumulation 
of Calcein (which is not a P-gp substrate) inside the cell.  
As in the bidirectional transport assay, DMSO concentration was diluted to 1% (v/v) in 
working solutions. Calcein-AM was made up to a stock solution of 0.5mM in DMSO 
before being diluted in transport buffer at 200x to a final concentration of 2.5µM 
(determined by protocols at AstraZeneca). Verapamil, Quinidine and the more potent P-
gp inhibitor Ketoconazole concentrations were made up as stock solutions of 20mM and 
diluted down to 100µM in transport buffer containing Calcein-AM. The inhibitors were 
used at in excess of their inhibitory potencies (IC50) (see Table 6). This ensured the 
maximum (100%) inhibition of the transporter by the respective inhibitor. 96 well 
MDCK-MDR1 plates were washed twice in pre-warmed transport buffer after medium 
removal and incubated with the respective solutions in the fluorescence plate reader 
(PolarStar Omega). Monolayers were examined before and after the assay under the 
microscope to ensure cells had not detached throughout the assay. MDCK-MDR1 plates 
were read at Ex: 485nm and Em: 540-10nm, gain 1200 for 71 cycles at 37°C. Calcein-AM 
was then tested on a cell line overexpressing the transporter BCRP to test for substrate 
cross specificity with BCRP versus P-gp.  
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2.3.9.2. Fluorescence assay to assess OCT2 functionality  
ASP+ was used as a probe substrate for OCT in the presence and absence of the OCT2 
inhibitors Ipratropium and Imipramine (Sigma Aldrich, UK). A concentration range for 
ASP+ generated through a literature search of ASP+ concentrations utilised in various cell 
types and methods, resulted in concentrations ranging from 1-25 µM [121][78]. From 
this 1µM, 5µM, 10µM and 20µM ASP+ was investigated in HEK-OCT2 cells in the 
presence and absence of the OCT2 inhibitors Ipratropium and Imipramine. Stock 
solutions of the inhibitors were made up at 20mM and diluted at 200x to 100µM in 
buffer containing ASP+. Pre-incubation solutions containing inhibitors at 100µM in 
transport buffer were also made up by adding DMSO in the place of the ASP+ stock 
(Table 7).  
For the HEK-OCT2 runs cells were washed twice with pre-warmed transport buffer after 
medium removal and incubated with the pre-incubation solutions for 15 minutes at 37°C. 
The pre-incubation solutions were then removed and the incubation solutions 
containing ASP+ were applied and incubated for 20 minutes at 37°C. After incubation the 
solutions were removed and the plates were checked under the microscope to ensure 
cells were still attached before washing with ice cold transport buffer 3 times. To lyse 
the cells acetonitrile was applied for 30 minutes at -20°C before centrifuging the plate at 
3000rpm for 15 minutes at 4°C. The supernatant was then sampled into a black bottom 
plate and read on the plate reader (PolarStar Omega) at Ex: 485, Em: 590, gain 1200.  
2.3.9.3. Fluorescence assay to assess BCRP functionality  
The fluorophore chosen as a BCRP substrate was Hoechst 33342 (H33342) [101], which 
is routinely used as a counterstain as it fluoresces when bound to DNA. H33342 was 
used in the presence and absence of the BCRP inhibitors Novobiocin and Ko143 (Sigma 
Aldrich, UK) to assess BCRP functionality on non-polarised monolayers of MDCK-BCRP. 
The concentrations of Hoechst 33342 described in the literature ranged from 1µM to 
8µM [122][101]. Therefore concentrations of 1µM, 5µM, 10µM and 20µM were applied 
to the cells. H33342 was made up to stock solutions in DMSO at 200x before being 
diluted in transport buffer (Table 7). Novobiocin was diluted from a stock solution of 
6mM to a final concentration of 30µM and Ko143 was diluted from a stock solution of 
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10mM to a final concentration of 50µM in transport buffer containing H33342.   
MDCK-BCRP plates were washed twice in pre-warmed transport buffer after medium 
removal and incubated with the respective solutions in the fluorescence plate reader 
(PolarStar Omega). Monolayers were examined before and after the assay under the 
microscope to ensure cells hadn’t detached throughout the assay. MDCK-BCRP plates 
were read at Ex: 355nm and Em: 460-10nm, gain 1200 for 71 cycles at 37°C. H33342 was 
then tested on a cell line overexpressing the transporter P-gp to test for substrate cross 
specificity with P-gp versus BCRP. 
 
Table 6: Inhibitor concentrations used and their IC50 profiles for the transporter 
functionality assays 
 
Table 7: Dilutions of ASP+ and H33342 in DMSO for 200x stock solutions to produce the 
range of working solutions for ASP+ and H33342 
Transporter Inhibitor Concentration used 
(µM) 
IC50 (µM) Reference 
P-gp Quinidine 100 14.9 [56] 
P-gp Verapamil 100 10.7 [24] 
P-gp Ketoconazole 100 3.07 [56] 
BCRP Novobiocin 30 0.40 [123] 
BCRP Ko143 50 0.01 [110] 
OCT2 Imipramine 100 6.00 [124] 
OCT2 Ipratropium 100 15.00 [124] 
Probe  Final probe 
Concentration 
200x concentration of 
probe 
Stock solution of 
probe 
ASP+, H33342 1µM 200µM 200µM 
ASP+, H33342 5µM 1mM 1mM 
ASP+, H33342 10µM 2mM 2mM 
ASP+, H33342 20µM 4mM 4mM 
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2.4. Results  
2.4.1. Rhodamine 123 assay development in MDCKII and MDCK-MDR1 cells  
2.4. 1.1. Rhodamine 123 concentration assessment in MDCKII cells 
Before looking at the functional activity of P-gp in MDCK-MDR1 cells overexpressing P-gp, 
functional activity of P-gp in wild-type MDCKII cells was measured using the bidirectional 
transport assay with the fluorescent substrate Rho123. P-gp functionality was initially 
assessed on the wild type MDCKII cells as an endogenous baseline for canine P-gp 
activity within the transfected MDCK-MDR1 cells. Culture conditions for MDCKII cells on 
transwells were initially established in terms of days in culture versus seeding density as 
assessed by the LY monolayer integrity assay (Appendices- Figure 51).  
To ascertain the optimal concentration of Rho123 for the bidirectional transport assay, 
pilot experiments were conducted to establish a concentration range in the absence of 
any inhibitors.  Initially, 7 concentrations of Rho123 were tested alongside a no 
substrate cell control in the A-B and B-A directions:  1µM, 5µM, 10µM, 20µM, 50µM, 
100µM, 200µM. The concentration of DMSO was controlled in the working solutions 
(transport buffer spiked with the stock solutions in DMSO) at 1% (v/v) due to the 
potential cytotoxic effects exerted at high concentrations (above 10%) [125]. LY 
permeability was assessed before and after the Rho123 assay in order to determine the 
monolayers were acceptable to run the assay, and monolayer integrity was not 
compromised during the assay. The experiment was repeated twice and is presented in 
the separate runs to demonstrate monolayer integrity effects on the permeability and 
active transport of Rho123.   
All wells in run 1 showed acceptable permeation percentages before the assay at below 
1% (Figure 7a). However there is evidence of damage to the cell monolayers by an 
increase in LY permeation after the assay (Figure 7b). The increase in the leakiness of the 
monolayer is predominantly seen in the B-A direction at the higher concentrations (>50 
µM) of Rho123 in the assay, with the percentage permeation of LY exceeding the 
threshold limit at 200µM post assay. This indicates higher concentrations of Rho123 
above 20µM can compromise monolayer integrity, which may be a consequence of 
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some form of toxicity, which is concurrent with findings elsewhere [59].     
In contrast to this, wells at 20μM, 50μM in both directions, and at 200μM in the B-A 
direction exhibited a higher percentage LY permeation than the acceptable limit before 
the assay in run 2 (Figure 8a). Post assay there was a similar increase in LY permeation in 
all wells to run 1, predominantly in the wells incubated at 50μM, 100μM and 200μM in 
the B-A direction. This may be due to the accumulation of Rho123 in the cells exerting a 
toxic effect (as P-gp is located on the apical membrane and would be subject to B-A 
transport), whereas Rho123 permeability through the apical membrane is more likely to 
be passive.    
Consequently Rho123 transport varied through the concentrations, exhibiting lower 
permeation in the B-A direction than the A-B direction at 5μM, 20μM and 50μM (Figure 
8c). ERs above 2 were exhibited at 1μM and 200μM, however due to high LY permeation 
post assay, this is not indicative of active transport.  
Rho123 permeability was found to be higher in the B-A direction than in the A-B as 
shown in Figure 8c for run 1 at all concentrations. This follows the expected transport of 
the substrate as P-gp is located on the apical membrane of polarised cell monolayers 
[126]. The resulting ERs indicate active transport of Rho123 through the monolayer as 
they are all above 2, with the highest ERs obtained at 20μM and 200μM. However, due 
to the increased permeability of the monolayer from high concentrations of Rho123, 
20μM would be the ideal concentration from run 1. 
The data collected from both runs confirms that tight monolayers of cells with LY 
permeation below the quality control criteria set can be used to determine the active 
transport of Rho123 by P-gp. In transfected cells lines overexpressing P-gp there would 
be an increase in the active transport of Rho123 compared to the wild type. However, 
the assay is not robust in the 12-well plates and consequently Rho123 transport is not 
consistent between runs. This is most likely attributed to biological variability regarding 
membrane integrity, caused by either differences in seeding density or biological 
variability between cell aliquots in the bank. Monolayer integrity presents a problem for 
any assay looking at permeability, however, scaled down experiments in 96-well 
transwells have been successfully implemented at AstraZeneca for these types of assays. 
Page | 42  
 
Fluorescence assay development for transporter characterisation Chapter 2 
 
They are also easier and less time consuming to handle, thereby reducing any operator 
error that may occur. The next step would therefore be looking at the Rho123 
permeability in wild type and cell lines overexpressing P-gp in a scaled down (96-well 
plate) system.   
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Figure 7: LY permeation values for wells used in the (a) A-B  and (b) B-A  directions at the 
1µM-200µM Rho123 concentration range before and after the bidirectional transport 
with (c) the Papp of Rho123 at the 1µM-200µM concentration range in the A-B and B-A 
directions with the ERs assay in Run 1  (Mean value ± SEM, n=3). The dashed red line 
indicates the threshold for acceptable LY permeation used 
 
(c
 
2.6 
3.2 2.9 4 
3.9 
3.8 
4 
0
1
2
3
4
5
6
1 5 10 20 50 100 200
P a
pp
 (1
0 
- 6
cm
/s
ec
)  
Concentration of Rho123 (µM) 
A-B
B-A
(a) 
0%
1%
2%
3%
4%
5%
1 5 10 20 50 100 200
Pe
rc
en
ta
ge
 L
Y 
pe
rm
ea
tio
n 
Concentration of Rho123 (µM) 
Before assay
After assay
(b) 
0%
1%
2%
3%
4%
5%
1 5 10 20 50 100 200
Pe
rc
en
ta
ge
 L
Y 
pe
rm
ea
tio
n 
Concentration of Rho123 (µM) 
Before assay
After assay
Page | 44  
 
Fluorescence assay development for transporter characterisation Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: LY permeation values for wells used in the (a) A-B  and (b) B-A  directions at the 
1µM-200µM Rho123 concentration range before and after the bidirectional transport 
assay with (c) The Papp of Rho123 at the 1µM-200µM concentration range in the A-B and 
B-A directions with the ERs in Run 2 (Mean value ± SEM, n=3). The Papp data determined 
for Rho123 is not considered to be acceptable based on failure of the LY acceptance 
criteria of <1% permeation (dashed red line) 
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2.4.1.2. Rhodamine 123 transport in MDCK-MDR1 and MDCKII cells  
The repeat of the Rho123 concentration experiment described in Section 2.4.1.1. was 
scaled down from 12-well to 96-well multiwell insert plates to assess the robustness of 
the assay, and to incorporate MDCK-MDR1 cells. MDCK-MDR1 cells are transfected 
MDCKII cells which overexpress human P-gp/MDR1, and were also cultured to validate 
the assay. The concentration range of Rho123 was modified to exclude 200µM which 
had displayed compromised monolayer integrity previously (Figures 7 and 8). The new 
range consisting of: 1µM, 2µM, 5µM, 10µM, 20µM, 50µM, 100µM Rho123 was applied 
as before in Section 2.4.1.1. MDCKII and MDCKI-MDR1 cells were cultured for 3-4 days. 
Monolayer integrity was assessed before the assay by noting the TEERs, with results of 
above 500Ω/cm² indicating suitable monolayer formation. This streamlined the 
protocols applied at AstraZeneca with the monolayer integrity methods applied in these 
assays. LY permeation was then tested after the assay to check whether the monolayers 
maintained integrity throughout the assay.    
All MDCKII and MDCK-MDR1 wells displayed TEERs of >500Ω/cm² before the assay 
(Appendices- Figure 52). A manual approach of measuring the TEER in transwells (which 
was trialled in the 12-well plate experiments) suffered from large measurement error 
introduced by physical movement of the operator. Therefore throughout the 96-well 
plate experiments automated TEER readers were employed. Although more accurate 
than manual techniques automated readers have been found to be sensitive to 
temperature between the beginning and the end of the plate. However, they are still 
widely used as a measure of monolayer integrity elsewhere [127][128]. The LY assay was 
therefore employed as the primary marker of monolayer integrity in the 12-well plates, 
and was applied post assay in the 96-well plates. 
Both cell lines exhibited increased transport of Rho123 in the B-A direction compared to 
the A-B as seen in Section 2.4.1.1. However, with the exception of 1µM the ERs were all 
lower in both cell lines than were attained in 12 wells (Figure 9) at similar concentrations. 
Furthermore, ERs at 2µM, 5µM, 10µM, 20µM and 50µM were lower in the MDCK-MDR1 
cells than in the MDCKII wild type. This is unexpected as P-gp is overexpressed in the 
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MDCK-MDR1 line and should exhibit greater transport of Rho123 in the B-A direction 
resulting in an increased ER.  
Active transport (indicated by ERs over 2) of Rho123 was only increased through the 
MDCK-MDR1 monolayer at 1µM and 100µM of Rho123 compared to the MDCKII cells. 
The highest ER was also found at concentration 1µM in the MDCKII line, contradicting 
the findings in the 12-well experiments showing 20µM Rho123 to be actively transported 
in the wild type (Section 2.4.1.1.).  
However, when looking at the LY percentage permeation after the assay, it is clear that 
the transport shown was due to monolayer damage as all wells in both lines apart from 
1µM in the MDCK-MDR1 cells, which showed LY permeation above the 1% threshold. 
Although this is contradictory to the 12-well plate experiment, the higher amounts of LY 
permeation in the B-A wells compared to the A-B wells is observed in both plate formats. 
This gives a further indication to the potential toxicity of Rho123 from either uptake 
from basolateral or efflux from apical transporters. However differences in monolayer 
integrity assessment and the accuracy of the TEER reader (due to variation throughout 
the plate) need to be taken into account when considering the degree of difference 
between the 12-well and 96-well plates at the same concentrations. From the data 
collated from the scaled down (96-well plate) experiment, the assay was repeated at a 
lower concentration range in the same format to determine whether monolayer 
integrity could be preserved.  
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Figure 9: The LY permeation percentages after assay (top) and Papp of Rho123 (bottom) at the 1µM-100µM concentration range in the A-B and 
B-A directions with the ERs in (a) MDCKII and (b) MDCK-MDR1 cells (Mean value ± SEM, n=3)  
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The concentration range was reduced from the previous assay run to include: 10nM, 
20nM, 50nM, 100nM, 500nM, 1000nM, 2000nM concentrations of Rho123 (Figure 10). 
As before, TEERs were taken before the assay, and LY permeation was applied after the 
assay. The TEERs for the wells were all of acceptable readings with little variation 
between the wells, although the readings were lower than in the previous run 
(Appendices- Figure 53).  
Both cell lines exhibited improved monolayer integrity in both directions after the assay, 
with LY permeation below the 1% threshold limit in 10nM-100nM and 500nM in the 
MDCK-MDR1 wells, and 10nM-100nM in the MDCKII wells in the A-B direction. The LY 
permeation is higher in the B-A direction as observed previously, and exceeds the 
threshold at concentrations 50nM, 100nM, 500nM, 1000nM and 2000nM in both lines 
and 20nM in MDCKII.  
Due to the increased leakiness of the monolayers (LY percentages above the 1% 
threshold), Papp and ERs at 50nM-2000nM in both cell lines must be disregarded. The ERs 
at the remaining concentrations in the MDCK-MDR1 cells conform to the expectation of 
increased transport of Rho123 compared to the MDCKII cells as P-gp is overexpressed in 
this cell line. This was not observed previously, and is shown at all concentrations except 
100nM. However, while the ERs are increased in MDCK-MDR1 cells, they are all below 2 
indicating the flux of Rho123 across the monolayers is not due to active transport. The 
lack of statistical significance between the B-A and A-B Papps at these concentrations also 
confirms no active transport is occurring across the MDCK-MDR1 cell monolayers.  
Therefore, whilst monolayer integrity was preserved after the assay at the lower 
concentrations in the scaled down experiment active transport cannot be observed, 
demonstrating the unsuitability of Rho123 for bidirectional transport studies in the 
scaled down format. To demonstrate the activity of P-gp on this cell line and to assess 
the functionality of the transporter with a fluorescence probe, Calcein-AM (a known P-
gp substrate) was employed in the MDCK-MDR1 cells (Section 2.4.2.1). This assay was 
first applied in non-polarised monolayers before being applied in primary cells (Section 
3.4.2.1.).  
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Figure 10: The LY permeation percentages after assay (top) and Papp of Rho123 (bottom) at the 10nM-2000nM concentration range in the A-B 
and B-A directions with the ERs in (a) MDCKII and (b) MDCK-MDR1 cells (Mean value ± SEM, n=3)  
 
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
10 20 50 100 500 1000 2000
Pe
rc
en
ta
ge
 P
er
m
ea
tio
n 
of
 L
Y 
A-B
B-A
(a) (b) 
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
20%
10 20 50 100 500 1000 2000
Pe
rc
en
ta
ge
 P
er
m
ea
tio
n 
of
 L
Y 
A-B
B-A
0.3 
0.2 
0.4 
1 1 1 1 
0
0.05
0.1
0.15
0.2
0.25
0.3
10 20 50 100 500 1000 2000
P a
pp
 (1
0-
6  c
m
/s
)  
Concentration of Rho123 (nM) 
Page | 50  
 
0.6 
0.5 
0.6 
1 2 2 2 
0
0.05
0.1
0.15
0.2
0.25
0.3
10 20 50 100 500 1000 2000
P a
pp
 (1
0-
6 
cm
/s
)  
Concentration of Rho123 (nM) 
Fluorescence assay development for transporter characterisation Chapter 2 
 
2.4.2. P-gp functionality assessment in MDCK-MDR1 cells using Calcein-AM 
2.4.2.1. Calcein-AM efflux in MDCK-MDR1 cells in the presence of P-gp inhibitors  
Due to difficulties in developing the bidirectional transport assay using Rho123, it was 
decided to develop an assay utilising the widely used substrate Calcein-AM on non-
polarised monolayers of cells (see Appendices- Figure 54 for full cycle graphs).  
In cells incubated with Calcein-AM alone there is 3.31 fold increase in fluorescence in 
run 1, indicating a time dependent increase in the generation of Calcein from Calcein-
AM (Figure 11). As expected the intracellular fluorescence due to the Calcein was 
increased in the presence of P-gp inhibitors. Comparing the inhibited samples to this 
non-inhibited baseline, inhibitor potency can be indicated alongside the P-gp 
functionality on the cells. 100µM Quinidine is the less potent inhibitor as shown by a 
3.96 fold increase in fluorescence to the baseline after 71 minutes. In the presence of 
100µM Verapamil this fold change is increased to 4.42 with statistical analysis via one-
way ANOVA showing a significant increase in the presence of Verapamil compared to 
Quinidine inhibited samples (p ≤ 0.05). The most potent of the 3 P-gp inhibitors was 
Ketoconazole (100µM) which produced a 9.72 fold increase in fluorescence compared to 
the baseline in run 2. This increase was statistically significant to both the non-inhibited 
and inhibited cells. However the fluorescence increase between Verapamil and 
Quinidine inhibited samples was not significant as shown by ANOVA in run 2.   
This assay demonstrated some variability in the 2 runs because the fluorescence in the 
second plate run was approximately 3 fold higher than the corresponding samples in the 
first plate. This indicates that variation due to operator error and possible dilution of the 
solutions is more likely rather than biological variability. Both assays also produced 
signal to noise ratios (SNRs) of >3 (IUPAC guidelines for analytical techniques), 
demonstrating fluorescence increases in the presence of inhibitors with a reduced 
chance of being obscured by methodological noise. Therefore these patterns in 
fluorescence are a clear indication that the P-gp expressed on the MDCK-MDR1 cells is 
functional and Calcein-AM is a suitable substrate to be used in this type of assay.   
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Figure 11: Calcein-AM (2.5µM) fluorescence in MDCK-MDR1 cells in the presence and 
absence of the P-gp inhibitors Verapamil (100µM), Quinidine (100µM) and Ketoconazole 
(100µM) after 71 cycles (approximately 71 minutes). The darker bars represent 
fluorescence from run 1 using Verapamil and Quinidine only. Data labels above the bars 
display fold changes in fluorescence from inhibited cells compared to the uninhibited 
data set. (Mean value ± SD, n=9 for each run). *  significant decrease from the 
uninhibited sample, p ≤ 0.05 (ANOVA with Tukey post hoc analysis)  
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2.4.2.2. Native fluorescence of P-gp inhibitors in the presence and absence of Calcein-
AM 
When applying the Calcein-AM assay to the MDCK-MDR1 cells, one repeat experiment 
resulted in abnormal RFUs being achieved. Briefly, there was no fluorescence exhibited 
by the non-inhibited or inhibited cells over the assay time period apart from quinidine 
inhibited cells, which exhibited an increase in fluorescence from the first cycle but did 
not change over the time period (Appendices- Figure 55). As factors had been kept 
consistent through the repeats yielding the expected results (see Section 2.4.2.1.), 
degradation of the Calcein-AM was suspected. Therefore the fluorescence of inhibitors 
in the presence and absence of Calcein-AM was investigated in the absence of cells to 
ascertain whether any fluorescence from inhibitors had contributed to the effects seen 
in Figure 11. The P-gp inhibitors Verapamil and Ketoconazole alongside the BCRP 
inhibitors Novobiocin and Ko143 were incubated with Calcein-AM, with fluorescence 
measured on the plate reader over 71 cycles. The concentrations of the inhibitors were 
those used in the respective assays and DMSO concentrations were kept at 1% (v/v).  
When compared to Calcein-AM only, the fluorescence of Verapamil, Novobiocin and 
Ko143 were all similar (within 22RFU), with Ketoconazole producing the highest increase 
in fluorescence with a 100RFU. All inhibitor containing wells were statistically 
significantly different to the Calcein-AM only well when ANOVA was run (p ≤ 0.05). 
However these differences would not have any biological significance as they are small 
relative to cell based assay fluorescence (Figure 12). It can therefore be concluded that 
although inhibitors produce a small increase in fluorescence in the presence of Calcein-
AM, they can be used in the P-gp functionality assay as they do not cross-react to give 
artificial fluorescence increases that may confound experimental results.  
2.4.2.3. Assessing Calcein-AM as a P-gp specific substrate   
Calcein-AM was applied to cells overexpressing the transporter BCRP to assess the 
specificity of Calcein-AM to P-gp (Figure 13). This was required as the eventual goal for 
this assay was to determine the functionality of P-gp on human PTCs expressing a range 
of efflux transporters. The assay was repeated using the same concentrations of Calcein-
AM (2.5µM), and the inhibitors: Ketoconazole to inhibit P-gp (100µM) and Novobiocin to 
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inhibit BCRP (100µM) with readings taken at cycle 1 and 71. Although there is a slight 
increase in fluorescence between Calcein-AM in the presence and absence of 
Ketoconazole at cycle 1, this fluorescence does not increase in the presence of the 
inhibitor (Figure 12). Furthermore, in the presence of Novobiocin, there is virtually no 
change through the cycles and the fluorescence actually decreases in the presence of 
the inhibitor from 391 RFU at cycle 1 to 385 at cycle 71. The initial values between 
Calcein- AM and Calcein-AM with Novobiocin are also very similar at 371 RFU and 395 
RFU respectively. This indicates that Calcein-AM is not a substrate of BCRP, and can be 
used as a selective P-gp substrate in systems expressing multiple transporter types to 
assess the functionality of P-gp. 
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Figure 12: The fluorescence of Calcein-AM alongside P-gp inhibitors Verapamil (100µM) 
and Ketoconazole (100µM) and BCRP inhibitors Novobiocin (30µM) and Ko143 (50µM) in 
the presence of Calcein-AM at Ex: 485 Em: 520 (Mean value ± SD, n=6) p ≤ 0.05 (ANOVA 
with Tukey post hoc analysis) 
Figure 13: Calcein-AM (2.5µM) fluorescence in MDCK-BCRP cells in the presence and 
absence of the P-gp inhibitors Ketoconazole (100µM) and Verapamil (100µM) and the 
BCRP inhibitor Novobiocin (30µM) (Mean value ± SD, n=6) 
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2.4.3. OCT2 functionality in HEK-OCT2 cells using ASP+ 
2.4.3.1. ASP+ uptake in HEK-OCT2 cells in the presence and absence of OCT2 inhibitors 
As OCT2 is an uptake transporter located on the basolateral membrane on polarised 
monolayers of cells, the methodology applied to the P-gp assays (Section 2.3.9.2.) to 
observe substrate efflux were unsuitable to observe uptake transporter functionality. 
ASP+ is a fluorescent compound transported by OCT2 into the cell [129] so an uptake 
assay was developed on non-polarised cell monolayers to observe ASP+ transport. Due 
to the nature of the transporter, in the presence of OCT2 inhibitors the uptake of ASP+ 
would be restricted and intracellular fluorescence would decrease.  
The amount of ASP+ recovered from lysed cells displays a concentration dependent 
increase, which was significantly inhibited by both OCT2 inhibitors (Figure 14). The ASP+ 
recovery was variable at each concentration in the non-inhibited cells as shown by the 
error bars representing the SD. However, in the presence of Ipratropium and Imipramine 
there is a significant 10% and 68% fold respective decrease in fluorescence from the 
non-inhibited cells at 20µM ASP+. The potency of the 2 inhibitors is similar, as at each 
incubation concentration the decrease in fluorescence from the no inhibitor control is 
approximately the same. However, in Imipramine inhibited cell samples there is a higher 
fold decrease in fluorescence at each concentration compared to the non-inhibited cell 
samples, and is therefore slightly more potent in the HEK-OCT2 cell line. The percentage 
of ASP+ recovered from Imipramine inhibited cells is lower by 2%, 15%, 10% and 9% at 
1µM, 5µM, 10µM and 20µM respectively than in Ipratropium inhibited cells. However, a 
significant decrease (p ≤ 0.05) in fluorescence is only observed in the presence of 
Imipramine at 10µM of ASP+ as well as with both inhibitors at 20µM ASP+, as calculated 
through ANOVA testing with Tukey post hoc analysis.  
As there is a detectable difference in fluorescence in the presence of OCT2 inhibitors 
(SNRs of ≥3 in the presence of inhibitors), the concentration of ASP+ to be used for 
human cell experiments is 20µM. This conclusion is also confirmed by the fact that there 
is a significant decrease in fluorescence by both inhibitors at 20µM, whereas this is not 
exhibited at any other concentration of ASP+. Although an increase in the concentration 
of ASP+ would most likely yield a higher inhibition i.e. a lower fluorescence value in the 
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presence of inhibitors, the increase in variability over increasing concentrations of ASP+ 
in the non-inhibited cells dictates that the concentration should be kept as low as 
possible.  
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Figure 14: The ASP+ uptake in HEK-OCT2 cells in the presence and absence of the OCT2 inhibitors Ipratropium (100µM) and Imipramine 
(100µM). Data labels above the bars display fold changes in amount of ASP+ uptake in inhibited cells compared to the uninhibited cell uptake.  
(Mean value ± SD, n=6).*  significant decrease from the uninhibited sample at the respective concentration p ≤ 0.05 (ANOVA with Tukey post 
hoc analysis) 
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2.4.5. BCRP functionality in MDCK-BCRP cells using Hoechst 33342 
2.4.5.1. Hoechst 33342 concentration assessment for efflux assay  
BCRP is an efflux transporter belonging to the same family of ABC transporters as P-gp. It 
is also located on the apical membrane of PTCs, so the same type of assay design used to 
test the functionality of P-gp on an overexpressed cell line could be employed on non-
polarised cell monolayers. At 1µM the fluorescence in the non-inhibited sample at the 
final cycle (see Appendices- Figures 56 and 57 for full cycle graphs) is relatively low 
compared to the higher concentrations, but produces a significant 3.54 fold increase in 
fluorescence in the presence of Ko143 according to ANOVA with Tukey post hoc analysis 
(p ≤ 0.05). When the concentration of Hoechst 33342 is increased 5µM, 10µM and 20µM 
show significantly similar fluorescence values for non-inhibited and inhibited samples 
(Figure 15). Throughout the concentration range Novobiocin (30µM) exerts slight but 
insignificant inhibition on BCRP shown by the small increase in fluorescence from the 
uninhibited cells, with SNRs >3 for all samples. Although Novobiocin was used at a low 
concentration compared to inhibitors in other assays, previous work has found 30µM 
Novobiocin to be a potent inhibitor of BCRP (see Table 6). However, the data above 
suggests that higher concentrations would potentially be required to produce significant 
inhibition when incubated with Hoechst 33342. 
Ko143 (50µM) is shown to be a potent inhibitor at all concentrations of Hoechst 33342 
by the higher fluorescence values compared to Novobiocin and non-inhibited samples at 
each concentration, but demonstrates the largest inhibition with the lowest amount of 
error at 20µM. When run again at 20µM (Figure 16) there is inhibition by both 
Novobiocin and Ko143 on the MDCK-BCRP system. This is exhibited by a significant 
increase in fluorescence from the non-inhibited sample of 1.17 and 3.39 fold for 
Novobiocin and Ko143 respectively, confirming that 20µM is an appropriate 
concentration for further experiments.    
Page | 59  
 
Fluorescence assay development for transporter characterisation Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Fluorescence of Hoechst 33342 at a range of concentrations in MDCK-BCRP cells in the presence and absence of the BCRP inhibitors 
Novobiocin (30µM) and Ko143 (50µM) after 71 cycles (approximately 71 minutes) Data labels above the bars display fold changes in 
fluorescence from inhibited cells compared to the uninhibited data set. (Mean value ± SD, n=8). *  significant decrease from the uninhibited 
sample at the respective concentration, p ≤ 0.05 (ANOVA with Tukey post hoc analysis) 
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Figure 16: Fluorescence of 20µM Hoechst 33342 in MDCK-BCRP cells in the presence and 
absence of the BCRP inhibitors Novobiocin (30µM) and Ko143 (50µM) after 71 cycles 
(approximately 71 minutes) Data labels above the bars display fold changes in 
fluorescence from inhibited cells compared to the uninhibited data set. (Mean value ± 
SD, n=18).  *  significant decrease from the uninhibited sample, p ≤ 0.05 (ANOVA with 
Tukey post hoc analysis) 
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2.4.5.2. Native fluorescence of BCRP inhibitors in the presence and absence of Hoechst 
33342 
The fluorescence of P-gp and BCRP inhibitors used were ascertained in the presence of 
Hoechst 33342 to investigate any native (non-cellular) fluorescence of inhibitors or 
whether fluorescent complexes are formed between the substrate and inhibitors.  
The fluorescence of BCRP inhibitors Novobiocin and Ko143 alongside the P-gp inhibitors 
Verapamil and Ketoconazole were measured on the plate reader in the presence of 
Hoechst 33342 (Figure 17). The concentrations of the inhibitors were those used in the 
respective assays and DMSO concentrations were kept at 1% (v/v).  
The fluorescence of Verapamil, Ketoconazole and Novobiocin in the presence of Hoechst 
33342 is significantly lower compared to Hoechst 33342 alone (p ≤ 0.05). In the presence 
of Ko143 there is an increase in fluorescence of 554RFU compared to Hoechst 33342 
alone. However as with Calcein-AM + inhibitor samples, this difference in fluorescence 
does not have any biological significance when compared to fluorescence increases in 
cell based assays. Therefore it can be concluded that BCRP inhibitors can be used 
without compromising the functionality of the assay. 
2.4.5.3. Assessing Hoechst 33342 as a BCRP specific substrate  
As with the Calcein-AM, it was important to assess the cross specificity of Hoechst 33342 
in a system expressing transporters with similar specificities as the eventual aim of this 
assay was to test BCRP functionality in human PTCs. Hoechst 33342 (20µM) was tested 
in the MDCK-MDR1 cell line against P-gp inhibitors Verapamil and Quinidine at 100µM 
(Figure 18). When initially looking at the fluorescence at the beginning and end of the 
assay, it appears that Hoechst 33342 is a P-gp substrate as there appears to be an 
increase in fluorescence through the cycles. However, when looking at the increase in 
fluorescence throughout the assay in the presence and absence of inhibitors, the 
fluorescence increases are similar, indicating little effect of the inhibitor on fluorescence. 
There is in fact a significant decrease in fluorescence between the Quinidine inhibited 
sample compared to the non-inhibited, although the increase between the Verapamil 
inhibited sample and the non-inhibited is significant (p ≤ 0.05). This suggests that 
Hoechst 33342 might be an overlapping substrate for P-gp, although the lack of 
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inhibition by Quinidine and evidence on the similar potency of Quinidine and Verapamil 
(Figure 11) contradicts this. Therefore Hoechst 33342 can be utilised in a multi-
transporter system to assess the functionality of BCRP in the presence of BCRP specific 
inhibitors, although the cross specificity of Hoechst 33342 should be taken into account.
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Figure 17: The fluorescence of Hoechst 33342 alongside P-gp inhibitors Verapamil 
(100µM) and Ketoconazole (100µM) and BCRP inhibitors Novobiocin (30µM) and Ko143 
(50µM) in the presence of Hoechst 33342 at Ex: 355 Em: 460 (Mean value ± SD, n=6) p ≤ 
0.05 (ANOVA with Tukey post hoc analysis) 
 
 
 
 
 
 
 
 
Figure 18: Hoechst 33342 (20µM) fluorescence increase in MDCK-MDR1 cells in the 
presence and absence of the P-gp inhibitors Verapamil (100µM) and Quinidine (100µM) 
through 71 cycles (approximately 71 minutes) (Mean value ± SD, n=6) p ≤ 0.05 (ANOVA 
with Tukey post hoc analysis) 
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2.5. Chapter discussion and conclusion 
2.5.1. Discussion 
The focus of this chapter addresses the need for low cost, safe and efficient assays to 
assess transporter capabilities, and the generation of a panel of assays for the 
assessment of renal specific transporters, to be utilised through the stages of testing 
during drug development. As such, bidirectional transport assays were the preferred 
assays as cells cultured in polarised monolayers more accurately reflect the barrier 
functions and transport capabilities of the cells in vitro. Rho123 was identified as a 
substrate for the efflux transport P-gp, and had been implemented successfully as a 
fluorescent substrate previously [119]. However, during the assays using polarised 
monolayers of MDCKII cells, Rho123 demonstrated varying results in larger scale 
systems. Active transport was observed in cell monolayers that were intact after the 
assay throughout the concentration range, but these results could not be reproduced 
without the permeability of the monolayers increasing above the threshold value. The 
problems with cell monolayer permeability were also exhibited in smaller scale systems 
in MDCKII and MDCK-MDR1 cells at the same concentration range. The increase in 
permeability after the assay suggests that Rho123 may exert a potentially toxic effect on 
cells above a certain concentration, which has also been suggested by [59].  
Another fluorescent substrate for P-gp was identified in the form of Calcein-AM, which 
fluoresces when cleaved by acetoxymethyl ester hydrolysis by intracellular enzymes to 
Calcein, which is not a substrate [130]. The nature of the probe required cells to be 
cultured as non-polarised monolayers. Consequently the results from these assays were 
an indirect indication for transport functionality in the presence and absence of P-gp 
specific inhibitors. The same limitations were applied for BCRP assessment, where 
Hoechst 33342 was used as a substrate and exhibited fluorescence after binding to DNA 
within the cells. Although these assays did not employ the optimal method of cell 
culture for quantifiable results, they did indicate the degree of transporter functionality, 
which could be used comparatively.   
ASP+ was an inherently fluorescent substrate for OCT2, and could have been utilised in a 
bidirectional transport assay to assess OCT2 uptake. However, due to the assay format 
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of the other two transporters, non-polarised monolayers of cells overexpressing OCT2 
were used in the generation of the panel of assays for transporter functionality on renal 
cells.    
2.5.2. Conclusion 
Fluorescence assays have been utilised within the pharmaceutical industry for high 
throughput assays, but less so in the later stages of pre-clinical drug testing. This has 
been identified as a major gap in the knowledge (refer to Section 2.2.3.4.). As such, one 
of the aims of this thesis was to generate a panel of assays for the assessment of renal 
specific drug transporters i.e. P-gp, BCRP, OCT2, OAT1 and OAT3 and MATE1 using 
fluorescent substrates, which does not currently exist. This chapter has described the 
generation assays to assess the functionality of both efflux and uptake transporters 
using fluorescent substrates in the presence and absence of transporter specific 
inhibitors. The assays have also been assessed for the potential cross-specificity that 
could occur when applied in multi-transporter systems. The unsuitability of certain 
fluorescent substrates that have been used previously for the assessment of 
transporters has also been identified and corroborated by reports in literature. The 
fluorescence assays developed for these transporters will be applied in primary cell 
systems to assess transporter functionality over time in in vitro culture, as discussed in 
Chapter 3.    
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3.1. Introduction 
Cell lines are useful to develop assays, with cell lines overexpressing the desired 
transporter(s) offering a transporter specific model e.g. MDCK-MDR1 cells, and other 
epithelial cell lines offering a model with many transporters expressed e.g. Caco-2 cells. 
They also offer the ease of reduced culture times compared to primary cells, and are 
relatively inexpensive. However, they cannot translate the native processes found in 
vivo for specific tissues in vitro which primary cells offer.   
Primary cells are notoriously difficult to culture in vitro, and while they may be able to 
display qualities such as attachment and doubling over many passages, they often 
exhibit a rapid, time-dependent, general loss of function [20]. However, when looking at 
model cell systems, they are the gold standard as they offer the native expression of 
transporter, enzymes and metabolic pathways found in vivo. When looking at model cell 
systems of the kidney, proximal tubule cells (PTCs) offer a variety of renal specific 
functions including reabsorption, metabolic and transport functions, the secretion of 
uremic toxins and xenobiotics, producing 1,25- dihydroxy vitamin D3 and performing 
immunomodulatory functions [131]. PTCs also possess a range of transporters: organic 
anion and organic cation transporters predominantly for basolateral drug uptake with 
ABC transporters present on the apical surface for luminal excretion. Many of the 
transporters are polyspecific i.e. accept compounds of different sizes and molecular 
structures, and have overlapping substrate specificities [132] (Table 2). For this reason, 
substrate and inhibitor specificity is an important factor in the assessment of transporter 
functionality.  
In this chapter, the characterisation of human PTCs (RPTECs) will be described in terms 
of transporter expression, visualisation and functionality over a series of Population 
doublings. The growth of RPTECs on porous surfaces with various coatings will then be 
described, looking at the monolayer integrity and TEERs for each condition.  
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3.2. Review of the literature 
3.2.1. Renal physiology  
3.2.1.1. Kidney anatomy  
The kidneys are a pair of bean-shaped organs located along the posterior wall of the 
abdominal cavity. They are primarily responsible for the excretion of waste products 
such as urea and ammonia from the body through the urine. However, they also provide 
a variety of significant secondary functions through homeostatic, endocrine, immune 
and metabolic processes. The kidney consists of 3 main sections; the renal cortex (outer 
section), the medulla (middle section) and the renal pelvis. Nephrons, the functional 
units of the kidney are located in the cortex (cortical) and between the cortex and the 
medulla (juxtamedullary). They have a unique architecture and are each associated with 
their own blood system (Figure 19). Each kidney has approximately 1 million nephrons 
and can process up to 170L of blood per day. After the blood has been processed the 
waste is then transferred to the renal pelvis and into the urinary bladder for excretion. 
The nephrons can be split into 5 distinct sections according to their function; the 
Bowmans capsule, Proximal tubule, Loop of Henle, Distal tubule and Collecting duct.  
The Bowman’s capsule (also known as the renal corpuscle) is an expansion at the closed 
end of the nephron and encases a bundle of capillaries known as the glomerulus. It is 
the site of ultrafiltration, where the blood entering the glomerulus through a wide 
afferent arteriole and leaving through a narrow efferent arteriole creates a build-up of 
pressure which forces small molecules from the blood into the capsule (ultrafiltrate). 
Large components such as proteins and cells remain in the blood and are supplemented 
with nutrients and metabolites further on in the nephron. The capsule membrane then 
extends to the proximal tubule, which is the main site of reabsorption and metabolism 
within the kidney and is discussed in length in Section 3.2.1.3. The isotonic ultrafiltrate 
then progresses into the loop of henle which in juxtamedullary nephrons extends into 
the medulla from the cortex. This is the site of water and ion (sodium; Na+, chloride; Cl-, 
potassium; K+, calcium; Ca2+, magnesium; Mg2+) reabsorption, with the descending limb 
impermeable to ions and slightly permeable to urea but permeable to water. The thin 
ascending limb is the reverse and is freely permeable to ions but impermeable to water. 
Page | 69  
 
Characterisation of human proximal tubule cells Chapter 3 
 
The transport of both molecules is passive due to the osmotic gradient created in the 
loop and the interstitium, and only in the thick ascending limb is salt actively transported 
from the filtrate. On exit from the Loop of Henle the remaining filtrate is returned to its 
isotonic state. The distal tubule extends the reabsorption of Na+ and Cl- whilst regulating 
the pH of the filtrate by secreting H+ and bicarbonate ions. It is also the primary site of 
hormone based calcium regulation in the kidneys in response to parathyroid hormone 
(PTH) and water reabsorption in response to anti-diuretic hormone (ADH). If ADH is not 
present the distal tubule is relatively impermeable to water. Once the filtrate has passed 
through the nephron it is transferred into the collecting duct and through to the renal 
pelvis. The collecting duct system is the final site of electrolyte regulation and is also 
influenced by the action of ADH. The filtrate leaves the kidney as urine through the renal 
pelvis and into the urinary bladder to be excreted.     
3.2.1.2. The renal interstitium  
The renal interstitium is comprised of the cellular elements and extracellular substances 
in the extravascular spaces of the renal parenchyma [133]. There are two contiguous 
cellular networks within the interstitium made up of fibroblasts and dendritic cells. 
Fibroblasts constitute the ‘skeleton’ of the kidney and are attached to the basement 
membranes of vessels and tubules by focal adhesions [134]. They play a major role in 
extracellular matrix (ECM) homeostasis by producing many of the ECM constituents 
(fibronectin, collagen I, III and V) alongside ECM-degrading proteases such as the matrix 
metalloproteinases [135]. Dysregulation of these (residential) fibroblasts however from 
injury and/or activation cause the appearance of myofibroblasts within the interstitium. 
These fibroblasts, characterised by the presence of alpha smooth muscle actin (αSMA) 
are the main cellular mediators of interstitial fibrosis, the main pathology of chronic 
kidney disease [136]. The generation of myofibroblasts is not well understood although 
possible sources include the activation of resident fibroblasts, the proliferation of 
fibroblasts expressing αSMA or the conversion of epithelial or endothelial cells to cells 
with a mesenchymal phenotype. Dendritic cells belong to the mononuclear phagocyte 
system and continually probe the surrounding environment responding to insults that 
arise from the parenchyma. They form an organ spanning network which is narrowly 
intertwined with the fibroblastic 
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Figure 19: Structure of the kidney showing (a) the 3 main sections and (b) the structure of the nephron and the function of the Bowman’s 
capsule, proximal tubule, loop of Henle, distal tubule and collecting duct. Adapted from [137][138]  
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skeleton. When activated from their immature phenotype they express increased levels 
of MHC II and co-stimulatory proteins with a high capacity for uptake of antigens [135]. 
Alongside the cellular network there is a vast array of ECM proteins making up the 
basement membranes for all parenchymal structures. The functions of the ECM in the 
cortex are distinctly different depending on its molecular components: in the glomeruli 
(glomerular basement membrane, Bowman’s capsule, mesangial ECM), in the 
tubulointerstitium (tubular basement membrane, peritubular capillary basement 
membrane, interstitial ECM) and in larger vessels (within and around the vessels). The 
glomerular basement membrane (GBM) contains four main macromolecules: laminin, 
collagen IV, nidogen and heparin sulphate proteoglycans, and is thicker compared to 
other basement membranes. Its main function is to act as a selective filtration barrier 
between the vascular system and urinary space depending on charge and size. In 
contrast the mesangial ECM provides more of a structural support for the glomerular 
capillary convolute, connecting with the extra-glomerular mesangium and assisting in 
cell-matrix signalling in a bidirectional manner. It’s composition is primarily fibronectin, 
collagen IV, collagen V, laminin A, B1 and B2, chondroitin sulphate and heparin sulphate 
proteoglycans, allowing for larger molecules to pass to the mesangium [136]. Tubular 
basement membranes (TBM) support the epithelial cells of the rest of the nephron and 
are critical to cell orientation and function, and if disrupted can lead to cell death and 
tissue destruction. Its function is also similar to the GBM in providing a selective barrier 
to macromolecules between the tubule and interstitium. The TBM is comprised mainly 
of collagen IV (approximately 50%) [139] laminin α1β1γ1 and α5β1γ1, entactin/ nidogen, 
perlecan and bamacan and displays heterogeneity throughout the nephron [140]. 
The interstitial connective tissue supports the TBM and is composed of collagen I, II, V, 
VI, VII and XV, sulphated and non-sulphated glycosaminoglycans, glycoproteins and 
polysaccharides. In the medulla the interstitial ECM is more prominent, increasing from 
the outer to inner medulla/papilla [136]. ECM proteins in the kidney are listed in Table 8.   
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Table 8: ECM proteins present throughout the kidney*  
Protein Location Reference 
Collagen I I-ECM [136][141] 
Collagen III I-ECM [136] [141] 
Collagen IV GBM, TBM, M-ECM [140] [141] 
Collagen V I-ECM, M-ECM [136] [141] 
Collagen XV I-ECM [136] [141] 
Fibronectin M-ECM [136] [141] 
Laminin (α, β, γ) Glomerulus, Nephron, M-ECM [140] [141] 
Entactin TBM [140] 
Nidogen TBM [140] [141] 
Osteonectin Nephron [141] 
Tenascin Stroma [141] 
Agrin GBM [140] 
Perlecan TBM [140] 
Bamacan TBM [140] 
Dystroglycan- α1 Nephron [141] 
Chondroitin sulphate M-ECM [136] 
Heparan sulphate 
proteoglycans 
M-ECM [136] 
 
*This is not an exhaustive list  
Abbreviations: I-ECM; Interstitial extracellular matrix, GBM; Glomerular basement 
membrane, TBM; Tubular basement membrane, M-ECM; Mesangial extracellular matrix
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3.2.1.3. Proximal tubule architecture and function     
The proximal tubule (PT) is the extension of the Bowman’s capsule primarily involved in 
the reabsorption of approximately 60-65% of the glomerular filtrate, amongst 
performing other secondary functions. The filtration, reabsorption and excretion rates of 
some substances within the kidney can be found in Table 9 [142].  The proximal tubule 
consists of two main sections; the proximal convoluted tubule (pars convoluta) and the 
proximal straight tubule (pars recta), which can in turn be further identified by 3 
morphologically distinct segments. The S1 segment constitutes approximately two thirds 
of the pars convoluta and begins at the Bowman’s capsule. It has a tall brush border on 
the apical surface of the cell (exposed to the lumen) with the basolateral membrane 
forming extensive lateral invaginations. Elongated mitochondria are found in the lateral 
processes which protrude from the apical surface and interlock with similar processes 
from other cells and provide energy for the nearby Na+-K+ ATPase pumps [155]. Sodium, 
water, glucose and bicarbonate reabsorption is approximately three fold greater in the 
S1 segment compared to the S2, and tenfold greater than in the S3 segment [142]. The 
ultrastructure of the S2 segment, which consists of the remainder of the pars convoluta 
and the initial portion of the pars recta is similar to the S1 segment. However the brush 
border is shorter and contains less prominent basolateral invaginations. The S3 segment 
is the remainder of the pars recta, and whilst possessing an intermediate brush border, 
lateral cell processes and invaginations are essentially absent. Complex extracellular 
compartments are formed between the interlocking lateral and basal processes 
between adjacent cells (Figure 20). The separation of this space by the plasma 
membrane and specialised tight junction (TJ) proteins (e.g. Zona occludens 1 (ZO-1), 
Claudin-2) allows a continuous band to be formed around the luminal surface of each 
cell. This creates a selectively permeable barrier for molecules dependent on their size, 
charge and the type of proteins present. Claudin-2, is the dominant form of the claudin 
proteins in the proximal tubule and is inherently leakier than other forms such as claudin 
4 or 8 (present in the collecting ducts). This results in a low transepithelial resistance 
(TER) and leakier membrane in terms of the paracellular permeability of molecules less 
than 4Å in size with a preference of cations over anions [156]. ZO-1 is also present on 
the PTCs and is indispensable in the formation of tight junctions in epithelial cells. The
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Table 9: The filtration, reabsorption and excretion rates of nutrients and electrolytes in the kidney, the percentage of filtrate reabsorbed in the 
proximal tubule and their transport mechanisms  
Substance Filtered 
(meq/24h) 
Reabsorbed 
(meq/24h) 
Excreted 
(meq/24h) 
Reabsorbed 
in the PT (%) 
Transport in the PT  
(uptake from lumen, efflux to interstitium) 
Reference 
 
Glucose 
(g/day) 
 
180 
 
180 
 
0 
 
100 
Na+-glucose symport- SGLT 1 and 2 (passive uptake) 
GLUT1 and 2 transporters (passive efflux) 
 
[142][143] 
 
Sodium 
(meq/day) 
 
25,560 
 
25,410 
 
150 
 
70 
Na+-K+ ATPase pump (active efflux) 
Na+ dependent HCO3- -Cl- exchanger (active efflux) 
Na+ ion channels (passive uptake) 
Na+-H+ antiport (active uptake) 
Na+-glucose symport- SGLT 1 and 2  (active uptake) 
Co-transport with phosphate, amino acids and bicarbonate 
(active uptake) 
 
[142][144] 
[145] 
Chloride 
(meq/day) 
19,440 19,260 180 60 
NaCl-H+ antiport (passive uptake) 
Cl- paracellular diffusion (passive uptake) 
Cl--OH- exchanger (active uptake) 
Cl--formate exchanger (active uptake) 
Cl--oxalate exchanger (active uptake) 
Cl- ion channel (passive efflux) 
K+ -Cl- co-transporter (active efflux) 
Na+ dependent HCO3- -Cl- exchanger (active efflux) 
 
 
[142][144] 
[146][145] 
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 Table 9 continued:
Substance 
Filtered 
(meq/24h) 
Reabsorbed 
(meq/24h) 
Excreted 
(meq/24h) 
Reabsorbed 
in the PT (%) 
Transport in the PT 
(uptake from lumen, efflux to interstitium) 
Reference 
 
Potassium 
(meq/day) 
 
10 
 
9.1 
 
1.5 
 
60-70 
K+ paracellular diffusion (passive uptake) 
Na+-K+ ATPase pump (active efflux) 
K+ -Cl- co-transporter (active efflux) 
 
[147][148] 
[149] 
Phosphate 
(g/day) 
6 5.51 0.49 60-70 
Na+ dependent HPO4 (active uptake) 
HPO4 diffusion (passive efflux) 
[150] 
 
Calcium 
(mg/day) 
 
10,000 
 
9,700 
 
300 
 
60 
Ca2+ paracellular diffusion (passive uptake) 
Ca2+ ion channels (passive uptake) 
Na+ -Ca2+ exchanger (active efflux) 
 
[151][144] 
Bicarbonate 
(meq/day) 
 
4,320 
 
4,318 
 
2 
 
85-90 
Extracellular dehydration and Intracellular generation of 
HCO3- (passive uptake) 
NaHCO3 co-transporter (active efflux) 
 
[142][148] 
[152] 
Water 
(L/day) 
169 167.5 1.5 60-80 
H2O paracellular diffusion (passive uptake) 
Aquaporin 1 and 7 H2O uptake (active uptake) 
[142][153] 
[154] 
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protein is located on the cytoplasmic side of the TJ strands and is involved in the 
sequential steps of assembly of adherent and tight junctions as well as the physical 
segregation of the membrane [157]. The remainder of the intercellular compartment 
between the TJs and basement membrane contain other types of cell-cell junctions; 
adhering junctions (zonula adherens), desmosomes (macula adherens) and gap junctions. 
The adherens junctions lie directly below the TJs and are responsible for holding the cells 
together through membrane glycoproteins (predominantly E-cadherin). Desmosomes 
also use cadherin proteins (desmoglein, desmocollin) to connect cells however they are 
connected to intracellular circular plaques to provide strong intercellular connections. 
Gap junctions allow small continuous channels to be formed between cells, allowing the 
movement of inorganic ions and other small water soluble molecules (smaller than 
1000kDa) [158]. 
With the intercellular movement of molecules restricted the major routes of nutrient 
and ion reabsorption occur by a variety of transporters and mechanisms through the 
cells. PTCs are also the major site of drug uptake, metabolism and excretion within the 
kidney, where most unbound polar drugs and metabolites are excreted in the urine after 
processing in the liver. Some of the transporters involved in drug uptake and secretion 
which are pharmacologically relevant in terms of drug-drug interactions are investigated 
in Chapter 2 and shown in Figure 20. Drug metabolism occurs in both the pars convoluta 
and pars recta cells through phase I (oxidation, reduction or hydrolysis) and II 
(conjugation) metabolism. Due to the increased amounts of smooth endoplasmic 
reticulum in the pars recta compared to other sites, S3 PTCs are also the main site of 
injury within the nephron from xenobiotic metabolite activation [159].    
The proximal tubule is also involved in secondary functions such as: immunomodulatory 
functions where the production of IL-6 in the kidney stimulates the production of IL-10 
in the liver influencing the outcome in endotoxin shock and gram-negative sepsis [160] 
and facilitating the activation of vitamin D from 25 hydroxyvitamin D to 1,25(OH)2D 
[161].  
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Figure 20: Structure of the PTC and the arrangements of proteins comprising the 
intercellular compartment. The diffusion of paracellular molecules are able to penetrate 
the proteins separating the cells through to the basal lamina and are dependent on size 
and charge. The location of drug transporters is also shown on the apical (lumen facing) 
or basolateral (basal lamina facing) membranes with the direction of molecule transport 
indicated by the arrows. Adapted from [162][163]  
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3.2.2. Cell sources for 2D models of the kidney   
PTCs are the optimal cell type for renal models in drug development due to the wide 
variety of functions performed by the proximal tubule in vivo including being the 
primary site of drug metabolism in the kidney. However, choosing the appropriate 
source for in vitro models is imperative when building robust models for the IVIVE of CDs.  
Primary human PTCs (hPTCs) are best suited when modelling the PT in vitro due to 
documented heterogeneity between species in the presence, localisation, kinetics or 
regulation of some transport systems. These include the Na+ -H+ (NHE) transporter 
regulation and apical tissue distribution, basolateral Na+, K+ -ATPase, organic anion and 
cation transport and paracellular pathways [164]. Moreover the down regulation of drug 
transporter expression (BCRP, OCT2, OAT3) between rat and human PTCs [165] and the 
differences in metalloproteinase inhibitor cytotoxicity between the rat, monkey and 
human [166] give evidence to the fact that human models are needed within the 
screening process in drug development for robust IVIVE to be made. hPTCs have been 
characterised in terms of high throughput screening as a predictive model (~76%-85% 
predictability) for tubular toxicity at early pre-clinical stage testing [167] and as a 
polarised primary cell culture model to look at xenobiotic transporter function [168]. 
They have also been shown to maintain measurable phase I (11 CYP enzymes and 3 
glutathione S-transferases) and phase II (3 UDP-glucuronosyltransferases and 3 
sulfotransferases) drug metabolising enzyme expression in in vitro culture [169]. 
Morphology, cellular energetics and redox status have also been validated in primary 
hPTC culture. However, it is well documented that the culture of epithelial cells in vitro 
can lead to the loss of differentiated properties, and in the case of PTCs: the loss of a 
brush-border plasma membrane, decreased expression and/or functionality of plasma 
membrane transporters, decreased expression of drug metabolising enzymes and a 
decreased mitochondrial function leading to the glycolytic pathway as the primary 
source of energy metabolism can occur [166]. There is also an issue of inter-donor 
variability which has been demonstrated by looking at the difference in marker gene 
expression in response to nephrotoxins from different hPTC donors [167]. This is 
problematic in terms of the reproducibility of results as the numbers of cells needed for 
drug screening assays far outweigh the availability of hPTCs. Two million PTCs are 
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typically isolated from one gram of cortical tissue [170], however for polarised 
monolayer assays approximately 3 million cells per 96-well plate are required. 
Furthermore issues of sterility are associated with primary cultures, and small degrees of 
contamination from other epithelial cell populations and interstitial fibroblasts can occur 
depending on isolation protocol used [166].           
Using transformed cell lines addresses the issue of cell number and donor variability as 
these cells can be cultured in vitro for prolonged periods of time (cell immortalisation). 
Mammalian cells are generally easier to immortalise than human cells, and lines 
originating from the kidney such as the MDCK line from canine and LLC-PK from porcine 
sources have been used to model the PT epithelia. MDCK cells have been extensively 
studied and retain many of the differentiated properties associated with the kidney 
tubular epithelium including apical microvilli, junctional complexes and lateral 
membrane infoldings and are able to transport sodium and water in an apical to 
basolateral direction [171]. This makes them an excellent source of cells to use as a 
standardised in vitro model for drug transport and interaction studies when manipulated 
to overexpress human transporters (Section 2.4.2). However, due to the extensive 
manipulation and inter-species variation they cannot be used as a model for the 
proximal tubule. The HEK293 cell line originates from an uncharacterised kidney cell in 
the human embryo transformed with sheared adenovirus 5 DNA. However, due to the 
manipulation process, the cells do not provide a relevant model, but are widely used in 
the transfection of drug transporters in screening and as an expression tool for 
recombinant proteins [172]. Human cell lines such as the HK-2, HKC and more recently 
the RPTEC/TERT1 have been developed from the manipulation of adult hPTCs utilising a 
variety of methods. HK-2 cells use the E6/E7 genes from the human papilloma virus 16 
(HPV16) to immortalise kidney tubular cells. These cells have survived for over one year 
in culture whilst retaining functional characteristics of primary PTC cultures such as 
typical BBM-associated enzymes and Na+ dependent glucose uptake [173]. However, 
dome formation, a hallmark of transporting epithelium that retains vectorial active 
transport, and the formation of functional TJs have not been identified in this cell line 
[174]. The HKC line is immortalised using a hybrid adeno-12-SV40 virus and when 
compared to the HK-2 cell line shows similar differentiated features in vitro. However 
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they also share the same caveat that they have the inability to form polarised 
monolayers capable of vectorial transport [175]. RPTEC/TERT1 cell immortalisation 
targets the overexpression of human telomerase (hTERT) with [176] or without [177] the 
SV40 Tag gene to stabilise telomeres and extend the cell life span. These cells have 
demonstrated growth for up to two years in culture and largely maintain the original 
differentiation status and functionality. The retention of high levels of brush border 
enzymes, significant Na+ dependent glucose uptake and phosphate uptake and the 
presence of microvilli have all been demonstrated by the cells throughout culture. 
Furthermore the formation of domes and the presence of TJs and desmosomes indicate 
the ability of vectorial transport as is present in situ, making them a valuable tool in the 
development of PTC models for many applications including drug screening.  
Utilising stem cells as a pluripotent and self-renewable source of cells could provide an 
abundant source of PTCs and other renal cells. Human embryonic stem cells have 
recently been differentiated into proximal tubule-like cells when cultured on Matrigel in 
renal epithelial cell medium and exposure to BMP2 and 7. Polarised monolayers of cells 
have been formed which expressed TJs and apical microvilli alongside the genetic 
expression of drug transporters present on hPTCs which were retained in both 2D and 
3D culture. However, the degree of de-differentiation is comparable to hPTCs in in vitro 
culture, although the issues of cell sourcing and inter-donor variability are addressed 
[178]. Induced pluripotent stem (iPS) cells also offer an abundant ethically sound source 
of cells which have been developed to derive cells of the renal lineage which give rise to 
apically ciliated tubular structures that co-express various PT markers [179]. However, 
the differentiation of pluripotent stem cells down renal cell lineages is still in the early 
stages and requires further characterisation before application in pharmaceutical and 
clinical research. Therefore, primary cells remain as one of the most reliable options for 
both applications in research as in vitro models and clinical uses.    
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3.2.3. Conclusion 
The proximal tubule is the main site of reabsorption, secretion and drug metabolism 
within the kidney. The anatomy of the PT, whilst fairly complex, relies on the 
compartmentalisation of the ultrafiltrate from the vascular network by the epithelial 
cells, non-parenchymal cells and ECM proteins to fulfill its function. To make and 
efficient barrier, TJ proteins must be present to restrict the intercellular movement of 
molecules and allow processing and vectorial transport of substances through the 
epithelial cell monolayer. A variety of cell sources exist to model the PT functions, 
although they fail to balance the ability of long term in vitro culture with the retention of 
specific functions found in vivo. Therefore, as one of the most reliable options is using 
primary cells as an in vitro model of the PT, focus on the method of culture to allow in 
vivo characteristics to be retained over culture in vitro must be applied. This chapter 
aims to address this aspect by investigating drug transporter genetic and surface 
expression and functionality on primary cells over time in in vitro culture, which has not 
been addressed in the literature to date. The proliferation of PTCs on protein coated 
porous membranes is also addressed to ascertain the formation of tight monolayers, 
thereby allowing the compartmentalisation that is found in vivo.     
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3.3. Materials and methods  
3.3.1. Cell Lines 
RPTEC (Human Renal Proximal Tubule Epithelial Cells; CC-2553) were purchased from 
Lonza (Belgium) at passage 3 and were cryopreserved at passages 5 and 7. Cells are 
guaranteed by the manufacturer for 15 population doublings (Pds), and transwell 
coating experiments used cells at a final passage of 7 (9 population doublings). 
Population doublings were calculated using Equation 2 (Appendices 2.2.).  
3.3.2. Cryopreservation and Cell Resuscitation 
RPTECs were cryopreserved at a density of 1.5 x 106 cells/ml in a freezing medium of 80% 
supplemented REGM basal medium (Lonza, Belgium), 10% (v/v) FBS (Fisher Scientific) 
and 10% (v/v) DMSO (Sigma Aldrich, UK). 
Cells were resuscitated by removal from liquid nitrogen storage and rapidly thawed in a 
37 °C water bath. Vials were half submerged and gently agitated until a sliver of ice 
remained. The vial was then transferred to the BSC and the cell suspension seeded into 
a T-flask containing pre-warmed supplemented REGM as per the manufacturer’s 
instructions (Lonza, Belgium).    
3.3.3. Medium Formulation 
REBM basal media was supplemented with 0.1% hEGF, 0.1% hydrocortisone 0.1% 
epinephrine, 0.1% (v/v) insulin, 0.1% (v/v) triiodothyronine, 0.1% (v/v) transferrin, 0.1% 
(v/v) Gentamicin and 0.5% (v/v) FBS. The complete growth medium was stored at 2 – 
8 °C and used within one month of preparation.      
3.3.4. Monolayer Culture  
3.3.4.1. T-flask culture 
RPTECs were cultured for 6-8 days with medium changes every 2 days until cells 
reached >80% confluency. On the day of passage, medium was aspirated and cells were 
washed with PBS. After the aspiration of PBS, pre-warmed 0.25% tryspin- EDTA was 
added to the flask and incubated at 37°C for 2 minutes for enzymatic digestion of the 
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cell adherence proteins to the tissue culture plastic. After incubation the trypsin 
digestion was quenched with approximately double the amount of pre-warmed culture 
medium and the cell suspension was centrifuged for 5 minutes at 220g. The supernatant 
was removed after centrifugation and the cell pellet was resuspended in the appropriate 
volume of culture medium. Cells were counted using the NC-3000 nucleocounter (see 
Section 3.3.5.) for calculation of desired seeding densities. RPTECs were grown for 1 
passage before seeding into other vessels for experimentation. 
3.3.4.2. Transwell culture  
Transwell types and seeding densities were established experimentally but final 
methods for transwell culture of RPTECs are as follows and summarized in Table 10. 
RPTECs were cultured on Corning 12-well polycarbonate transwell inserts (0.4 µm pore 
size, 1.12cm² surface area; Sigma Aldrich, UK). Before seeding, transwell plates were 
incubated with culture medium for 1 hour at 37°C to equilibrate. Culture medium was 
then aspirated and fresh medium was added to the wells. Cell suspension from tissue 
culture flask passages was added to the inserts at 4.5 x 105 cells/cm2. The plates were 
then incubated statically for 1 day at 37°C before transferring to a shaking incubator at 
90rpm at 37°C for the remainder of the culture period. Cells were cultured for 8-16 days 
with medium changes every 2 days.  
3.3.4.3. Plate culture 
Due to loss of cells during the assay duration in 96-well clear bottomed black plates (BD, 
UK), wells were coated in matrigel overnight at a concentration of 0.125 µg/µL (see 
Section 3.3.7.1. for full method) for P-gp and BCRP assays. For the OCT2 assay 48-well 
plates were coated at the same concentration.  RPTECs were seeded at 4 Pd 0, 5, 7 and 9 
at 1.6 x 104 cells/cm2 in 96-well 48-well plates and cultured for 4 days with medium 
changes at 2 days. Plates at Pd=0 were seeded directly from frozen whereas plates at 
later doublings were cultured in uncoated T-75 and T-175 flasks before seeding. The Pds 
were calculated according to the RPTEC growth curve generated (Appendices- Figure 58).       
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Table 10: Culture conditions for the various cell types used on different plates  
 
3.3.5. Cell counting- Aquadin orange and propidium iodide exclusion (automated cell 
counts) 
Automated cell counts via aquadin orange (AO) permeation and PI exclusion were 
carried out on the NuceloCounter NC-3000 automatic mammalian cell counter using one 
viability and cell count cassette.  
Total cells, viable cells, Non-viable cells (cells/mL) and viability (%) were calculated by 
the machine alongside estimated cell diameter (µm) from 200µl samples of cell 
suspension.    
3.3.6. Fluorescence assays to assess transporter functionality  
Functional assays were performed after cell culture (see Section 3.3.4.3.). The IC50 
concentrations for each of the inhibitors used for the transporters: P-gp (Section 
3.3.6.2.), BCRP (Section 3.3.6.3.) and OCT2 (Section 3.3.6.4.) and concentrations used 
are summarised in Table 6 (Chapter 2).   
3.3.6.1. Transport buffers for functional assays  
The transport buffer used was modified Krebs buffer based on [168] (see Table 11) 
balanced to pH 7.4.  
3.3.6.3. Fluorescence assay to assess BCRP functionality  
H33342 was made up to a stock solution of 4mM before being diluted at 200x in 
transport buffer to 20µM. Novobiocin was diluted from a stock solution of 6mM to a 
final concentration of 30µM and Ko143 was diluted from a stock solution of 10mM to a 
Cell line Plate type Seeding density 
(cells/cm2) 
Culture 
period 
Medium changes 
RPTEC Transwell (12-
well) 
4.5 x 105 16 days Every 2 days 
RPTEC 48 and 96-well 
plates (coated) 
1.6 x 104 4 days Every 2 days 
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final concentration of 50µM in transport buffer containing H33342.  RPTEC plates were 
washed twice in pre-warmed transport buffer after medium removal and incubated with 
the respective solutions in the fluorescence plate reader (FluoStar Omega). RPTEC plates 
were read at Ex: 355nm and Em: 460nm, gain 1000.  
 
Table 11: Modified Krebs buffer component concentrations 
Additive mmol/L g/L 
NaCl (Sodium Chloride) 140 8.18 
KCl (Potassium Chloride) 5.4 0.4 
MgSO4 (Magnesium Sulphate) 1.2 0.14 
K2HPO4 (Potassium Hydrogen Phosphate) 0.3 0.041 
Na2HPO4 (Sodium Hydrogen Phosphate) 0.3 0.036 
CaCl2 (Calcium Chloride) 2 0.22 
Glucose 5 0.90 
HEPES 10 2.38 
 
3.3.6.4. Fluorescence assay to assess OCT2 functionality  
ASP+ was made up to a stock solution of 4mM before being diluted at 200x in transport 
buffer to 20µM. Stock solutions of the Imipramine and Ipratropium were made up at 
20mM and diluted at 200x to 100µM in buffer containing ASP+. Pre-incubation solutions 
containing inhibitors at 100µM in transport buffer were also made up (see Table 7). 
RPTECs were washed once with pre-warmed transport buffer after medium removal and 
incubated with the pre-incubation solutions for 20 minutes at 37°C. After incubation the 
solutions were removed the incubation solutions containing ASP+ were applied and 
incubated for 50 minutes at 37°C. After incubation the cells were washed with ambient 
temperature transport buffer twice. To lyse the cells lysis buffer containing 1% TritonX-
100 (v/v) was applied for 1 hour at room temperature on a shaking platform at 100rpm. 
After pipette mixing the plate was centrifuged at 3000rpm for 15 minutes and the 
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supernatant sampled. The samples were read on the plate reader (FluoStar Omega) at 
Ex:485, Em:590, gain 1200.       
3.3.7. Transwell Coatings and monolayer integrity analysis 
Corning 12-well polycarbonate transwell inserts were used for the coating experiments 
using RPTECs. During coating periods, inserts were removed from the well plates and 
transferred to Nunc 6-well plates. Unless otherwise stated, during coating periods plates 
were kept in the BSC in covered plates. Corning transwell-Col (bovine collagen I and III 
coated wells) 12-well inserts were transferred into plates containing coated transwells. 
Wells were pre-incubated with medium to equilibrate and RPTECs (Pd=9) were seeded 
at 4 x 105 cells/ insert. Cells were cultured for 16 days on a shaking incubator at 90rpm 
with LY assays (as described in Section 2.3.7.) performed every 2 days from day 2. TEER 
measurements were taken before LY assays on each day and medium changes were 
performed after the assays.    
3.3.7.1. Matrigel Single Coating 
All pipette tips and stripettes were frozen, and medium, plates and centrifuge tubes 
were refrigerated before use and placed in cold beads in the BSC. Matrigel (BD 
Bioscience, UK) was thawed in the fridge and diluted in cold DMEM (Life Technologies, 
UK) to make a 0.125µg/µL solution. A volume of 150µL was placed in the inserts and 
refrigerated overnight. Before seeding with cells, the plates were removed to room 
temperature for 1 hour and residual medium was aspirated.  
3.3.7.2. Gelatin Single Coating  
A 0.2% gelatin in PBS solution was generated from 2% (v/v) gelatin (Sigma Aldrich, UK). A 
volume of 250µL was placed in the inserts and left overnight. Before seeding residual 
solution was aspirated and the inserts were rinsed with PBS. 
3.3.7.3. DOPA + Collagen IV Double Coating 
Tris buffer (10mM Trizma base at pH 8.5; Sigma Aldrich, UK) was used to dilute 3,4-
Dihydroxy-L-phenylalanine (DOPA; Sigma Aldrich, UK) to a 0.2% solution. A volume of 
150µl was placed in the inserts and left overnight.  
Page | 87  
 
Characterisation of human proximal tubule cells Chapter 3 
 
Human collagen IV (Sigma Aldrich, UK) was submerged in cold beads and slow thawed at 
4°C for 3 hours before suspending in HBSS to generate a 150µg/ml solution. DOPA wells 
were washed with PBS 3 times, and 200µL of collagen added to the wells. The plates 
were left for 2 hours at room temperature, and before seeding residual solution was 
aspirated and the inserts were washed with PBS and kept in the fridge.  
3.3.8. Immunostaining procedure and analysis   
Immunostaining was used to visually detect drug transporters using antibodies on the 
surface of RPTECs. The transporters and corresponding primary and secondary 
antibodies and antibody dilutions used can be found in Table 12. A range of dilutions 
were first carried out in optical bottom black plates (Nunc) to determine the appropriate 
dilution for each antibody. RPTECs were cultured on clear bottom 96-well black plates 
coated with 0.125µg/µL Matrigel for 4 days with medium changes every 2 days until the 
cells were confluent. On day 4 medium was aspirated and cells were washed with PBS 
before fixing in 4% paraformaldehyde (PFA; BD Bioscience, UK) for 20 minutes at room 
temperature. After aspiration of fixative and washing with PBS, wells were incubated 
with blocking buffer (1 x PBS, 5% normal goat serum, 0.3% triton-X100; Sigma Aldrich, 
UK) for 1 hour at room temperature away from light.  After aspiration of the blocking 
buffer, the primary antibody solutions diluted in 1% BSA were added to the wells and 
incubated at 4°C overnight away from light. Primary antibodies were then removed and 
wells were washed thoroughly (5 times) with PBS before the addition of fluorophore 
conjugated secondary antibodies and phalloidin to the wells (see Table 12). Antibodies 
were incubated for 1-2 hours at room temperature away from light and washed 
thoroughly with PBS after antibody removal. The cells were then counterstained with 
300nM DAPi (Life Technologies, UK) solution for 5 minutes at room temperature away 
from light before mounting with Prolong gold anti-fade mounting solution. 
Images were taken on the Nikon Eclipse Ti fluorescence microscope and analysed on the 
Nikon software NIS-elements. Individual cells were isolated in the image and the mean 
intensity in the FITC channel (AlexaFluor 488 bound to primary antibodies) was 
calculated. Exposures and LUTs were kept consistent through doublings for each 
transporter. The gain was kept consistent at 1.00x for all images. See Table 13 for 
analysis settings.  
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3.3.9. RT-PCR and preparation 
3.3.9.1. RNA extraction for RT-PCR 
RNA was extracted from cells cultured in T-25 flasks for 4 days with medium changes 
every 2 days. Extraction methods were carried out using the RNeasy Plus mini kit 
(Qiagen, UK) according to manufacturer’s protocols. The RNA concentration was then 
determined using the NanoDrop 2000c (Thermo Scientific, UK) before samples were 
frozen.  
3.3.9.2. RNA integrity assessment  
The integrity of the RNA was checked using the Agilent RNA 6000 Pico kit and Agilent 
2100 Bioanalyser (Agilent Technologies, UK). The gel and dye was prepared according to 
the manufacturers protocol and loaded onto the gel alongside the supplied RNA ladder. 
RNA was diluted down to 5ng/µl in RNase free water for analysis and 1µl was applied to 
the chip (11 samples per chip).    
3.3.9.3. RT-PCR 
All reagents and consumables were sourced from Life technologies for RT-PCR. The 
primers for the 4 genes of interest plus the reference gene primer can be found in Table 
14. The Taqman gene expression assays and express One-step superscript Universal 
reagents were used alongside stock RNA diluted to 50ng/µl. MicroAmp 96-well plates 
and films were used and the reactions were run in the StepOne plus RT-PCR system 
(Applied Technologies, UK). The standard cycling program was used according to the 
manufacturer’s protocol for the Express one-step SuperScript kit.   
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Table 12: List of primary antibodies to selected transporters and fluorescent secondary 
antibodies and fluorophores used in RPTEC immunostaining  
Antibody/ 
Fluorophore 
Host Antibody type Supplier Dilution 
Anti- P-gp Mouse Primary Abcam 1:10 
Anti- OCT2 Rabbit Primary Sigma Aldrich 1:20 
Anti- BCRP Mouse Primary Abcam 1:20 
Anti- MRP2 Mouse Primary Abcam 1:10 
Anti- MATE1 Rabbit Primary Abcam 1:50 
Anti- OAT3 Rabbit Primary Abcam 1:100 
AlexaFluor 488 
anti-mouse 
Goat Secondary Life 
Technologies 
1:1000 
AlexaFluor 488 
anti-rabbit 
Goat Secondary Life 
Technologies 
1:1000 
AlexaFluor 594 
Phalloidin 
- Secondary-
Conjugated 
Life 
Technologies 
1:40 
 
 
Table 13: Analysis settings for transporter fluorescence quantification (FITC channel) 
Transporter Number of cells analysed 
 Pd=0            Pd=5          Pd=10       Pd=15 
Exposure  
(s) 
LUTs 
P-gp 816 533 434 488 5 L: 200     R: 2400 
OCT2 770 546 450 436 10 L: 300     R: 2600 
BCRP 885 552 415 472 10 L: 300     R: 1300 
OAT3 833 581 431 480 7 L: 400     R: 1600 
MRP2 998 528 402 511 27 L: 1000  R: 2400 
MATE1 730 547 442 383 5 L: 200     R: 3000 
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Table 14: The name of the primers and identification designated by Life technologies 
Transporter Gene Assay identification 
P-gp ABCB1 Hs00184500_m1 
BCRP ABCG2 Hs01010790_m1 
OCT2 SLC22A2 Hs01010723_m1 
MATE1 SLC47A1 Hs00217320_m1 
OAT3 SLC22A8 Hs00188599_m1 
- GAPDH Hs02758991_g1 
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3.4. Results 
3.4.1. Transporter expression on hPTCs 
3.4.1.1. Transporter gene expression on hPTCs through passages 
RNA integrity was shown to be acceptable for all 3 biological repeats at each doubling 
(Appendices- Figure 59). Pds 5, 7 and 9 were used to investigate transporter expression 
and function to allow the expansion of cells up to a certain doubling whilst retaining 
similar transporter characteristic to the initial population. There was a lot of variability in 
BCRP and MATE1 expression between the biological repeats over the population 
doublings, as is seen in Figure 21. This is particularly evident at Pd=5 and 9 for BCRP and 
Pd=5 for MATE1. Due to this variability a significant difference was not observed in 
expression of these genes over the doublings compared to Pd=0. However the mean 
expression appears to increase over time for BCRP and decrease over time for MATE1 
compared to the initial population (Pd=0). P-gp expression was significantly decreased at 
Pd=5 and 7 compared to Pd=0 with a 34% and 39% decrease respectively. However, 
there was no difference at Pd=9 from the initial doubling, which could indicate the up 
regulation of the ABCB1 gene after a certain period of time in culture. OCT2 expression 
decreases over time, although only at Pd=7 and 9 were the fold changes significant with 
a 54% and 61% decrease respectively.  The decrease in gene expression concurs with the 
idea that over time specific cell functions including transporter expression is lost in vitro 
[20]. 
The OAT3 assay was also applied to the RNA at the various Pds alongside the other 
primers for the transporters mentioned above. However a CT value was not able to be 
determined at any of the Pds. Troubleshooting to investigate the cause of the assay 
failure included; running the OAT3 assay alone to eliminate possible fluorescent noise 
from the other transporter wells, increasing the number of cycles from 40 to 45, and 
increasing the RNA concentration from 50ng/µl to 70ng/µl. After consultation with the 
manufacturer no flaws in the assay methodology could be found so a new batch of 
primer was applied for OAT3 detection to the increased RNA concentration. However, a 
CT value still could not be ascertained. It was therefore decided to not pursue the OAT3 
gene expression detection via PCR when considering the time and cost limitations. OAT3 
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expression was detected on the RPTECs at all doublings via immunostaining (Section 
3.4.1.2.), so it can therefore be concluded that the primer used is not suitable for 
assessing OAT3 gene expression using the one-step RT-PCR method outlined in Section 
3.3.9.3.      
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Figure 21: The comparative gene expression of P-gp, OCT2, BCRP and MATE1 on RPTECs over 9 population doublings compared to Pd=0. Data 
labels display the fold change from Pd=0 (set at 0 for each transporter). (Mean value ± SEM, n=3). *  significant decrease in expression from the 
respective genes at Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc analysis)    
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3.4.1.2. Transporter visualisation in hPTCs through doublings  
Morphological differences were observed throughout the population doublings of the 
RPTECs. At Pd=0 dome formation, considered as a feature of transporting epithelia in 
culture, was exhibited and was also seen across some wells at Pd=5: OCT2 (Figure 26b), 
MATE1 (Figure 23b) and BCRP (Figure 22b) but to a lesser extent. This phenomenon is 
characterised by the swirl formation of cells which are slightly raised above the cell 
monolayer (Figures 22-27a). The cells also exhibited cobblestone morphology at the 
earlier doublings consistent with PTCs from the proximal convoluted tubule. However, at 
the later doublings (Pd=7 and 9) the cells are more elongated (Figures 22-27c and d) and 
resemble cells from the Pars Recta [180]. This change in morphology is most likely due 
to the extended period of culture in vitro and concurs with the idea that transporter 
expression on cell monolayers decreases over time.  
From the intensity analysis a decrease from Pd=0 is indicated for BCRP expression 
(Figure 22) although the mean intensity appears similar across all doublings. This 
decrease in expression however is visible in the images (Figures 22a-d) and is particularly 
noticeable at the later doublings (Pd=7 and 9) compared to Pd=0. For MATE1 the 
decrease in expression between Pd=0 and Pd=5 is extremely noticeable and is 
concurrent with the statistical analysis indicating a slight increase in expression at Pd=7, 
and a significant decrease (p ≤ 0.05) in expression overall compared to Pd=0 (Figure 23). 
A significant decrease in expression of MRP2 can also be visualised through the 
doublings compared to Pd=0 (Figure 24). The background noise from the antibody 
staining (green) was quite high in the original images, however the antibody applied 
does not cross react with other MRPs in the kidney and is more likely non-specific 
binding of the antibody (green spots). Contradictory to most transporters OAT3 
expression appears to increase over time, peaking at Pd=5 (Figure 25b). This can be 
visualised at Pd=5 and 9 with more cells stained for the transporter compared to Pd=0 
(Figure 25a), but less so at Pd=7 (Figure 25c). Non-specific binding of the antibody is 
again observed in these images. The decrease in intensity can be seen between Pd=0 
and 5 for OCT2, indicating a decrease in transporter expression (Figure 26e). However 
OCT2 expression appears to be similar at Pd=7 and 9, concurring with the PCR results 
that there is a significant decrease in gene expression from Pd=0, but contradicting the 
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intensity analysis. This may be due to the non-compliance of the intensity 
measurements to the ANOVA assumptions regarding the homogeneity of variance. 
Although the data was transformed to better satisfy the assumption (by using the log of 
each value) the results of the ANOVA are not as robust as if all the criteria were met. 
Consequently the results of the ANOVA on intensity can only be used as an indication 
rather than a cut off. For most transporters the images and intensity measurements 
correlate with the output of the ANOVA. This can be seen for P-gp expression also, 
where the intensity decreases from Pd=0 overall, but increases at Pd=7 from the other 
doublings (Figure 27). However this expression pattern contradicts the results of the PCR 
where expression at Pd=9 is increased from Pds 5 and 7. This may indicate that the 
protein translation in cells at Pd=9 might be inefficient compared to the earlier 
doublings, causing a decrease in the surface expression of P-gp.       
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Figure 22: RPTECs stained for BCRP (green) at (a) Pd=0 (b) Pd=5 (c) Pd=7 and (d) Pd=9 
with cytoskeletal (red) and nuclei staining with DAPi (blue) at 10x magnification. Mean 
intensity across doublings is shown in (e) (Log mean value ± SEM). *  indicates a 
significant difference in intensity from Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc 
analysis). Scale bars = 10µm     
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Figure 23: RPTECs stained for MATE1 (green) at (a) Pd=0 (b) Pd=5 (c) Pd=7 and (d) Pd=9 
with cytoskeletal (red) and nuclei staining with DAPi (blue) at 10x magnification. Mean 
intensity across doublings is shown in (e) (Log mean value ± SEM). *  indicates a 
significant difference in intensity from Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc 
analysis). Scale bars = 10µm     
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Figure 24: RPTECs stained for MRP2 (green) at (a) Pd=0 (b) Pd=5 (c) Pd=7 and (d) Pd=9 
with cytoskeletal (red) and nuclei staining with DAPi (blue) at 10x magnification. Mean 
intensity across doublings is shown in (e) (Log mean value ± SEM). *  indicates a 
significant difference in intensity from Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc 
analysis). Scale bars = 10µm    
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Figure 25: RPTECs stained for OAT3 (green) at (a) Pd=0 (b) Pd=5 (c) Pd=7 and (d) Pd=9 
with cytoskeletal (red) and nuclei staining with DAPi (blue) at 10x magnification. Mean 
intensity across doublings is shown in (e) (Log mean value ± SEM). *  indicates a 
significant difference in intensity from Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc 
analysis). Scale bars = 10µM  
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Figure 26: RPTECs stained for OCT2 (green) at (a) Pd=0 (b) Pd=5 (c) Pd=7 and (d) Pd=9 
with cytoskeletal (red) and nuclei staining with DAPi (blue) at 10x magnification. Mean 
intensity across doublings is shown in (e) (Log mean value ± SEM). *  indicates a 
significant difference in intensity from Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc 
analysis). Scale bars = 10µm   
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Figure 27: RPTECs stained for P-gp (green) at (a) Pd=0 (b) Pd=5 (c) Pd=7 and (d) Pd=9 
with cytoskeletal (red) and nuclei staining with DAPi (blue) at 10x magnification. Mean 
intensity across doublings is shown in (e) (Log mean value ± SEM). *  indicates a 
significant difference in intensity from Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc 
analysis). Scale bars = 10µm    
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3.4.2. Transporter functionality in hPTC 
3.4.2.1. P-gp functionality through population doublings 
Wells throughout the doublings range showed similar patterns of fluorescence in the 
presence and absence of Verapamil and Ketoconazole compared to those found in the 
MDCK-MDR1 cells over 71 cycles (Appendices- Figure 60). However the fold change in 
fluorescence of the inhibited samples is lower in the RPTECs over all doublings than in 
the cell line equivalent (Figure 11). This fluorescence decrease indicates a lower amount 
of functional P-gp present on the primary cells than the modified cell line (Figure 28). 
  At Pds 0 and 5 the difference in the fold change increase in fluorescence between the 
uninhibited cells and the inhibited samples at each doubling decreases by approx 15%, 
as is expected in primary cells due to reported the loss of functionality over time in other 
primary cell types. However, although there is a significant increase in fluorescence (p ≤ 
0.05) for Ketoconazole inhibited cells at Pd=5 compared to uninhibited cells, there is a 
high degree of variability which results in a SNR of 3. This indicates that the fluorescence 
at this doubling although significant may be obscured by methodological noise.  The 
variability in this sample can be accounted for by the difference in fluorescence between 
the 2 plates that were run, and is not seen through any of the other samples at that Pd. 
Therefore the amount of error may be explained by: a loss of functional P-gp in the cells, 
a loss of cells from that plate or the dilution of the solutions from incomplete removal of 
washing buffer in those wells. As the cells were seeded from the same batch and 
cultured in identical culture conditions between plates the most likely cause of this 
variation is the dilution of the Ketoconazole solutions in samples at that end of the plate.  
At Pd=7 the fold change in fluorescence decreases further in the Verapamil inhibited 
samples from the previous Pds, whereas Ketoconazole inhibited cells exhibit an increase 
from Pds 0 and 5. Although the SNRs for these samples are >3 indicating a reduced 
chance of interference of fluorescence by methodological noise, Verapamil inhibited 
cells do not demonstrate a significant difference in fluorescence from the uninhibited 
cells. Furthermore, at Pd=9 the highest fold change in fluorescence from uninhibited 
cells overall is exhibited by Ketoconazole inhibited cells at 6.96. The fold change in 
Verapamil inhibited cells is also the highest out of all Verapamil inhibited cells, and both 
Page | 103  
 
Characterisation of human proximal tubule cells Chapter 3 
 
samples exhibit a significant increase according to ANOVA with Tukey post hoc analysis.  
It can therefore be concluded that whilst functional on cells through all Pds, P-gp 
increases through the Pds with the most functional transporters present at Pd=9. This 
may be indicative of upregulation of P-gp at Pd=9, which would concur with an 
insignificant decrease in P-gp gene expression between Pd=0 and Pd=9 but a significant 
decrease at Pd=5 and 7 from Pd=0 (Figure 21). However, this is not corroborated by the 
immunostaining images (Figure 27), which show a decrease in fluorescence intensity 
from Pd=0 with the lowest mean intensity at Pd=9.      
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Figure 28: Calcein-AM (2.5µM) fluorescence in RPTECs at Pd 0, 5, 7 and 9 in the presence and absence of the P-gp inhibitors Verapamil (100µM) 
and Ketoconazole (100µM) after 71 cycles (approximately 71 minutes) Data labels above the bars display fold changes in fluorescence from 
inhibited cells compared to the uninhibited data set. (Mean value ± SD, n=36). *  indicates a significant increase in fluorescence from the 
respective samples at Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc analysis)  
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3.4.2.2. OCT2 functionality through population doublings 
The OCT2 assay was originally performed on cells cultured in 96-well plates as were the 
other assays. However, due to the nature of the assay there was a substantial loss of 
cells from numerous wash steps and buffer removal through the assay. Consequently 
the results of these assays demonstrated a large amount of error. The assay was then 
transferred to a 48-well format where a reduced amount of cell loss was observed 
through the assay.  
Basal uptake of ASP+ decreases significantly through the Pds (Figure 29) until Pd=9, 
where there is no significant difference from Pd=0 (p ≤ 0.05). This decrease is 
independent from noise signal as SNRs are above 4 at all Pds for basal ASP+ fluorescence. 
When looking at the fold change decrease between the inhibited and non-inhibited 
samples (Figure 29), the amount of ASP+ uptake appears to follow the same pattern as 
Calcein-AM fluorescence. At Pds 0 and 5 the amount of ASP+ uptake decreases, only to 
increase at Pd=7 with Imipramine exerting the more potent inhibition. However 
statistical significance is only exhibited between the uptake in the Imipramine inhibited 
samples versus the non-inhibited samples at Pds 0, 5 and 9. Furthermore the SNRs for 
the Imipramine inhibited samples are mostly below 4 indicating fluorescence is 
interfered with by noise. Only Imipramine inhibited cells at Pd=0 show a significant 0.67 
fold decrease in ASP+ from uninhibited cells which is independent from noise signals.  
From the data collected in this assay functional OCT2 appears to be only present on cells 
at the earliest doubling (Pd=0) and diminishes through the later doublings. However, 
due to the loss of cells through the assay at all doublings alongside interference from 
noise (Pd=5 Imipramine inhibited cells) and insignificant fluorescence results, OCT2 
functionality cannot be confirmed at the later doublings.  
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Figure 29: ASP+ (20µM) uptake in RPTECs at Pd 0, 5, 7 and 9 in the presence and absence of the OCT2 inhibitors Ipratropium (100µM) and 
Imipramine (100µM). Data labels above the bars display fold changes in fluorescence from inhibited cells compared to the uninhibited data set. 
(Mean value ± SD, n=12). *  indicates a significant decrease in fluorescence from the respective samples at Pd=0,  p ≤ 0.05 (ANOVA with Tukey 
post hoc analysis) 
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3.4.2.3. BCRP functionality through population doublings  
Similar to the assay results in the MDCK-BCRP cells (see Appendices- Figure 61 for full 
cycle graphs), RPTECs at Pd=0 show a significant increase (p ≤ 0.05) in fluorescence 
between the basal and Ko143 inhibited samples (Figure 30) indicating that Ko143 is the 
more potent inhibitor. However, no significant increase in fluorescence is exhibited in 
the presence of Novobiocin at Pd=0 or any other Pds, although all fluorescence 
measurements were independent of background noise.  
The fold changes in fluorescence from the uninhibited and Ko143 inhibited samples 
seem to agree with those found in the P-gp assay up until Pd=9. A significant decrease in 
fold change from the uninhibited sample is exerted at Pd=5 from Pd=0 before increasing 
at Pd=7 in the Ko143 inhibited cells. However, there is no significant increase in 
fluorescence at Pd=9 in the Ko143 inhibited cells from the uninhibited cells.  
As with the Ketoconazole inhibited cells in the P-gp assay (Figure 28) there is a high 
degree of variability displayed at Pds 0 and 7 in the Ko143 inhibited cells, which is not 
seen by the Novobiocin inhibited or uninhibited cells of the same Pd. This can again be 
attributed to operator error, specifically dilution of the incubation solutions with wash 
buffer in the Ko143 inhibited wells leading to a difference in starting fluorescence 
between the 2 plates.  
Despite this variability it appears that like P-gp, there is more functional BCRP on cells at 
Pd=7 demonstrated by the increase in fluorescence in the presence of Ko143 compared 
to the earlier Pds. This differs from both gene expression data which did not 
demonstrate a change in expression from the initial population (Figure 21) (although 
error between the repeats was high), and surface expression, where all doublings 
decreased in the intensity of BCRP from Pd=0. These differences in expression and 
functionality may be due to post translational inefficiencies at later doublings as 
described for P-gp.  
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Figure 30: Hoechst 33342 (20µM) fluorescence in RPTECs at Pd 0, 5, 7 and 9 in the presence and absence of the BCRP inhibitors Novobiocin 
(30µM) and Ko143 (50µM) after 71 cycles (approximately 71 minutes) Data labels above the bars display fold changes in fluorescence from 
inhibited cells compared to the uninhibited data set. (Mean value ± SD, n=36).  *  indicates a significant increase in fluorescence from the 
respective samples at Pd=0, p ≤ 0.05 (ANOVA with Tukey post hoc analysis) 
0
10000
20000
30000
40000
50000
60000
70000
80000
Hoechst 33342 Hoechst 33342 + Novobiocin Hoechst 33342 + Ko143
RF
U
 
Pd=0
Pd=5
Pd=7
Pd=9
1.04 
0.99 1.04 0.98 
1.57 
1.31 
1.76 
1.10 
* 
* 
* 
Page | 109  
 
Characterisation of human proximal tubule cells Chapter 3 
 
3.4.3. hPTC growth on porous surfaces  
RPTECs were seeded at a high density on transwells compared to MDCKII cells as per the 
supplier’s instructions and previous attempts at RPTEC culture on inserts. From 
preliminary experiments, culturing cells whilst continuously shaking appeared to yield 
better results in terms of monolayer integrity compared to static culture (Appendices- 
Figure 62). This generated the investigation into membrane coatings for improved 
RPTEC monolayer formation on the transwells and subsequent applicability to the fibres 
in the hollow fibre bioreactor. Coatings were selected either for their commercial 
availability (Bovine collagen coated PTFE transwell inserts), regular usage for cell 
attachment (Gelatin and Matrigel) or reference in literature (DOPA + Collagen IV) (Figure 
30) [181].   
All conditions failed to produce RPTEC monolayers at or below the 1% permeation 
threshold of LY over the 16 days (Figure 31). It is thought that primary cells are 
inherently leaky [182], however raised thresholds of 2-3% were still not achieved by the 
cell monolayers at any condition. TEER measurements inversely correlated the 
percentage LY permeation for each of the samples, however, their use in assessing 
monolayer integrity alone was not done due to high variability between readings for 
each well. This variability arose from the manual method used as opposed to the 
automated method utilised in Section 2.4.1.2.  
There is no significant (p ≤ 0.05) difference in LY permeation between the control 
(uncoated) and coated wells form days 2-6, although the lowest mean amount of LY 
permeation is observed at day 4. However, for Matrigel the mean LY permeation 
significantly decreases from day 8 onwards compared to the uncoated control. Although 
bovine collagen demonstrates the lowest amount of LY permeation at day 6, it is only 
from day 12 onwards that the permeation differs from the control. Gelatin exhibits the 
lowest amount of LY permeation at day 8 which is significantly different from the control, 
however, it is double the amount of the threshold value. DOPA + Collagen IV does not 
demonstrate any significant decrease in LY permeation from the control at any day, with 
the lowest amount of LY permeation at triple the threshold value and a fairly consistent 
LY permeation amount throughout the culture period.   
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To check the effects of the coatings on the porosity of the transwell inserts, wells coated 
without cells were also run alongside their seeded counterparts as porosity controls. The 
mean of the controls throughout the culture period was then taken for each condition 
(Figure 32) and an ANOVA test was run on the samples. The Matrigel coated wells 
demonstrate a lower permeability of LY throughout the culture period compared to the 
control, which is also confirmed by the ANOVA with a statistically significant decrease in 
the LY permeation. This indicates that the concentration of Matrigel applied blocks the 
pores and therefore does not accurately indicate monolayer formation via the LY assay.   
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Figure 31: Percentage LY permeation and TEER readings of RPTECs cultured on (a) Uncoated transwells or inserts coated with (b) Bovine 
collagen (c) Matrigel (d) Gelatin (e) DOPA + Collagen IV. RPTECs were cultured for 16 days with measurements every 2 days (Mean value ± SEM, 
n=3). *  indicates a significant difference in LY permeation from the uncoated control (a), p ≤ 0.05 (ANOVA with Tukey post hoc analysis)
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Figure 32: Percentage LY permeation of control PCT transwells at Uncoated (PCT) and 
coated with Bovine collagen, Matrigel, Gelatin, DOPA + Collagen IV. Percentage 
permeation was averaged over the 16 days (Mean value ± SEM, n=3). *  indicates a 
significant difference in LY permeation from the uncoated control, p ≤ 0.05 (ANOVA with 
Tukey post hoc analysis) 
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3.5. Chapter discussion and conclusion 
3.5.1. Discussion 
The focus of this chapter is on the characterisation of the transporter capabilities on 
primary cells over periods of in vitro culture dependent on population doublings. 
Extensive research has been applied to hepatocyte culture leading to the view that 
primary cells lose their specific functional capacity in in vitro culture [20]. In the case of 
PTCs, the loss of a brush border plasma membrane, decreased expression and/or 
functionality of plasma membrane transporters, decreased expression of drug 
metabolising enzymes and a decreased mitochondrial function leading to the glycolytic 
pathway as the primary source of energy metabolism is thought to occur [166]. As such, 
this is an important aspect to be considered in the generation of a BAK device 
incorporating this cell source, primarily as a measure of the degree of functionality of 
cells within the device. It is also crucial to consider the costs of cell culture and quantity 
versus functionality to reflect the end point of the device (for pharmaceutical research).  
A few options were available as a source of primary PTCs including freshly isolated cells 
or commercially sourced primary cells. Although freshly isolated cells would be 
comparatively cheaper, the harvest protocols and validation of PTC retrieval would 
introduce time and variability into the process compared to commercially sourced cells.  
From the panel of 6 drug transporters identified as pharmacologically relevant, genetic 
and surface expression and functionality of P-gp and OCT2 generally decreases, 
corroborating the widely held belief that drug transporters loose expression of culture in 
vitro. The genetic expression of BCRP and MATE1 contradicts this belief, although the 
functionality (for BCRP) and surface expression data complies. This belief is also 
contradicted by the surface expression of OAT3 where the mean intensity is significantly 
higher than the starting population in all for the later doublings. Although P-gp 
expression generally decreases over time as said before, there is an increase in genetic 
expression and functionality at the latest doubling, adding to the hypothesis that not all 
drug transporter capabilities are lost over time in in vitro culture. Upregulation of drug 
transporters could occur for renal proximal tubule epithelial cells over time in in vitro 
static culture, although this has not been investigated in literature.      
Page | 114  
 
Characterisation of human proximal tubule cells Chapter 3 
 
The second aspect of this chapter was to assess the extent of monolayer formation on 
porous inserts with different protein coatings in order to mimic the 
compartmentalisation aspect of the physiological environment of the PT. The results 
indicate that cells perform the best on Matrigel coated inserts. However, the hypothesis 
is that this decrease in LY permeation could be due to pore blocking by the gel instead of 
the cell monolayer formation. LY permeation could also be impeded by binding to 
Matrigel, as it is a complex ECM with a variety of components as opposed to the simpler 
coatings such as gelatin. However, no such interactions between Matrigel or general 
proteins and LY have been reported in literature.  
3.5.2. Conclusion 
A variety of cell sources are available to use as an in vitro model of the PT. However, due 
to the lack of retention of renal specific functions and transporter capabilities by cell 
lines, primary renal PTCs have been identified as the appropriate cell source. For device 
development, variability within the process needs to be minimal. For this reason 
commercially sourced PTCs from the same donor have been utilised over freshly isolated 
cells. To address the gap in the knowledge regarding the expression of drug transporters 
on PTCs over time in in vitro culture, the characterisation techniques mentioned above 
have been implemented with varying degrees of success. The fluorescence efflux assays 
developed previously (Chapter 2) have been successfully implemented in the primary 
cell cultures, although the uptake assay was not suitable due to cell loss throughout. 
Genetic expression via PCR has also successful in comparing the expression in P-gp and 
OCT2 over time compared to the initial doubling, whereas for BCRP and MATE1, the 
variability between biological repeats was too large. Surface transporter expression has 
also successful, showing a general decrease in the panel of transporters over time in 
culture. PTC culture has not successful on porous membrane inserts, even after coating 
with various proteins. For BAK device generation a suitable porous culture substrate is 
required. Therefore polymer blend development to generate a suitable renal cell culture 
substrate will be described in Chapter 4. 
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4.1. Introduction 
It is widely regarded that different cell types require different material surface 
properties for optimal proliferation, viability and functionality. In the case of primary 
human renal cells, surface properties such as hydrophilicity and negative charge are 
thought to be preferable. It has been reported that some positively charged surfaces 
achieved by coatings (e.g. poly-D-lysine) may enable renal cells to attach more easily, 
however, they might not encourage cell proliferation and/or sustain growth [181]. The 
adhesiveness of a surface can be influenced by the amount of functional groups such as 
carboxyl and hydroxyl groups present [183], which is paramount when looking at protein 
adsorption and subsequent cell adhesion on porous surfaces. However, in the case of 
porous surfaces, the roughness determined by the existence of the pores may reduce 
the available surface area, as well as inhibiting the contact with the existing functional 
groups [184]. This consequently results in loose cell attachment. 
A hollow fibre bioreactor for cell culture typically depends on fibre porosity to allow 
nutrient and gas exchange to the cells. Considering this, fibres must be suited to the cell 
type as well as being sufficiently porous to allow the permeation of nutrients and 
metabolites. It is therefore important to consider membrane tailoring i.e. using 
polymers with additives or using treatments during production, as opposed to 
membrane coating for the hollow fibre production. Whilst coating commercially sourced 
fibres could be more consistent, there is a possibilityof lowering the degree of porosity 
as a result of pore blockage due to coatings (see Section 3.4.3.), although this deduction 
needs further confirmation. Therefore producing hollow fibres with tailored properties 
is the preferable option, and will be adopted in this thesis.  
This chapter describes the production of four types of polysulfone (PSF) based 
membranes using several different types of molecules as additives: polyvinylpyrrolidone 
(PVP), malonic acid (MA) and glutaric acid (GA). Characterisation of the generated flat 
sheet membranes was performed with the aim of investigating the physical properties 
of each blend and to assess cell performance with regards to cell adhesion on different 
chemistries. This knowledge was the used for the production of hollow fibres to be used 
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in the bioreactor. The hollow fibre production and characterisation together with device 
assembly and cell cultivation will be described in Chapter 5.  
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4.2. Review of literature  
4.2.1. Biomaterial surface features desirable for cell growth  
Biomaterials are used in a wide range of applications including medical implants and 
devices, scaffolds for cellular models and tools for cell culture and expansion. 
Accordingly there are a variety of requirements that a biomaterial must possess 
depending on their application with the major one being biocompatibility. However 
biocompatibility is a complex phenomenon and is difficult to define due to the fact that 
the applications of the materials are specific to the parts of the body or cell type in 
question. For medical devices and implants, materials should not initiate immunological 
or inflammatory reactions, generate toxic or carcinogenic products or produce 
unwanted deterioration of the material and tissue to be classed as biocompatible. For 
cell scaffolds and cell culture equipment, biocompatible materials are also required to 
take into account the properties of the cell type(s) that are being cultured when 
considering the composition and configuration of surfaces and biomolecules [185].  
Cells do not interact directly with the man-made surface when cultured on biomaterials; 
instead there is a rapid chain of events initiated when the material is exposed to the 
biological fluid or medium containing serum. This results in a layer of extracellular 
biomolecules adsorbed to the surface (Figure 33a). Therefore the biological 
adhesiveness of the surface to proteins is a major factor in the biocompatibility of the 
selected material. Initial contact with water produces a mono or bi-layer of water 
molecules on the surface. The molecule arrangement is dependent on the material 
properties. Hydrophilic (wettable) surfaces have the ability to interact with water 
molecules in two ways depending on their reactivity. Highly reactive surfaces form a 
hydroxylated (OH- terminated) surface from the dissociation of water molecules, whilst 
less reactive surfaces interact with intact water molecules via hydrogen bonding. In 
contrast, hydrophobic (non-wettable) surfaces have a weak tendency for binding water. 
The subsequent binding of hydrated ions form a water shell, to which small proteins 
from the fluid, serum or coating begin to adsorb to [186]. Alongside wettability, other 
physiochemical properties that are thought to influence protein adsorption to a surface 
include: the characteristics of the protein, the surface free energy, chemical nature, 
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thickness, density and roughness of the material, as well as the mobility of the exisiting 
functional groups on the surface. On hydrophilic surfaces, protein adsorption occurs 
through polar and ionic interactions between the hydrophilic amino acid side chains and 
the water layered surface, leading to a weak and reversible adsorption of the intact 
protein. However protein adsorption on hydrophobic surfaces is often irreversible due 
to the dehydration of the interface providing the entropic driving force for binding. This 
leads to a conformational structural change of the proteins with partial or total 
unfolding thus exposing the hydrophobic core to the hydrophobic patches of the surface. 
The degree of conformational change of the protein balances the strength of the 
protein- surface interactions, resulting in the distribution of the polar charged residues 
towards the aqueous boundary [185]. The electrostatic interactions between the 
charged residues of the protein and the surface play a lesser, but equally important role 
in protein adsorption. As proteins generally bear a net negative charge, anionic surfaces 
generally adsorb less protein that cationic surfaces [187]. Secondary layers of proteins 
bind reversibly to the protein adsorbed on the surface due to the low affinity of the 
molecules. This process occurs within the first few seconds of contact between the 
surface and the protein contained in the medium and promotes and facilitates cell 
adhesion, growth and proliferation.               
Cell adhesion relies on the affinity of the anchorage proteins on the cell membranes 
(primarily integrins) to the proteins adsorbed on the surface. From the initial association 
if protein affinity is high, the cells will start to spread across and interact with the surface 
forming points of adhesion (i.e. focal points) and thus initiating the biochemical cues for 
growth and proliferation. However if the affinity to the surface proteins is low the cells 
will stay loosely attached and display a rounded morphology, which in most cases 
eventually leads to apoptosis (Figure 33b). Generally, hydrophilic surfaces promote cell 
adhesion due to the adsorption of proteins in their native conformation. In contrast 
hydrophobic surfaces counteract cell adhesion due to the conformational change of 
adsorbed proteins causing a lack of specific recognition sequences required for 
extracellular protein interaction [186].    
Page | 120  
 
Tailoring polymer blends for hollow fibre production Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Mechanisms of (a) protein adsorption and (b) cell attachment on hydrophilic and hydrophobic surfaces. Proteins on hydrophilic 
surfaces retain their native conformation and adsorb to the surface, whereas proteins interacting with hydrophobic surfaces partially or fully 
denature to protect their hydrophobic cores.  As a result cell adhesion and proliferation could be affected with cells exhibiting a rounded 
loosely attached morphology on hydrophobic materials. Light blue dots represent water molecules, red dots represent hydrophilic portions of 
the proteins with the hydrophobic cores indicated by the purple dots.Modified from [185] and [186] 
(a) 
(b) 
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4.2.2. Materials used for renal replacement devices and potential therapies  
Early BAK devices consisted of renal cells seeded into a haemodialyser with the intention 
of developing a clinical tool to surpass conventional dialysis treatments. Haemodialyser 
cartridges contain hollow fibres made from a range of porous semi-permeable 
membranes with properties supporting the low, medium and high flux of small 
molecules (e.g. electrolytes, low molecular protein breakdown products from blood). 
The movement of these molecules occurs mainly through diffusion along the 
concentration gradient from the blood to the dialysis fluid, but is also subject to 
convection, adsorption to the membrane and as a consequence of fluid flux across the 
membrane. Haemodialysis cartridges are not best suited for the cultivation of renal cells 
within the lumen of these fibres due to the presence of a smooth skin layer designed to 
prevent the adhesion of erythrocytes and proteins from the blood on the inside, and a 
larger porous surface on the outside [12]. They have, however, provided a valuable 
starting point for bioreactor design and material choice for renal cell cultivation.   
4.2.2.1. Cellulosic and synthetic membranes 
Regenerated cellulose membranes are formed from the dissolution of cellulose (chains 
of β linked D-glucose subunits) pulp, and have a wide variety of applications including 
wound healing, encapsulation and as hollow fibre membrane material in the early 
iterations of haemodialysis cartridges [188]. Modifications to the hydroxyl groups on the 
cellulose subunits (cellobiose unit) have produced a variety of membranes with 
increased biocompatibility (reduction in complement activation), whilst retaining the 
hydrophilic and microporous properties [189]. However, when looking at the 
applicability of RC membranes for BAK or kidney in vitro models, poor renal cell growth 
has been observed, with primary hPTCs unable to form differentiated epithelia on these 
membranes [181].  
Synthetic membranes utilised in haemodialysis cartridges can be divided into four 
groups depending on the techniques used for hydrophilisation: hydrophilic by nature, 
hydrophilic by process, hydrophilic by blending and hydrophilic by treatment. PSF, 
polyacrylonitrile (PAN) and polyamide are hydrophobic by nature and require treatment 
to render them hydrophilic to increase biocompatibility and allow the filtration of blood 
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toxins, whereas ethylvinylalcohol co-polymers (EVALs) are naturally hydrophilic [189]. 
Out of these four groups, PSF based membranes have been the most commonly utilised 
in the development of BAK devices, although EVALs have been extensively used for BAK 
generation by Saito et al [190].  
PSFs are amorphous (non-crystalline) thermoplastic polymers characterised by the 
presence of the para-linked diphenylsulfone group as part of the aromatic backbone 
repeating units. There are three commercially relevant types of PSFs which exhibit slight 
changes in some of the polymer properties: PSF, polyethersulfone (PES) and 
polyphenylsulfone (PPSF). Generally PSF membranes exhibit excellent thermal stability, 
a high glass-transition temperature, minimal shrinkage during fabrication, high strength, 
stiffness and resistance to many forms of radiation. The hydrophilicity of PES is higher 
than PSF due to the substitution of the hydrophobic isopropylidene unit with the 
hydrophilic sulfone group [191]. Differentiated hPTC epithelium has, however, been 
observed on both PES and PSF membranes, although the formation was relatively slow 
[181]. PSFs also have the ability to be blended with various molecules in order to modify 
their surface characteristics. A prime example is the addition of PVP to increase the 
hydrophilicity of the PSF or PES membranes. This has been historically utilised in water 
separation and more recently BAK applications. Untreated PES/PVP and PSF/PVP 
however, have not been able to produce differentiated PTC epithelia in some 
experiments [181][192]. Other moieties blended with PSF or PES bases include Fullcure 
(an acrylic based monomer) [181] and the phospholipid polymer PMBU [193] which 
reported improved renal epithelium formation and increased cytocompatability when 
compared to the unblended membranes respectively. 
Other membranes which have been employed (primarily in 2D culture platforms) include 
polycarbonate (PCT) and polyester (PET) membranes, most commonly in the form of 
commercially available Transwell© inserts. When applied to hPTCs there were 
contradictory reports in the literature regarding the achievement of polarised cell 
monolayers [194][168], although the results from the RPTEC growth on porous 
membranes in Section 3.4.3. concurred with others [194]. Monomeric units of the 
various materials used for renal cell culture platforms are shown in Figure 34 and a 
summary of membrane properties is provided in Table 15.     
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Figure 34: Structures of polymer units commonly used for haemodialysis, BAK devices 
and renal cell growth applications 
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Table 15: Properties of membranes commonly used for haemodialysis, BAK devices and renal cell growth applications 
Polymer Sub-types Properties Applications Use in PTC cultivation References 
Regenerated 
cellulose (RC) 
 
 
 
 
HemophanTM- 
Etherification with DEAE, 
SMCTM- Substitution of 
benzyl with hydroxyl group, 
PEG modified cellulose, 
Cellulose acetate 
Very hydrophilic (CA ~12˚), 
Functional hydroxyl groups 
on the surface, 
Negative surface charge (-
9.5mV) 
Haemofiltration 
cartridges, Reverse 
osmosis membranes, 
Wound care, 
Encapsulation, Cell 
scaffolds 
Investigation into PTC growth [188][181] 
[195][196] 
[197][198] 
Polysulfone 
(PSF) 
 
 
 
 
PES 
PES bound with PVP 
PSF bound with PVP 
PSF bound with FC 
PSF bound with PMBU 
Hydrophobic (CA ~70˚), 
Functional sulfone groups 
on the surface, 
Negative surface charge (-
2mV) 
Haemofiltration, 
Ultrafiltration 
membranes, Medical 
instruments, Gas 
separation, Industrial 
filtration 
Membranes coated with Poly-L-
lysine, Gelatin, Pronectin, 
Collagen and deposited ECM 
Haemofiltration / hollow fibres 
coated with: Pronectin L, 
DOPA+Collagen IV 
[181][190] 
[191][192] 
[131][195] 
 
Ethyvinyl 
alcohol co-
polymer (EVAL) 
 Hydrophobic (CA ~65˚), 
Functional hydroxyl groups 
on the surface, 
Negative surface charge 
Haemofiltration, Cell 
scaffolds, Hydrogels, 
Active food packaging 
Haemofiltration fibres coated 
with attachin for PTC cultivation 
[190][199] 
[200][201] 
[202] 
Polycarbonate 
(PCT) 
 
 Hydrophobic (CA ~63˚), 
Functional carbonate 
groups on the surface, 
Negative surface charge (~-
25mV) 
Cell culture platforms, 
Electronics, Packaging 
2D renal model using PCT 
transwell inserts, Renal tubule-
on-a-chip microfluidic device 
coated with Matrigel 
[168][203] 
[204] 
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Table 15 continued 
 
Abbreviations: DEAE; dimethylaminoethyl, CA; Contact angle, mV; Millivolts, FC; Fullcure, UPy-U; ureido-pyrimidinone- urea, PLGA; poly(lactic-
co-glycolic acid) 
Polymer Sub-types Properties Applications Use in PTC cultivation References 
Polycaprolactone 
(PCL) 
 
UPy-U 
PCL and PLGA 
composite 
Hydrophobic (CA ~82˚), 
Functional carboxyl group on the 
surface, 
Negative surface charge (-36mV) 
Drug delivery, 
Sutures, Wound 
dressing, Fixation 
devices, Cell scaffolds 
Electrospun membranes for 
PTC cultivation, Biomaterials 
development for in vivo 
applications 
[194][205] 
[206][207] 
[208] 
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4.2.2.2. Surface modifications for renal cell attachment and proliferation 
To aid the cell attachment and proliferation of renal cells on the membrane types 
described, various methods of surface treatment have been employed. These methods 
either increase the presence of functional groups on the surface and increase 
hydrophilicity, or increase the amount of protein adsorption on the surface of the 
membranes preferable for hPTC cultivation. Here, several methods of interest for the 
current application such as: oxygen plasma treatment, oxidising agent treatments and 
protein coatings are described.  
Oxygen plasma treatment is utilised in many disciplines for cleaning surfaces and 
depositing functional groups or activating the surface. This occurs when oxygen plasma 
consisting of neutral atoms, atomic ions, electrons, molecular ions and molecules in 
both excited and ground states, interacts with the surface. Compared to untreated 
surfaces/membranes, the deposition or activation of functional groups (e.g. carboxylic 
groups) facilitates protein adsorption on the surface, thus aiding renal cell attachment 
[181].  
Oxidising agents can also be used to introduce functional groups such as carboxyl and 
hydroxyl groups on the surface rendering it more hydrophilic. Combinations of acids (e.g. 
nitric, phosphoric, sulphuric acid) with hydrogen peroxide can alter the surface 
chemistry of a polymer via various reactions, the most common being hydrolysis [209]. 
When applying to PES/PVP membranes, hydrogen peroxide was shown to reduce water 
contact angles by approximately 20˚ when compared to the untreated sample (62.5˚) 
[181].    
Another type of surface modification widely used in the cultivation of specific cell types 
is the coating of the culture surface with a specific protein. Most often, these are either 
proteins which induce a general change in the surface characteristics of ECM proteins 
specific for cultivation of the cell type in question. For example poly-L-lysine (PLL) bears 
a net positive charge and has been shown to aid cell attachment [210]. As outlined in 
Table 8 there are many proteins which make up the basement membrane for the 
proximal tubule with collagen IV being the most abundant. As a result, when cultured on 
Tissue culture plastic (TCP) coated with either collagen IV, laminin or complex ECM 
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coatings (i.e. a mixture of 4 basement membrane proteins) hPTCs exhibited excellent 
monolayer and tight junction formation [131]. However when applying ECM coatings to 
polymer surfaces for use in BAK generation, collagen IV was not shown to generate 
confluent monolayers of hPTCs with tight junction formation on PSF+PVP membranes. 
Treating the surface with DOPA before applying the collagen IV coating appeared to 
generate differentiated hPTC epithelium after one week [181][192]. Alternative ways of 
generating more complex ECM coatings that simulate the physiological stimuli 
experienced by cells in vivo are to apply a combination of proteins (complex ECM 
coatings) or use the ECM proteins deposited by other cells (e.g. HK-2 cells [131], 
Matrigel). However, these methods of protein coating are costly, and are less 
reproducible when complex ECM deposition from cell lines is used in terms of batch 
variation and heterogeneity of protein deposition. Furthermore, issues such as pore 
blocking (as indicated in Section 3.4.3.) are detrimental when the transport of substrates 
through cells are being assessed.   
4.2.2.3. ECM scaffolds for organ regeneration 
Recent developments in bioengineering and regenerative medicine have identified the 
use of decellularised scaffolds as a method for organ regeneration. These preserve the 
native architecture and ECM structure whilst removing the cellular components. The 
most widely utilised method for decellularisation is flushing the structure with ionic 
detergent to remove cells from the basement membranes. Although this is effective at 
completely removing cells, there has been evidence of some ECM disruption. Alternative 
methods include the use of other chemical agents such as solvents and alcohols, 
biological agents such as enzymes or chelating agents and physical methods involving 
temperature, force or pressure [211]. Reseeding of simple structures such as vessels and 
bladders has demonstrated good short and mid-term results when implanted into 
patients [212]. Successful decellularisation of the more complex kidney structure has 
also been achieved [213], and decellularised ECM scaffolds seeded with proximal tubule 
cells have been developed to generate functional in vitro proximal tubule models [214]. 
However these models are yet to be optimised and validated for use in clinical and 
pharmaceutical applications. Taking this into consideration for the generation of in vitro 
Page | 128  
 
Tailoring polymer blends for hollow fibre production Chapter 4 
 
renal models, membrane tailoring by optimising formulations or surface treatments are 
the preferred options. 
4.2.3. Methods of membrane production  
The fundamental methods for asymmetric polymeric membrane production have been 
developed over the years to generate membranes with tuneable features for separation 
processes. These methods are still utilised for many of the membranes commonly used 
(see Table 15) for renal cell growth and bioartificial kidney devices.  
The dry-wet phase inversion method also known as non-solvent induced phase 
separation (NIPS) was originally developed for seawater desalination using cellulose 
acetate [215]. The polymer and additives are most often dissolved in a strong highly 
volatile solvent to produce a dope solution which can then either be cast onto a flat 
surface to produce asymmetric membrane sheets, or processed through a spinneret to 
produce hollow fibres. Two desolvation steps then take place to form the porous 
polymer membrane: solvent evaporation immediately after casting and solvent-non-
solvent exchange when the casted film is immersed in the non-solvent 
(coagulation/gelation) bath. A smooth skin layer is formed on the top of the flat 
membranes due to the fast solvent evaporation, followed by the diffusion of solvent out 
of the film in exchange for the non-solvent, which is usually water. Thus the creation of 
solid films from liquid dispersions can be generated by solvent/non-solvent exchange. By 
altering the amount of polymer in the dope solution, the properties of the membrane 
(e.g. the porosity of the skin layer) can be modified. Polymer membranes produced by 
this method possess a broad pore size distribution range which limits selectivity for size-
based separations, but is adequate for nutrient and gas permeability for cell cultivation 
[195][216]. To address this issue, other phase separation methods have been developed 
to generate membranes with more isotropic cross-section morphologies. These methods 
include thermally induced phase separation (TIPS), evaporation induced phase 
separation (EIPS) and vapour induced phase separation (VIPS) which are typically used in 
the production of commercially available microfiltration membranes [216]. 
Electrospinning has gained interest as a method for producing membranes over the past 
5-10 years due to its ease of use, adaptability and the ability to engineer fibres on the 
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nanometer scale in terms of porosity and surface topography. This method uses a high 
voltage source to apply a charge of a certain polarity into the polymer solution, which is 
then accelerated towards a collector of opposite polarity or ground plate. As the 
solution travels through the atmosphere the solvent evaporates, depositing the solid 
polymer onto the collector. Electrospinning can be used to make sheets or fibres from 
biodegradable, non-biodegradable and natural materials with typical diameters ranging 
from nanometers to micrometers. This method has been utilised in tissue engineering 
[217][218][219]  and drug delivery [220][221] applications especially due to the size of 
the fibres produced [222], but has also been applied in separations research [223][224]. 
4.2.4. Conclusion 
There are many factors that affect the biocompatibility of a biomaterial including: 
wettability, surface chemistry, surface free energy, surface roughness and the mobility 
of functional groups on the surface. These characteristics ultimately affect the degree of 
protein adsorption on the surface, subsequently affecting cell adhesion and proliferation. 
There has been a wide range of materials used to generate renal cell culture substrates 
for both BAK devices and in vitro model development. These have employed both 
material and surface modification and protein coating. The most common of these 
polymers if PSF as it is versatile, robust and can be blended with additives to generate 
membranes with modified surfaces. However, as of yet there is no polymer porous 
membrane material that is standard for the cultivation of renal cells. This chapter aims 
to address this need by comparing standard polymer blends with experimental blends in 
order to develop an optimal renal cell culture substrate for the cultivation of PTCs within 
the BAK device.   
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4.3. Materials and methods  
4.3.1. Formulation 
Four polysulfone based dope solutions were created to generate porous polymer 
membranes. Weight percentage of polymers and solvent in each solution can be found 
in Table 16. PSF pellets were dissolved in 1-methyl-2- pyrrolidinone (NMP) by continuous 
stirring using a magnetic stirrer for 24 hours to ensure PSF was thoroughly dissolved. 
PVP, MA or GA in powder form (Sigma Aldrich, UK) were then added and continuously 
stirred for a further 24 hours.  
 
Table 16: Amounts of solvent and polymer used in the generation of PSF based dope 
solutions  
 
4.3.2. Membrane generation 
Flat sheet membranes were generated by casting the dope solutions described in 
Section 4.3.1. onto glass slides using a spin coater (Delta 20BM; BLE, Germany)  and 
immersing in water, thus allowing phase inversion of the solvent to generate the solid 
membrane. 1mL of the dope solution was applied to a glass slide (4cm x 4cm) and spun 
at 500rpm for 30 seconds. Coated slides were then removed from the spin coater and 
immersed in deionized water. After natural peeling, the glass slides were removed and 
water was changed twice a day for 48 hours as part of membrane washing in order to 
remove any traces of unreacted reagents.  
Dope 
solution 
PSF (%) PVP (%) MA (%) GA (%) NMP (%) 
PSF 25 - - - 75 
PSF + PVP 20 5 - - 75 
PSF + MA 20 - 3 - 77 
PSF + GA 20 - - 3 77 
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4.3.3. Wettability  
Wettability of the membranes was measured by the static sessile drop method using an 
OCA 20 goniometer (DataPhysics, Germany). 2µL water drops were dispersed onto the 
membrane and captured after approximately 5 seconds to allow the drop profile to 
settle. The mean advancing contact angles of the drop were then calculated using the 
SCA20 software. The reported contact angles are an average of 6 different drops (12 
contact angles) per membrane. 
4.3.4. Surface chemistry  
Flat sheet membrane samples were analysed using the K-AlphaTM X-ray photon 
spectrometer system (Thermo Scientific, UK). A survey scan was performed to 
determine the chemical and atomic signatures. The binding energies were then cross 
referenced to functional groups and bond types present using the Handbook of X-ray 
Photoelectron Spectroscopy [225]. Two points were measured on each membrane at a 
take off angle of 90˚ and analysed using the Thermo Scientific Avantage data system.   
4.3.5. Surface topography   
Membrane topography was analysed using the Veeco Explorer atomic force microscope 
(AFM) (Veeco Instruments, USA). Membranes were cut to fit the sample platform and 
analysed on the tops and bottoms of each polymer blend. Three points on each of the 
samples were analysed at both 20µm x 20µm and 5µm x 5µm sample areas and the 
maximum peak height (Rmax), average roughness (Ra) and root square mean roughness 
(Rrms) were calculated by the software.  
4.3.6. Membrane and fibre imaging  
Membranes were imaged using the Field Emission Gun Scanning Electron Microscope 
(FEGSEM) (Carl Zeiss, Germany) after sputtering with gold (Emitech SC7640 Sputter 
Coater; Quorum Technologies, UK). The coating was applied for 90 seconds in a vacuum 
(10-2mbar) with a current of 20µA at 20kV to produce a coating thickness of 
approximately 10nm. Images were acquired at 1, 5, 10 and 15 thousand times 
magnification using the SE2 lens.  
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4.3.7. Membrane sterilization 
Membranes were cut into discs with a surface area of 1.8cm² and placed in 24-well 
plates. Each membrane was tested twice with the following sterilization methods: 
4.3.7.1. Immersion in IMS 
1mL of 70% IMS was placed in each well and kept at RT in a covered plate in the BSC for 
30 minutes. The IMS was then removed and the membranes were left to dry at room 
temperature in a covered plate. 
4.3.7.2. Incubation with antibiotic/antimycotic solution 
1mL of antibiotic/antimycotic solution containing 10,000 units/mL penicillin G, 10mg/mL 
streptomycin and 25µg/mL amphotericin B (Sigma Aldrich, UK) was placed into each well 
and kept at 4°C for 6 hours in a covered plate. The solution was then removed, the wells 
were washed 3 times for 3 minutes with sterile PBS and then left to dry at room 
temperature in a covered plate.  
4.3.7.3. Autoclaving and sterility testing      
Discs were placed in autoclavable boxes before inserting into plates. Discs were then 
autoclaved for 15 minutes at 121°C before placing into plates in the BSC.   
After sterilization, one plate was incubated with nutrient broth (Sigma Aldrich, UK) 
prepared to manufacturer’s instructions (13g to 1L deionized water) for 48 hours at 37°C. 
After incubation 1mL of the broth was removed and the optical density (OD) was read at 
600nm against a sterile broth blank and a positive control of E.coli K-12 (NCIMB, UK) 
incubated for 48 hours at 37°C.  
500µL of the broth was also removed and spread onto nutrient agar spread plates 
(prepared to manufacturer’s instructions- 40g agar, 13g nutrient broth, 1L water; Sigma 
Aldrich, UK) using aseptic technique. The positive control was diluted 10 and 100 fold 
before plating. The plates were then incubated at 37°C overnight and colonies were 
manually counted.    
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The second plate of membranes was then imaged using the FEGSEM to ascertain any 
damage to the membranes during the various sterilization processes.  
4.3.8. Cell viability assay- Presto blue  
The Presto Blue assay incorporates resazurin, an oxidation-reduction (REDOX) indicator 
to detect cell metabolic activity. When applied, resazurin, a virtually non-fluorescent, 
non-toxic molecule permeates into the cells and is reduced to produce the fluorescent 
resorufin. Viable cells continuously reduce resazurin, allowing the quantitative measure 
of cytotoxicity and cell viability.   
Before seeding, 24-well plates containing autoclaved membrane discs attached to the 
bottom of the plates by a thin layer of agar (Sigma Aldrich, UK) were incubated with 
medium for 1 hour at 37°C alongside untreated TCP. Medium was then aspirated and 
RPTECs were seeded at a density of 2 x 105 cells per well. Plates were incubated for 4 
hours at 37°C to allow cell attachment to the membrane prior to the viability assay. 
100µL of the spent medium was then aspirated from each well before the addition of 
the Presto Blue reagent (Invitrogen; Life technologies, UK). Plates were then statically 
incubated for 40 minutes at 37°C in the dark (wrapped in aluminium foil) before 
sampling. 100µL samples were taken from 3 points in each well, and each membrane 
was tested in triplicate. The samples were then run against a positive control, negative 
control and blank on a 96-well optical bottom black plates (Nunc). The positive control 
was represented by 100% reduced 10% (v/v) Presto Blue in growth medium achieved by 
autoclaving. The negative control was represented by 0% reduced 10% (v/v) Presto Blue 
in growth medium while the blank was represented by fresh growth medium. 
Fluorescence intensity was measured on the microplate plate reader at Ex: 544nm, Em: 
590nm, gain 1067. 
To assess cell recovery, the reagent was removed and the seeded membranes were 
washed three times with PBS. The cells were then trypsinised off the membrane surface 
and counted on a NucleoCounter NC-100. A calibration curve equating the fluorescence 
from the reduction of Presto Blue to cell number was also generated to predict cell 
numbers (Appendices- Figure 63).    
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4.4. Results  
4.4.1. Predicted chemistries and structures of polymer blends   
Four polymer chemistries were employed in the study presented in this chapter. The 
exact compositions of the polymer blends are presented in Table 16 (see Section 4.3.1.). 
The formulations without additive and with PVP as an additive were identified as being 
suitable from the literature research [226][227]. The formulation using MA and GA as 
additives were chosen based on the predicted properties required for renal cell 
attachment and proliferation. 
The predicted binding of pure PSF membranes after casting leaves the hydroxyl groups 
on the sulphur available for binding to the cells via electrostatic interactions (Figure 35a). 
The addition of PVP is thought to increase the biocompatibility of a surface [228] by 
making it more hydrophilic than pure PSF. When dissolved in NMP the PVP binds to the 
oxygen on the sulphone, where the formal charges of the sulphur (positive) on the PSF 
molecule and oxygen on the PVP molecule (negative) are sustained (Figure 35b). During 
coagulation in water the negative charge of the oxygen on the PVP molecule attracts 
hydrogen from a water molecule. The remaining hydroxyl group is attracted to the 
positive charge on the sulphur in the PSF molecule to nullify the charge, thus 
precipitating to form the porous membrane. PVP is therefore strongly bound to the PSF 
molecule, and is thought to be able to withstand fluidic forces as the membrane blend 
has been used in microfiltration applications and heat treatment of 300˚C [229][230].   
Increasing the presence of functional groups is also applied to surfaces through methods 
like oxygen plasma treating and surface coating (as tested in Section 3.4.3) to aid cell 
attachment. Carboxyl and hydroxyl groups present on the surface have also been shown 
to aid cell attachment [231] so on this basis two carboxylic acids MA (Figure 35c) and GA 
were added to increase hydroxyl groups on the surface with different length carbon 
chains. The mechanism of binding of the acids to the PSF backbone is similar to PSF+PVP. 
In NMP the oxygen on the sulphone molecule interacts with the carbon of the acid, 
causing a formal negative charge on the acid oxygen and a formal positive charge on the 
sulphur in the PSF. When cast into water the formal negative and positive charges 
attract a hydrogen and hydroxyl group from the water molecule respectively thus 
causing the precipitation of the polymer. This increases the net surface charge due to an 
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increase in functional (hydroxyl and carboxyl) groups present on the surface. As there 
are two oxygen species on the sulphone for acid binding on the PSF molecule, twice the 
amount of acid to PSF was used in the dope solutions. 
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Figure 35: The predicted reaction mechanisms of (a) PSF, (b) PSF+PVP and (c) PSF+ (malonic) acid. PVP and MA additive reactions in NMP are 
described from (b) 1-4 and (c) 1-3 respectively, after which the precipitation mechanisms in water for PSF (a), PSF+PVP (b) 4-7 and PSF+MA (c) 
3-6 are detailed 
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4.4.2. Membrane wettability  
Membrane hydrophilicity was assessed by measuring the water contact angles (WCA) of 
water on the top and the bottom of the four generated polymer membranes of different 
chemistries. According to the literature the expected WCA of PSF is 70° [53]. This value 
was measured on the bottom of the PSF membranes. However, on the top of the PSF 
membranes the WCA recorded was lower, being 63.1°±1.6˚ (Figure 36e). The 
membranes formulated with additives exhibited similar WCA values both on the top and 
bottom, with the PSF+PVP formulation possessing the lowest value on the top of the 
membrane (60.2°±1.5˚). This is a common phase separation phenomena due to 
instantaneous demixing at the interface resulting in a skin layer being formed on the top 
of the PSF based membranes [232]. The similarity in surface topography therefore leads 
to a similarity in WCA (see Section 4.4.4). Subsequently when ANOVA tests were run on 
the WCAs for the top sides of all blends, there was no significant difference (p ≤ 0.05) 
between the formulation containing MA as additive and the pure PSF. However there 
was a significant increase in WCA between pure PSF and PSF+GA indicating an increase 
in hydrophobicity. On the other hand PSF+PVP showed a significantly lower WCA than all 
other polymer blends indicating an increase in hydrophilicity which is concurrent with 
findings in literature [228]. The WCAs on the bottom were not taken into account in the 
statistical analysis as the method of fibre spinning would mimic the reactions at the top 
of the membranes (NIPS).   
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Figure 36: Photographs of water droplets on the top side of (a) PSF, (b) PSF+PVP, (c) 
PSF+MA and (d) PSF+GA membranes. (e) Water contact angles on the top and bottom 
sides of the flat sheet membranes (Mean ± SD, n=6). * indicates statistically significant 
difference to the highlighted samples, ** indicates statistically significant difference to 
all top samples, p ≤ 0.05 (ANOVA with Tukey post hoc analysis) 
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4.4.3. Surface chemistry analysis 
Although the ratio of MA and GA associated with PSF could not be discerned from the 
XPS data, PSF+PVP membranes were able to be analysed compared to PSF membranes 
by XPS (Figure 37). In all samples there was nitrogen contamination present in the form 
of nitrates and ammonia. This could have originated from the membrane formation 
process or be down to NMP residue on the membrane surface. The PSF membranes 
produce atomic breakdowns on XPS similar to the expected atomic breakdown, the only 
difference being the nitrogen based contaminations. In the PSF+PVP membranes the 
amount of nitrogen from the PVP is shown by the increase in the peak indicating C+N 
and C+S from the PSF peak (3.58%). Comparing this difference to the percentage of S 
present gives a ratio of 1.2:1, indicating each PSF molecule is bound to approximately 
one PVP molecule. When comparing the PSF+MA to the PSF membrane, the amounts of 
C and O present are relatively similar compared to pure PSF. This indicates that there is 
little MA associated with the surface. In contrast, the amount of C is slightly higher than 
PSF in the PSF+GA membranes indicating the presence of GA. However, the Oxygen 
content is lower than all of the other blends indicating that there is little GA bound to 
the surface. This XPS data concurs with the membrane wettability results that the 
PSF+PVP membranes are more hydrophilic due to the association of PVP at the surface 
with the hydrophobic portion of the PSF molecule. The content of MA or GA bound to 
the surface is also in agreement with the WCA measurements that show little or null MA 
or GA association with the PSF. 
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Figure 37: XPS spectra of (a) PSF, (b) PSF+PVP, (c) PSF+MA and (d) PSF+GA membranes 
showing the expected atomic % breakdown (blue) and the atomic % breakdown 
recorded by XPS analysis. The percentage of bond types cumulating in the elemental 
percentage is shown and an overlay of the spectral regions for each element is shown in 
(e). C=Carbon, O=Oxygen, N=Nitrogen, S=Sulphur, NO3=Nitrate, SO2-4=Sulphate, 
NH3=Ammonia, R2- SO2=Sulphone 
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4.4.4. Membrane topography 
A marked difference in the topography of the water facing ‘top (T)’ of the membranes 
and the glass facing ‘bottom (B)’ of the membranes was seen (refer to Figure 38). This 
surface difference was expected due to the fast exchange of solvent during the 
membrane production and water resulting in a ‘smooth’ layer on the top surface. 
Contrary to the top, the bottoms of the membranes demonstrated a slower exchange of 
solvent and water as a result of the contact between the polymer and the glass slide 
resulting in a rougher surface. This was confirmed by the roughness values measured an 
presented in Table 17. PSF displayed the roughest surface of all the membranes on the 
top and bottom sides given by the Ra and Rrms values, although the Rmax was the highest 
for the bottom side of the PSF+PVP membrane. Basic correlations between water 
repellency and surface roughness were originally described by Wenzel and Cassie and 
Baxter. In the Wenzel state the liquid conforms to the surface roughness which 
increases its interfacial contact area and increases the hydrophilic/hydrophobic 
character of the surface. In contrast the Cassie-Baxter bridging state reduces the contact 
area of the liquid, with gas bubbles filling the hollows and the liquid sitting on top of the 
roughness. This is also known as the ‘Fakir effect’[233][234]. Reports in literature have 
also linked the surface roughness with the WCA values, with a rougher surface exhibiting 
a low WCA [229]. Although this does not fully support the mean WCA and the roughness 
values measured, the membranes displayed similar roughness on the top and bottom 
sides. No significant difference (ANOVA, p ≤ 0.05) was recorded between the different 
polymer blends. 
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Figure 38: Representative AFM images of the tops (top row) and bottoms (bottom row) of PSF (a)(e), PSF+PVP (b)(f), PSF+MA (c)(g) and 
PSF+GA (d)(h) membranes. Each image displays a 20µm x 20µm sample area  
(a) (b) (c) (d) 
(f) (e) (g) (h) 
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Table 17: Parameters of the polymer surfaces (Mean value ± SEM, n=3)
Polymer Side Rmax (nm) Rrms (nm) Ra (nm) 
PSF Top 95.96 ± 27.3 14.30 ± 4.8 11.03 ± 4 
Bottom 163.88 ± 8.4 48.73 ± 10.6 35.73 ± 7.9 
PSF+PVP Top 50.13 ± 3.5 11.57 ± 3.1 7.70 ± 1.4 
Bottom 188.32 ± 7 27.87 ± 1.6 21.20 ± 1.2 
PSF+MA Top 46.05 ± 4.8 7.83 ± 1.3 5.57 ± 0.7 
Bottom 131.42 ± 5.2 21.30 ± 0.7 16.53 ± 0.9 
PSF+GA Top 65.35 ± 13.1 10.33 ± 2 7.63 ± 1.5 
Bottom 134.78 ± 42.3 26.20 ± 9.3 20.60 ± 7.6 
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4.4.5. Membrane structure  
As seen in the AFM images acquired (see Figure 38), all of the polymer blends produced 
a similar structure of the top (water exposed) sides of the membranes. There were no 
pores observed at the magnification used, however some pores were visible on the 
bottom and were most likely as a result of the slower exchange of solvent and water 
taking place during membrane production. These pores were not evenly distributed on 
the bottom surface of the flat sheets, and were more numerous on the PSF+PVP 
membranes (Figure 39). This finding could be attributed to the viscosity of the dope 
solutions when casting. Thus the PSF+PVP dope solution was noticeably less viscous than 
the other polymer blends enabling it to cover the slide quicker during the spin coating 
and minimising the exposure time to the atmospheric humidity. The cross sections of 
the membranes show the characteristic ‘finger like’ macrovoids with porous walls 
generated by the slowest exchange of solvent and water occurring in the middle of the 
membranes. There are contradicting reports that PVP may cause the suppression or 
enlargement of macrovoids [235][236], but there was no difference observed between 
these membrane blends. Although clean cut cross sections could not be generated due 
to sample preparation, the structural integrity of the membranes could be identified and 
assessed.  
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Figure 39: SEM images of PSF (a), (e), (i), PSF+PVP (b), (f), (j), PSF+MA (c), (g), (k) and PSF+GA (d), (h), (l) top sides (a-d), bottom sides (e-h) and 
cross sections (i-l) at 5K magnification. Scale bars = 2µm 
(a) (b) (c) (d) 
(e) (f) (g) (h) 
(i) (j) (k) (l) 
Page | 146  
 
Tailoring polymer blends for hollow fibre production Chapter 4 
 
4.4.7. Membrane preparation and cell viability  
4.4.7.1. Membrane sterilisation  
All methods of sterilisation employed were proven effective for all the membrane 
blends as any microbial growth was prevented. The OD of the incubated nutrient broth 
for each sample was found negative against the positive E.coli control. Furthermore, 
colony counts from each membrane sample except for PSF sterilised with antibiotics and 
PSF+GA sterilised by autoclaving were zero, indicating no microbial growth (see 
Appendices- Figures 64 and 65). However, for the two samples that did show some signs 
of microbial growth based on the colony counts (2 colonies per mL), the OD 
measurements were contradictory indicating no microbial contamination. The 
contaminations were therefore recorded as operator error within the aseptic technique 
employed.    
Membrane discs were then sterilised using the methods described in Section 4.3.7. and 
imaged via SEM to assess if any visible structural changes occurred compared to the 
unsterilized samples (Figure 40). No obvious structural change was observed, with all 
samples showing similar structures to the unsterilized membranes on both the top and 
the bottom sides (Figure 38), as well as the cross sections (Appendices- Figure 66). 
However, despite no evident structural changes, the membranes sterilised with the 
antibiotic/ antimycotics displayed a yellow staining from the solution that was not 
removed during the washing step. The presence of stains on the membrane suggests a 
degree of absorption within the internal structure, which would possibly require a more 
vigorous and thorough washing to be performed. The length of time required for 
sterilisation was also the longest and as a result, this sterilisation method was not 
employed further. The sterilisation method based on immersion in IMS required the 
shortest sterilisation time; however, it also required extensive washing to remove the 
IMS from the membrane. Within literature membrane sterilisation using the 3 
techniques used here have been assessed, with autoclaving reported to have achieved 
high biocompatibility on PSF+PVP membranes [237][226]. Autoclaving provided the 
easiest and quickest method overall with no visible membrane structural change and 
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high efficiency. Therefore, autoclaving has been selected as the main method employed 
for membrane sterilisation.   
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Figure 40: SEM images of the tops (top row) and bottoms (bottom row) of PSF, PSF+PVP, 
PSF+MA and PSF+GA membranes after sterilisation. Images at 5K magnification. Scale 
bars = 2µm  
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4.4.7.2. Cell attachment and viability on membranes  
Presto blue reduction was measured to assess cell viability after 4 hours post seeding 
and was corrected against a fully reduced sample. Cells on the membranes exhibited 
between 8%-10% reduction of Presto Blue compared to the positive control (fully 
reduced Presto Blue), with similar amounts of Presto Blue reduction observed on the top 
and bottom of all the membrane blends. TCP was used as a control for cell attachment 
and displayed a significantly higher percentage of Presto Blue reduction than all the 
membranes with the exception of the top side of PSF+PVP (Figure 41a). This finding 
indicates that the top surface of the PSF+PVP membrane is a favourable surface for renal 
cell culture.  
Contrary to the Presto Blue percentage reduction, the cell recovery (Figure 41b) from 
the top surface of the PSF+PVP membranes was one of the lowest values cell, indicating 
a lower degree of initial cell attachment. However, when compared to the TCP, all 
membrane formulations had a poorer performance. Due to the opaque nature of the 
membranes cell detachment could not be confirmed by visually by light microscopy. 
Taking into consideration that the same cell harvesting protocol (e.g. trypsin incubation 
time) was applied for all culture substrates, there is the possibility that the harvesting 
protocol presented different efficiencies on different culture substrates. As a result, the 
low cell recovery from the PSF+PVP membranes could be attributed to the harvesting 
protocol employed. In order to improve the harvesting efficiency, the cells cultured on 
the different substrates were incubated in trypsin for additional time and then mixed 
thoroughly before sampling. However even after the improvement, complete cell 
harvesting from TCP was still not achieved which may also account for the lower 
numbers of cells recovered from the membranes. Taking into account both percentage 
reduction of Presto Blue and the cell recovery, the PSF+PVP membrane was assumed to 
be the best performing formulation for RPTEC culture.  
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Figure 41: Cell performance on the top and bottom of the flat sheet membranes shown 
by (a) Presto blue percentage reduction and (b) cell recovery from initial seeding 
numbers. (Mean value ± SEM, n=3) * indicates significant difference to TCP, p ≤ 0.05 
(ANOVA with Tukey post hoc analysis) 
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4.5. Chapter discussion and conclusion 
4.5.1. Discussion 
This chapter focuses on the generation and characterisation of PSF based membranes as 
an improved cell culture substrate for renal PTCs. Although the group of sulfone based 
membranes is not a good renal cell culture substrate without protein coatings according 
to some reports in literature [181], its robustness, ease of handling and modification 
make it an attractive polymer backbone to employ. Alongside PSF and PSF+PVP, which 
have been used as renal cell culture substrates previously; carboxylic acid additives have 
also been applied in this work in an attempt to beneficially modify the surface of the PSF 
backbone. These additives should have theoretically introduced hydroxyl and carboxyl 
groups on the surface, however, these were not detected through the characterisation 
techniques. This may be due to a lower amount of acid being present in the system than 
is required for random binding to PSF and the presence of carboxylic acids on the 
surface. Nitrogen contaminations were also detected on the surface of the membranes, 
which were most likely introduced from the air during production. Methods of dope 
solution generation in literature use a vacuum to degas the solutions, which may be 
beneficial in further membrane development [238].  Consequently, renal cell 
attachment and metabolism was not beneficially affected on either membrane with the 
carboxylic acid additive. PSF+PVP did improve surface characteristics as expected, which 
resulted in improved renal cell attachment and metabolic activity comparative to 
standard TCP. Although graphically this similarity is not evident, ANOVA on the results 
indicates no significant difference between the top surface of PSF+PVP and TCP. 
Through the method of membrane casting and production the effects of smooth 
surfaces versus porous surfaces was also investigated. This is important to ascertain as 
literature has reported smooth, haemocompatible skin layers of fibres like those found 
in haemodialyser cartridges may be unsuitable for cell cultivation [192]. However, the 
results presented in this chapter indicate that smooth skin layers are not 
disadvantageous to PTC metabolic activity, and, in the case of PSF+PVP, are actually 
beneficial.    
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4.5.2. Conclusion 
There are many biomaterials that have been generated for the culture of renal cells. 
Whilst some of these use natural polymers such as cellulose, most applications employ 
synthetic membranes due to their robustness and surface modification or treatment 
potential. Sulfone based polymers have been utilised previously and were implemented 
in this work as the backbone for polymer blends from the predominantly positive 
reports in literature. Physical properties of the membranes have been characterised due 
to their effect on cell attachment and proliferation. Although the test polymer blends 
incorporating carboxylic acids did not appear to beneficially modify the membrane 
surface, the addition of PVP increased the hydrophilicity of and was detected on the 
surface. Furthermore renal cell attachment and metabolic activity on the top of PSF+PVP 
membranes is comparative to TCP. The membranes were also easy to sterilize through a 
variety of methods, which did not appear to alter their intra-membranal structure. This 
has in part satisfied the aim of generating an improved porous renal cell culture 
substrate. The production of hollow fibres from this membrane blend, subsequent 
characterisation device assembly and cell cultivation will be discussed in Chapter 5.    
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5.1. Chapter introduction 
Various applications in the tissue engineering field have utilised bioreactors, such as the 
culture of cells on biodegradable scaffolds for implantation into the body, the 
development of 3D in vitro models for diseased states and pharmaceutical research and 
for extracorporeal support for patients waiting for organ transplants [239]. These types 
of bioreactors have advantages such as the controllable and adaptable environment for 
cell cultivation, increased nutrient and oxygen transfer to cells compared to 2D 
platforms and an increased similarity to the physiological architecture. For this reason, 
existing bioartificial kidney devices have mainly utilised hollow fibre bioreactors, initially 
in the form of haemofiltration cartridges seeded with renal cells for both renal 
replacement therapies and as in vitro models [190][178].  
Hollow fibre bioreactors have been utilised in many applications including wastewater 
treatment [240], fermentation [241] and enzyme reactors [242] alongside tissue 
engineering applications. As such, hollow fibre bioreactors have been extensively 
developed and optimised for the selected application. In terms of tissue engineering, 
numerous mathematical models have been developed in order to understand how 
parameters such as nutrient and gas transfer, fluid flow and transmembrane flux are 
affected under different operating conditions. As a result, the conditions most suitable 
for promoting cell proliferation whilst maintaining cell function could be predicted.    
This chapter focuses on the assembly and sterilisation of the developed device, 
alongside the assessment of transmembrane flux through the fibre and physical 
characterisation of the fibres. RPTEC performance was then assessed on the fibres under 
static conditions, and after exposure to flow within the developed bioreactor.   
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5.2. Review of literature  
5.2.1. Bioreactors in tissue engineering  
Bioreactors have been frequently utilised in many diverse areas including fermentation, 
water treatment and animal cell culture for the production of proteins, vaccines [239] 
and more recently, in cell expansion for cell therapies [243]. Bioreactors can generally be 
defined as devices in which closely monitored and tightly controlled environmental and 
operating conditions such as: pH, temperature, pressure, nutrient supply and waste 
removal allow for the cultivation of cells and/or the development of biochemical 
processes [239]. For tissue engineering applications, various bioreactors have been 
employed to aid the culture of cells in environments mimicking physiological conditions 
more closely. A summary of the types of bioreactors detailed below can be found in 
Table 18. 
5.2.1.1. Stir tank bioreactors   
Continuous stir tank bioreactors have historically been used in bioprocessing; typically 
for the large scale fermentation of microorganisms e.g. yeast. Smaller scale vessels such 
as spinner flasks have been utilised in cell culture on 3D porous scaffolds for the 
generation of cartilage and bone constructs. For example, Vunjak-Novakovic et al (1996) 
suspended scaffolds with needles inside the spinner flask vessel and performed cell 
inoculation in a dynamic manner. A magnetic stirrer was placed at the bottom of the 
vessel and used for nutrient and oxygen mixing and reduction of the concentration of 
boundary layer at the construct surface [244][239]. As a result of mixing, an eddy was 
formed by the fluid flowing over the superficial scaffold pores, aiding the transport of 
fluid to the centre of the scaffold. However, despite the improvement in fluid transport, 
mass transfer in spinner flasks was not sufficient to deliver nutrients and gas 
homogenously to the cells [245]. Typically eddies are associated with the transition and 
turbulent flow and consist of clumps of fluid particles which have a swirling motion 
superimposed on the mean linear motion of the fluid particles [246]. Cartilage 
constructs have been cultured to a diameter of 5mm in spinner flasks, although this is 
not sufficient to be used clinically, which requires a construct of 1-5mm thick with a 5cm 
diameter. However, the ability to adjust nutrient concentration over time and the 
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exposure to shear stress are advantageous to chondrocyte proliferation. This is through 
the countering of ECM deposition to allow construct permeability and through the 
improved cell morphology and cartilage properties [247]. Bone constructs are also often 
cultured in spinner flasks due to the increased expression of alkaline phosphatase (ALP), 
osteocalcin (OC) and calcium deposition in this culture method [248]. Spinner flasks and 
stir tank bioreactors have also been employed in cell expansion, especially in the 
emerging field of regenerative medicine. In these vessels, adherent cells such as 
mesenchymal stem cells (MSCs) have been expanded with the use of microcarriers at 
small and large scales under serum and serum free conditions. Regardless of the 
conditions employed, MSCs were able to retain multipotency indicated by the 
maintenance of their characteristic immunophenotype and expansion down to the 
osteogenic, chondrogenic and adipogenic lineages after 14 days in culture [243][249].                      
5.2.1.2. Rotating wall bioreactor  
For cells sensitive to shear, rotating wall bioreactors (RWBs) could be a valid option. This 
type of bioreactor has been utilised for a variety of cell types, including chondrocytes 
[250], cardiac [251] and tumour cells [252][253]. The RWB consists of two concentric 
cylinders, within which the pre-seeded scaffold submerged in medium is contained. The 
outer wall of the vessel is capable of rotation, thus producing an upward hydrodynamic 
drag force that balances out the downward gravitational force. This micro gravitational 
environment allows the scaffold to be suspended, providing a more homogenous cell 
distribution compared to the static culture. As the tissue construct grows within the 
bioreactor, the wall speed needs to be increased to balance out the gravitational force 
and allow the continued suspension of the scaffold. Chondrocyte culture in RWBs has 
been relatively successful, exhibiting a 95% construct seeding efficiency within the first 
24 hours of culture and extensive proliferation and ECM deposition after 28 days [254]. 
Cardiac constructs consisting of spontaneously and synchronously contracting elongated 
cells have also been cultured from neonatal rat and embryonic chick cells after 14 days 
[251]. However, when comparing RWBs with static and spinner flask culture for rat 
marrow stromal cells [255]  and hMSCs [256], a lower expression of osteoblastic markers 
(OC, ALP) was exhibited. This is thought to be due to the low shear stresses on the cells 
or the collision of scaffolds in the bioreactor [248].  
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5.2.1.3. Compression and strain bioreactors  
For the formation of tissues that typically experience physiological stresses in vivo, 
bioreactors capable of exposing constructs to mechanical stimuli are required. The 
exposure to different mechanical stimuli could enhance cell functionality in vitro. 
Compression bioreactors are typically used to engineer cartilage and bone constructs, 
and are capable of applying both static and dynamic loading. Dynamic loading has 
provided better results in terms of cartilage formation over other stimuli and static 
loading, and is more representative of physiological stimuli [245]. When applied to bone 
marrow MSCs the application of cyclic loading has resulted in predifferentiation down 
the osteogenic lineage, indicated by the genetic expression of ostegenic markers [257].  
Mass transfer was also improved as fluid flow through the scaffold was increased from 
the compressive motion applied.  
Strain bioreactors typically have similar designs to compression bioreactors; consisting 
of a motor, a system providing linear motion and a controlling mechanism. The 
difference lies in the way the force is transferred to the construct, either directly or 
using a rubber membrane to anchor the scaffold and deforming the membrane [245]. 
Tensile strain bioreactors are commonly utilised for the engineering of tendon [258], 
ligament [259] and cartilage. However, scaffold constraint in bioreactors directly 
attached to the construct was shown to impede the differentiation of chondrocytes 
from MSCs. 
5.2.1.4. Perfusion bioreactors  
Perfusion bioreactors have been used to engineer various tissue and constructs 
including bone [260], keratinocytes [261], hepatocytes [262], cardiomyocytes [263] and 
chondrocytes [264]. Perfusion bioreactors generally consist of a pump connected to a 
scaffold chamber by tubing, and sometimes contain a medium reservoir. Medium is 
perfused through the stationary scaffold, thus reducing the mass transfer limitations at 
both the construct periphery and within the scaffold pores. As a result, homogenous cell 
distribution can be achieved [265]. When compared to static culture, fluid flow as in 
spinner flasks or RWBs, a higher cell density was achieved in a perfusion bioreactor after 
14 days [266]. Shear forces from fluid flow through the bioreactor provided mechanical 
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stimuli to the cells, which was shown to enhance the osteoblastic phenotype expression 
[260]. However, the effects of direct perfusion in 3D cultures was highly dependent on 
medium flow rate and the stage of cell maturation within the constructs, as 
demonstrated in chondrocyte cultures [267]. Therefore, perfusion bioreactors must be 
designed to balance the mass transfer of nutrients and waste removal, as well as to 
retain newly laid ECM by the cells for optimal performance [239].     
5.2.1.5. Hollow fibre bioreactors 
Hollow fibre bioreactors (HFBs) consist of a fibre (a cylindrical lumen surrounded by a 
porous wall or membrane) or fibre bundles, contained in an external housing. Cells are 
most often contained in the extracellular compartment with medium flow through the 
lumen to transport nutrients and gas through the membrane via diffusive and 
convective transport. In this way, cells are immunoisolated and protected from shear 
stress, whilst mass transfer is improved within the device compared to static culture. 
However, different HFB designs have been previously employed dependent on the 
application.  
HFBs have been widely used in the early development of bioartificial liver devices (BALs) 
which have progressed through to clinical trials. Devices such as the Extracorporeal liver 
assist device (ELAD, Amphioxus technologies) [268] and Bioartificial liver support system 
(BLSS, Excorp medical) [269] have utilised human cell line and porcine cells respectively, 
cultured in the extracapillary space (ECS) of the bioreactor. Other devices such as the 
HepatAssist (Circe biomedical) [268] utilised porcine aggregates attached to 
microcarriers within the fibre lumen. This set-up has allowed direct interaction between 
the cells and the perfusate (Plasma), although it has removed the immunological barrier 
[269]. The results of these phase I and II trials were largely positive and the treatment 
was well tolerated by patients. However, improvements on the design have been further 
investigated. Multi-compartmental devices consisting of interwoven hollow fibres have 
been devised to mimic the physiological environment of the liver more closely. Counter 
current medium perfusion and gas supply is provided in the fibres with human 
hepatocytes cultured in the ECS. This bioreactor design has been used in both the 
clinical setting [270] and pharmacological  applications as a scaled down in vitro model 
[271].For the engineering of blood brain barrier (BBB) models HFBs have also been 
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utilised to co-culture brain endothelial and glial cells on the lumen and ECS sections 
respectively. Perfusion of medium through the lumen exposes the endothelial cells to 
shear stresses mimicking the conditions in the brain capillaries resulting in tight 
monolayers with improved barrier function, with cells able to remain in culture for 30 
days [272][273]. The modelling of HFBs for bone tissue engineering [274] and culturing 
skin cells [275] has also been investigated. However, alongside BALs HFBs have been the 
primary bioreactor type for the development of BAK devices.  
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Table 18: Properties of bioreactors used in tissue engineering. Images modified from [239]  
Bioreactor Advantages Disadvantages Applications References 
Stir tank bioreactor/ 
Spinner flask 
 
 
 
 
 
 
Enhanced fluid transport 
Reduction in the concentration 
boundary at the construct 
surface 
Controllable shear within the 
flask 
Easy to scale up 
 
Poor mass transfer when 
applying to static scaffolds 
Non-homogenous distribution 
of cells in the scaffold 
Perception that high shear 
stress can have damaging 
effects of cells 
 
Cell cultivation on 
scaffolds 
(Cartilage, Bone) 
Cell expansion 
(MSCs) 
Spheroid 
formation 
 
[239][243] 
[245][247] 
[248][276] 
 
Rotating wall bioreactor 
 
 
 
 
 
 
 
Enhanced fluid transport 
Produces a low shear 
microenvironment 
More homogenous distribution 
of cells than static culture 
 
Common for scaffolds to collide 
with other scaffolds or the sides 
of the vessel 
Low, non-controllable shear 
microenvironment 
 
Cell cultivation 
on scaffolds 
(Chondrocytes, 
Cardiomyocytes, 
Tumour cells, 
Bone, MSCs) 
 
[239][248] 
[250][251] 
[252][253] 
[254][255] 
[256] 
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Table 18 continued: 
Bioreactor Advantages Disadvantages Applications References 
Compression/ Strain 
bioreactor 
 
 
 
 
 
 
 
 
 
Application of loading similar to 
physiological stimuli 
Fluid flow and mass transfer 
improved 
 
 
 
Direct attachment of the 
construct to the bioreactor 
impedes cell differentiation 
 
 
 
Cell cultivation 
on scaffolds 
(Cartilage, Bone, 
MSCs, 
Chondrocytes) 
 
 
 
[245][257] 
[258][259] 
[277] 
 
Perfusion bioreactors 
 
 
 
 
 
 
 
Higher cell density achieved than 
in other bioreactors 
Mechanical stimulation (shear) 
from fluid flow 
Reduction in mass transfer 
limitations at construct periphery 
and within the scaffold 
 
Perception that high shear 
stress can have damaging 
effects of cells 
Fluid flow and shear may 
disrupt the microenvironment 
within the scaffold 
 
Cell cultivation 
on scaffolds 
(Bone, 
Keratniocytes, 
Hepatocytes, 
Cardiomyocytes, 
Chondrocytes) 
 
[239][260] 
[261][262] 
[263][264] 
[266][267] 
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Table 18 continued: 
Bioreactor Advantages Disadvantages Applications References 
Hollow fibre bioreactor 
 
 
 
 
 
Mechanical stimulation 
(shear) from fluid flow 
Easy to scale up 
Cells can be protected from 
shear 
Potential for 
immunoisolation 
Efficient surface area for cell 
attachment 
Non-uniform cell distribution 
Fibre membrane can act as a 
physiological transport 
barrier 
Large nutrient, metabolite, 
pH and pO2 gradients can 
occur along the fibre 
Difficult to monitor in situ 
Cell expansion (skin 
cells) 
Bioartificial liver devices 
(ELAD, BLSS, 
HepatAssist) 
Bioartificial kidney 
devices (RAD) 
Model systems (Blood 
brain barrier, kidney) 
Bone tissue engineering 
[239][245] 
[268][269] 
[270][271] 
[272][273] 
[274][275] 
[278] 
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5.2.2. Existing bioartificial kidneys 
One of the first BAKs to assemble both an ultrafiltration device and a unit containing 
semi-permeable hollow fibres seeded with renal PTCs was described by Aebischer et al 
in 1987. MDCK and LLC-PK1 cell lines were cultivated on an acrylic copolymer and 
polysulfone fibres until confluency (within three weeks on the acrylic copolymer), and 
showed distinct differentiated morphology depending on the chemical and physical 
properties of the polymers. This was thought to influence the ability of the cells to 
perform specialised tasks [9]. Further work by the same group investigated the effects of 
attachment substrates on cellulose nitrate membranes, the age of the cells on glucose 
transport and the transport of inulin, PAH and glucose through confluent membranes of 
MDCK and LLC-PK1. They showed that cells cultured on Matrigel were the best 
performing with regards to glucose transport. Active transport of the solutes was 
exhibited by the cell monolayer and the net glucose flux across the LLC-PK1 monolayer 
increased with the age of the cells [279]. The control of water flux within the BAK was 
also investigated by looking at the effect of transmembrane pressure (TMP) on cell 
morphology and the influence of cells on the hydraulic permeability (L(p)) in a flow 
chamber. Asymmetric fluid transport occurred on the seeded membranes in the 
basolateral to apical direction, with the L(p) being reduced on cell seeded membranes 3-
10 fold compared to the cell free membranes. The cell seeded membranes were also 
found to be strongly dependent on TMP, with a higher TMP resulting in a higher L(p). 
However, the magnitude of the applied TMP had no effect on the L(p) on cell free 
membranes. The application of shear rates between 2.6 and 10.5 sec-1 did not have an 
effect on L(p) or cell attachment. Furthermore the application of TMP in the apical 
chamber had a positive effect on cell morphology, with the maintenance of their 
squamous morphology, whereas cells became more columnar with increased 
intercellular space in the reverse direction [10].  
   BAKs were then developed for clinical use as renal replacement devices to surpass 
conventional dialysis methods. Where haemodialysis simply filters the blood which is 
then replenished with an electrolyte balancing solution before administering back into 
the patient, BAKs were additionally thought to provide the excretory and metabolic 
functions of the kidney through renal PTCs. The renal assist device (RAD) coined by 
Page | 164  
 
Assembly and assessment of the bioartificial kidney device  Chapter 5 
 
Humes et al (2004) was the first BAK device to be tested in a Food and Drug 
administration (FDA) approved trial (Figure 1a). Similarly to the device designed by 
Aebischer et al (1987) the extracorporeal device consisted of a standard haemofiltration 
cartridge combined with a pronectin L coated hemofiltration cartridge inoculated with 
(108) cells. In pre-clinical studies using several large animal models including various 
canine and porcine models [280][281][282][283], BAKs were shown to effectively 
replace the filtration, transport, metabolic and endocrinologic functions, and have 
measurable effects on circulating mediators of inflammation whilst improving 
cardiovascular performance associated with changes in cytokine profiles. From these 
positive outcomes the RAD was then tested under phase I/IIa clinical trials in patients 
suffering from acute kidney injury (AKI) and multiple organ failure (MOF). Although the 
cells within the RAD demonstrated differentiated metabolic and endocrinologic activity 
and the 28- day mortality rate was improved by 27%, the phase IIb trial was halted due 
to suboptimal clinical protocol design and fabrication and manufacturing hurdles [278]. 
Furthermore the clinical trial has drawn some criticism noting: the lack of 
documentation on the expected effect size, the incomplete treatment of patients 
assigned to continuous veno-venous haemofiltration and RAD treatment and the lack of 
statistical significance of the primary results with comparisons performed as an as-
treated rather than an as-randomised intention-to-treat sample [284].  
The promising results from the clinical trials prompted further investigation into various 
aspects of BAKs such as the hollow fibre membrane material (Table 15), the cell sources 
and the device design itself. These studies have been aimed both at developing the BAKs 
for clinical use but also for utilising them in research as potential renal models as a result 
of flow being thought to be a potent modulator of PTC phenotype [285]. Mammalian cell 
lines such as MDCK and LLC-PK1 have been previously employed in the development of 
BAKs for long term use. Although Na+ transport was demonstrated in MDCK cultures for 
two weeks [286] and LLC-PK1 cells actively transported water, sodium and glucose for 10 
days, transport deteriorated after this period alongside cells forming multilayers within 
the device [287]. hPTCs have therefore been used as the primary source of cells in BAK 
development, although recent studies have investigated the potential of the 
differentiation of human embryonic stem cells into renal epithelial like cells (described in 
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Section 3.2.2.). BAK designs have also evolved for both research and clinical purposes. 
The emergence of microfluidic devices and the development of ‘Kidney on a chip’ 
devices are addressing the need for simple and reliable 3D in vitro models (Figure 1b). 
These devices utilise either hollow fibres [288] or membranes for cell culture assembled 
within a PDMS body, and have a significantly smaller footprint than the haemofiltration 
cartridges used previously. The application of medium exerting 0.2 dyn/cm2 (tubular 
shear stress is estimated in the range of 0.2-20 dyn/cm2) through the channel seeded 
with cells has shown improved results in cytoskeletal protein, tight junction protein, ion 
transporter and drug transporter (e.g. OCT2) expression compared to the static models. 
Furthermore exposure to nephrotoxic compounds has shown the ability of the 
microsystem to recapitulate the in vivo toxicity of the drugs [289][14]. However, the 
development of these devices is at an early stage and requires further optimisation. The 
functional characterisation of clinically relevant drug transporters should be investigated 
to establish an ideal in vitro model system.  
A new generation of BAKs for clinical use has been developed, characterised by a more 
compact design and the ability to be cryogenically frozen and stored as described om 
Section 1.1.(Figure 1c). BRECS incorporates niobium coated porous carbon discs coated 
with collagen IV for cell culture, with the therapeutic dose set at 108 in a perfusion 
bioreactor. After cryopreservation a 10% loss in viable cells was reported for the device. 
Flow rates were optimised to provide adequate nutrient and oxygen delivery and cells 
were maintained in the BRECS for over 5 months, with a consistent metabolic profile 
throughout the in vitro culture and the presence of differentiated apical membrane 
enzymes. Pre-clinical testing in a porcine model with acute renal failure demonstrated 
therapeutic efficacy and prolonged survival time alongside improved cardiovascular 
performance. These initial results are promising and the reduced footprint of the device 
compared to the RAD is favourable in terms of handling, shipping and storage [15]. The 
major advantage of this system is the ability to cryogenically freeze and reconstitute the 
device allowing it to be used in time-critical situations in the clinic.  
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5.2.3. Engineering a hollow fibre bioreactor  
The development of bioreactors require a multidisciplinary approach, therefore when 
designing the system many engineering concepts need to be understood to be able to 
accurately model and develop systems suitable for cellular applications. These are 
especially important in the development of HFBs as monitoring parameters such as 
concentration gradients, pH and pO2 cannot be measured directly due to the size and 
design of the device. Some important aspects to consider are described below. 
5.2.3.1. Fibre geometry and fluid dynamics 
Many groups have utilised the Krogh cylinder approximation of HFBs when developing 
numerical models. This model views the fibres in an idealised hexagonal arrangement 
within the casing [242]. The cylinder consists of a lumen, membrane and extracapillary 
space, with one fibre being representative of the entire bundle (Figure 42). The flow 
through the membrane and ECS is mostly neglected in modelling axial flow HFBs when 
the pressure drop across the membrane or ECS is not significant. Flow through the 
lumen can therefore be described by Poiseuille’s law [290]. In closed shell configurations 
of HFB systems i.e. when there is no net convective flow from the lumen to the ECS, the 
axial pressure drop causes the lumen pressure to be greater than the ECS in the first part 
of the device. At the end of the fibre the reverse is true, and the resulting pressure 
profile causes a recirculation flow (analogous to the Starling recirculation flow in 
capillary tissue systems), where fluid flux out of the lumen to the ECS is balanced by flux 
into the lumen at the end of the fibre [291]. However in models assuming significant 
permeation through the membrane, Navier-Stokes equation and/or Darcy’s law have 
been used [291][292][293]. These laws apply to laminar (smooth) flow through the 
lumen, which is commonly seen in small scale bioreactors, but must be considered in the 
case of turbulent flow which can occur during cross flow microfiltration with porous 
membranes or when scaling up the device [294]. When cultivating cells, especially those 
sensitive to shear within the device, the shear stress exerted on the wall should be 
considered. Shear stress can be calculated using the Poiseuille- Hagen equation. A longer 
fibre equates to a greater pressure drop, resulting in the need for an increase in flow 
rate to provide a defined shear stress on the cells throughout the device. However, high 
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flow rates exert shear stresses which may be damaging to the cells or remove them from 
the surface [295].     
5.2.3.2. Mass transfer  
When culturing cells in HFBs, it is important to assess substrate mass transfer within the 
device. Large concentration gradients along the fibre have been identified as one of the 
major flaws in HFB design, with simulations demonstrating that diffusion limitations may 
exist at the far end of the reactors [296]. Many groups have therefore modelled various 
substrate transport profiles within HFBs, the most common being oxygen which is 
considered as the rate limiting nutrient. Oxygen consumption also varies between 
different cell types, and as such models have been developed for bone tissue [292][297], 
hepatocytes [298][299][300][301][302][303][304], cardiomyocytes, pancreatic cells and 
chondrocytes [290]. Michaelis-Menten kinetics are commonly used to model oxygen 
uptake, capturing the dependence of uptake on the underlying concentration. However 
due to the non-linear nature of Michaelis-Menten kinetics numerical solutions alongside 
analytical solutions have been described in literature. A strategy to address this problem 
has developed operating parameters dependent on oxygen consumption by different 
cell types; with analytical approaches being used for high oxygen requirements within 
the device, and numerical solutions required for low oxygen requirements [290]. 
Modelling of other substrates required for cell growth such as glucose have also been 
developed and applied with oxygen uptake models [292]. Collectively, these models 
provide useful information on the design and optimisation of HFBs for different cell 
types. These models have not, as of yet been applied to renal cell culture within small 
scale devices as required within the pharmaceutical sector, although microfluidic devices 
are being developed. This therefore highlights an important optimisation step to be 
implemented in the development of BAKs for widespread use within the industrial 
setting.   
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Figure 42: The idealised hexagonal arrangement of the fibre bundle comprised of seven 
Krogh cylinder units (left) and a cross section through one fibre including the fluid 
velocity profile in the lumen (right). L= fibre length, z= axial direction of flow, d= radius 
of the lumen, s= membrane thickness, l= depth of the ECS and r= radial diffusion. odified 
from [290]  
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5.2.4. Conclusion 
A wide variety of bioreactors are utilised in tissue engineering applications as they can 
create environments for cell culture similar to the physiological environment. In terms of 
BAK device generation, hollow fibre bioreactors have been intensively studied in the 
past with various cell types, mostly for the generation of RRTs. Current iterations of 
these devices have incorporated perfusion bioreactors for the scale down of these 
systems for both clinical and research model end points. This chapter aims to add to the 
existing wealth of knowledge by incorporating the characterised hPTCs on the 
developed membrane for the cultivation of cells in the HFB. The metabolic activity of the 
cells throughout the culture period will be assessed with the aim of generating a 
complete monolayer of cells, which can be characterized using the assays previously 
utilised as a comparison between 2D and 3D dynamic culture. Although computational 
modeling will not be employed in this project, it is imperative to understand the 
concepts of mass transfer and fluid flow, and is valuable in the further development of 
this device. 
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5.3. Materials and methods  
5.3.1. Hollow fibre production 
Based on polymer selection studies performed in Chapter 4, the PSF+PVP dope solution 
was further employed for hollow fibre production in a rig using a custom spinneret 
(University of Bath, UK) of approximately 700µm bore size (see Figure 43). Three 
separate batches were produced using different pressures and bore fluid water flow 
rates (see Table 19). Once the fibres were produced and, collected they were immersed 
in deionised water for 3 days with daily water changes in order to remove any impurities 
and traces of reagents.  
 
Table 19: Process parameters and sizes of 3 batches of PSF+PVP hollow fibres  
 
Batch Pressure Water flow 
rate 
Mean Inner 
diameter 
Mean Outer 
diameter 
Batch 1 5 bar 8mL/min 656µm 738µm 
Batch 2 4 bar 7mL/min 725µm 805µm 
Batch 3 5 bar 10mL/min 860 µm 995 µm 
 
5.3.2. Fibre porosity measurements  
The density of the dry fibres was measured using a pycnometer (multi-volume 
pycnometer 1305; Micromeritics, USA). The fibre sections were then immersed in 
deionised (DI) water for 2 days to allow complete soaking, followed by straining and 
lightly drying by gently tapping with filter paper. Then the hydrated fibres were weighed 
after absorption of DI water and then dried for a week until constant weight was 
acheived and weighed. The porosity of the fibres from each batch was then calculated 
using Equation 6 (refer to Appendices 2.6.) [305].  
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5.3.3. Surface topography  
Fibre topography was analysed using the JPK Nanowizard 3 Bioscience AFM (JPK 
Instruments, UK). Fibres from each batch were cut and mounted on glass slides to 
expose the exterior and luminal sides. Three points on each of the samples were 
analysed over a 20µm x 20µm sample area and the peak to valley roughness (RT), Ra and 
Rrms were calculated.  
5.3.4. Module assembly, sterilisation and disassembly 
Glass casings were autoclaved before use alongside fibres (contained in autoclavable 
boxes) at 121˚C for 15 minutes. After transferring to the BSC, the sterile fibres were 
placed in the modules and attached vertically to the plastic vial holders. Epoxy resin 
(Evo-Stik; Bostik Ltd, UK) was applied to the top end of the module and allowed to 
permeate approximately 1cm into the casing. The modules were then rotated 180˚ and 
set overnight. The next day the same method was applied to the other end of the 
module to seal both sides. The modules were left for 3 days overall to allow the resin to 
set, and then trimmed to remove excess fibre. The modules were attached to a syringe 
of sterile filtered DI water, and after flushing water through the lumen the module 
outlet was blocked. Water was pumped through the lumen at 500nl/min using a syringe 
pump (PHD Ultra; Harvard Apparatus, USA) overnight to allow water permeation into 
the pores of the fibre, as well as to remove any remaining impurities. The sample ports 
and ECS were left unblocked and clear. The module outlets were then unblocked and 
water was removed from the lumen. Assembled modules were then autoclaved at 121˚C 
for 20 minutes to ensure complete sterility. After use, the modules were autoclaved 
again for 15 minutes at 121˚C. The ends of the modules were then heated using a power 
Bunsen burner to melt and remove the resin. The modules were allowed to cool down 
to room temperature and then were soaked in acetone overnight followed by thorough 
cleaning to remove any residue.  
5.3.5. Hydraulic permeability  
Modules were assembled with a syringe of DI water at the inlet, two pressure gauges 
(DPI 705; GE Druck, UK) connected by three way valves and a clip on the outlet. A third 
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pressure gauge was connected to the top sample port by a T-connector (Fisher, UK) with 
a clip to block the ECS. Water was flushed through the lumen before blocking the outlet, 
and the ECS was left open. Both three way valves were opened and all the pressure 
gauges were set to zero. The pressure within the fibre was increased to approximately 
15mbar and then allowed to reach a consistent TMP overnight with DI water pumped in 
at 500nl/min. On the day of the experiment the ECS was filled with DI water and blocked, 
the pressure in the fibre was released and all pressure gauges were set to zero. The flow 
rate of 500nl/min was resumed and applied for 4.5 hours, with water samples collected 
every 30 minutes. The water samples were weighed and applied into Equations 7 and 8 
(see Appendices2.7. and 2.8.) to calculate the volumetric water flux and hydraulic 
permeabilities of the fibres. Each module was repeated 3 times and a total of 3 modules 
were assessed. 
5.3.6. Module integrity assessment 
Modules were assembled with peristaltic pumps feeding (Dose It; Integra Biosciences 
Group, USA) into two reservoirs and two pressure gauges (DPI 705; GE Druck, UK) 
connected by three way valves. With the three way valves closed to the pressure gauges 
water was flowed for 1 hour at 10mL/min through the modules to wet the fibres. The 
water was then removed from the lumen circuit and replaced with 100µM LY solution. 
The valves were opened and the inlet and outlet pressures were recorded. 300µl 
samples were taken from the reservoirs before closing the valves and leaving the 
modules to run at 10mL/min. After 24 hours the valves were opened and the inlet and 
outlet pressures were recorded alongside taking 300µl from the reservoirs. After flowing 
water through the lumen and at 10mL/min for 1 hour to remove the LY, the modules 
were autoclaved at 121˚C for 15 minutes. The pressure drop measurements and 
incubation with LY were then repeated.     
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Figure 43: Schematic of the extrusion rig used to produce hollow fibres from PSF + PVP dope solution using water as the bore fluid and 
external coagulant
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5.3.7. Fibre seeding- static culture  
Fibres from each batch were immersed in DI water and autoclaved at 121˚C for 15 
minutes. After sterilisation, the fibres were cut into 1.5cm pieces with a sterile scalpel 
and placed in a Corning 24-well ultralow attachment plate (Sigma Aldrich, UK). Three 
fibre sections from each batch were used. 0.5mL FBS was added to the wells and 
incubated overnight to condition the fibres by allowing proteins to be adsorbed onto the 
surface and help facilitate cell adhesion to the fibres. Before cell inoculation, the fibres 
were washed with RPTEC medium, after which cells were seeded at 2.3 x 105 cell/cm2 
and incubated for 2 hours at 37˚C. The cell suspension was then removed and the fibres 
were turned over before dispensing the cell suspension back into the wells. Cells were 
cultured for 9 days with medium changes performed every 2 days.  
5.3.8. Cell viability assay- Presto blue  
For analysis of cells seeded on the fibres in static conditions, the Presto Blue reagent was 
added into the wells at a 1:10 dilution and incubated for 40 minutes at 37˚C (as 
described in Section 4.3.8.). Three samples of 100µl were taken from each well and read 
on a microplate reader (FluoStar Omega; BMG Labtech, Germany) at Ex: 544nm, Em: 
590nm and a gain of 1000 measured against a positive and negative control and a 
medium blank.  
For the analysis of cells within the fibres under flow conditions the Presto Blue reagent 
was diluted in medium at a 1:10 dilution. 0.5mL of the solution was then aspirated into 
2.5mL luer lock syringes (Terumo Medical Corporation, USA) and pumped through the 
fibre lumens at 50µl/min for 8 minutes. The bioreactors were incubated in static 
conditions for 40 minutes at 37˚C in the dark before applying flow through the lumen at 
50µl/min for 10 minutes to collect the sample. Three samples of 100µl were taken from 
each module and measured on the microplate reader at Ex: 544nm, Em: 590nm and a 
gain of 1000 against positive and negative controls and medium blanks.   
5.3.9. Cell visualisation- Live/ dead staining 
On day 9 of static cell culture on fibres, cells were stained using the live/dead staining kit 
(Life Technologies, UK). Ethidium bromide (dead stain) was added to PBS at a 1:500 
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dilution and mixed thoroughly by vortexing in the dark. Calcein-AM (live stain) was then 
added at a 1:2000 dilution and mixed thoroughly. Medium was aspirated from the wells 
and fibres were incubated in 0.5mL live/dead stain for 40 minutes at 37˚C in the dark 
before imaging on the Nikon Eclipse Ti fluorescence microscope.   
5.3.10. Bioreactor seeding and cell cultivation 
Sterilised modules were exposed to a UV cycle on the BSC (1 hour) on both sides before 
assembling with sterilised (autoclaved) platinum cured silicone tubing (Polymax, UK) and 
luer locks (Cole-Parmer, UK) as shown in Figure 44. All components were sterilised by 
autoclaving at 121˚C for 20 minutes and exposing to a UV cycle after assembly. The fibre 
lumens were pre conditioned with FBS overnight at 37˚C before rinsing with RPTEC 
medium. RPTECs at Pd=5 were seeded at 4.38 x 105 cells/cm2 and rotated 90˚ every hour 
for 4 hours to allow cell attachment to the fibre. The ECS was left clear and cells were 
incubated for 2 days under static conditions at 37˚C. The ECS was then filled with RPTEC 
medium and the module was connected to 20mL syringes (Terumo Medical Corporation, 
USA). Initially an incubation chamber was assembled to house the modules during 
culture (Appendices- Figure 67), however, due to problems with CO2 control the 
bioreactors were set up in an incubator at 37˚C with 5% CO2. RPTEC medium was 
pumped through the lumen and ECS at 50µl/min for 6 hours, after which the bioreactors 
were transferred to the BSC to replace the medium from the bottle (Eppendorf, UK) 
back into a new syringe. Every 2 days the medium was removed from the reservoirs and 
replaced with fresh medium after the Presto Blue assay. Cells were cultured for 9 days 
(including the static incubation period). Tube lengths and fittings sizes are described in 
detail in Table 20.   
5.3.11. Spent medium analysis  
To assess nutrient and metabolite concentrations of RPTECs within the device, 2mL of 
spent medium was aspirated daily and frozen until analysis. Samples (1mL) were run on 
the Cedex Bio HT Bioprocess analyser and glucose, lactate and ammonium 
concentrations were measured.   
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Figure 44: Schematic of the bioreactor layout incorporating medium flow through the ECS (blue) and lumen (green) (left) at a 50µl/min flow 
rate in both flow paths.  An image of the device setup in the incubator (right) shows the medium reservoirs in front of the modules with the 
pump for the ECS circuit on top and the pump for the lumen loop on the bottom left. Every 2 days medium was removed from the reservoirs 
and replaced with fresh medium in the syringe and reservoirs for each circuit.   
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Table 20: Components used in the assembly of the HFBs 
Component Description Size/ 
Length 
Manufacturer 
Silicone 
tubing 
Connection between the luer locks 
and module/syringe 
2cm  
 
 
Polymax, UK Connection from lumen port to 
medium reservoir 
15cm 
Connection from syringe to ECS port 40cm 
Connection from ECS port to medium 
reservoir 
20cm 
Luer fittings  Male luer lock to barb connector 1/16 inch ID  
Cole-Parmer, UK Female luer lock to barb connector 1/16 inch ID 
Luer lock caps  - 
Syringes 20 mL medium syringes  20mL  
Terumo medical 
corporation, USA 
2.5mL luer lock syringes for cell 
seeding and Presto Blue assay 
2.5mL 
Medium 
reservoir 
bottles 
100mL glass bottles. Cap attached to 
autoclavable air filter and line into 
bottle 
100mL  
Eppendorf, UK 
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5.4. Results 
5.4.1. Fibre structure after sterilisation 
Fibres were sterilised by autoclaving and imaged on the outer side, lumen side and cross 
section. As damage occurred during preparation of the flat sheet membranes for 
imaging by slicing (Section 4.4.5.), fibres were pulled apart until breaking and attached 
to the carbon pad. The outer and lumen surfaces displayed a smooth surface with the 
absence of visible pores. This concurs with the images of the top side of the flat sheet 
membranes as water was used for the bore fluid and gelation bath during fibre 
production, allowing fast evaporation of solvent and producing a smooth surface.      
Batch 1 fibres show the most uniform fibre wall thickness of ~82µm (Figure 45c). 
However, the structure within the fibre wall was vastly different to the other batches. 
The structure is less organised with round macrovoids between the exterior and the 
lumen and small cubical voids closer to the edges of the fibre. This irregularity could be 
due to both different rates of solvent evaporation within the fibre and the non-uniform 
dispensation of the dope solution from the spinneret.  
 
Batch 2 fibres displayed a mean wall thickness of 80µm, however the thickness around 
the fibre drastically varied (Figure 45g). The mean thicknesses of the thinner and thicker 
sides were 63µm and 122µm respectively. A lower pressure and slower water flow rate 
was used in the fibre production, which may have resulted in the coagulated fibre in the 
gelation bath pulling the newly forming fibre, therefore distorting the shape of wall. The 
fibres did however show a similar structure within the wall to those observed in the flat 
sheet membranes i.e. finger like macrovoids with pores in the dividing structures.  
Batch 3 fibres also showed this characteristic structure, although the dividing sections of 
the macrovoids were thicker (Figure 45k). The mean thickness of the membrane was 
135µm, although there was some variation around the fibre wall and along the length of 
the fibre. Due to the increased water flow rate the lumen side would be smoother due 
to the faster rate of solvent evaporation compared to the other fibres. However, no 
differences in structure were observed on the lumen side between any of the fibres at 
5K magnification.  
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Figure 45: SEM images of the PSF+PVP hollow fibres: Batch 1 (top row), batch 2 (middle row) and batch 3 (bottom row) outer sides (a, e, i), 
lumen sides (b, f, j) and cross sections (c, d, g, h, k, l). Magnifications at 5K were used for outer and lumen side imaging, and 200 (c, g, k) and 1K 
(d, h, l) magnifications were used for the cross sections. Scale bars = 10µm 
(a) (b) (c) (d) 
(e) (f) (g) (h) 
(i) (j) (k) (l) 
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5.4.2. Physical characteristics of the fibres 
As seen in the images (Figure 45c), batch 1 fibres displayed the lowest and relatively 
consistent thickness of all the fibre batches. Batch 2 fibres displayed a similar value 
(within the error range) to batch 1 fibres, although the variability was higher. As seen in 
Figure 45g this was due to the fibre containing different wall thicknesses around the 
circumference of the fibre which was observed throughout the batch. Due to the 
fragility and variation within the batches of fibre integrity, the hydraulic permeability 
could not be determined. Batch 3 fibres had the thickest wall, which allowed the 
hydraulic permeability to be measured. As the porosity of the batch 3 fibres was the 
lowest of all the batches, the water flux was also expected to be lower. When compared 
to initial results from batch 2 fibres (Appendices- Table 22) the water flux was similar in 
both batches. However the consequent hydraulic permeability was ~35% lower in batch 
3 fibres than batch 2 fibres owing to a larger TMP within the larger fibres. 
The surface roughness of the fibres was also investigated. Batch 2 fibres exhibited the 
best growth of RPTECs over 8 days (See Section 5.4.5.- Figure 49) and displayed the mid 
Rrms and lowest Ra values. Batch 3 fibres, which exhibited poor RPTEC performance, had 
the lowest and highest average Ra and Rrms values respectively. However batch 3 fibres 
also displayed the highest average exterior RT values, indicating that peaks and troughs 
may have been present on the surface resulting in large variability in average roughness. 
The Rrms and Ra lumen values for batch 2 and 3 fibres were similar to the exterior batch 2 
values, although the RT values were lower in batch 3 fibres. All batches showed similar 
surface patterns on the lumen surface as opposed to the exterior surfaces where they 
varied significantly (Appendices- Figure 68). However, when comparing the values 
between batches via ANOVA with Tukey post hoc analysis, there was no significant 
difference (p ≤ 0.05) found between the lumen and exterior of all the batches, indicating 
that surface topography was not a major factor in cell performance on the exterior of 
the fibres. Surface roughness has been identified in affecting cell attachment and 
proliferation within the literature, with varying degrees of roughness beneficially 
affecting different cell types [306]. However, the effect of surface roughness has not 
been investigated in renal cells. The physical characteristics are presented in Table 21. 
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Table 21: Physical characteristics of the 3 batches of fibres (Mean value ± SEM, n=3)
Fibre Batch Mean Wall 
Thickness (µm) 
Surface Roughness (nm) 
                  RT                                        Rrms                                           Ra    
Porosity  
(%) 
Lp 
(109 Pa m3/m2·s) 
Batch 1 82.13 ± 6.59 Exterior: 1540 ± 210 
Lumen: 1720 ± 200 
Exterior: 237.13 ± 13.4 
Lumen: 437.83 ± 52.17 
Exterior: 188.43 ± 5.50 
Lumen: 375.17 ± 45.95 
86.66 ± 0.63 - 
Batch 2 92 ± 11.06 Exterior: 1870 ± 320 
Lumen: 1470 ± 410 
Exterior: 265.47 ± 26.13 
Lumen: 260.67 ± 95.52 
Exterior: 214.67 ± 23.04 
Lumen: 205.33 ± 74.30 
83.90 ± 1.42 - 
Batch 3 135.38 ± 14.49 Exterior: 2150 ± 190 
Lumen: 1270 ± 180 
Exterior: 287.03 ± 25.28 
Lumen: 282.83 ± 54.71 
Exterior: 141.65 ± 70.02 
Lumen: 234.13 ± 49.62 
70.10 ± 1.23 154.84 ± 8.67 
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5.4.3. Module sterilisation 
Modules were initially assembled on the benchtop from the fibres and casings, and were 
sterilised by autoclaving for 15 minutes at 121˚C. However, after plating out medium 
incubated in the module ECS and lumen, floating impurities were visible under the 
microscope. As it was unclear whether this was a sign of microbial infection, alternate 
methods of assembly and sterilisation were investigated. Fibres and casings were 
autoclaved for 15 minutes at 121˚C and then transferred to the BSC to be assembled. 
Modules were either sterilised by soaking the ECS and lumen in 70% IMS for 15 minutes 
and drying overnight, or pumping with water overnight and then autoclaved for 20 
minutes at 121˚C. The modules were then incubated with medium overnight before 
removing and plating in a 48-well plate. After 2 days of incubation, the autoclaved 
modules did not present with any microbial infection, whereas one of the modules 
soaked in IMS showed a clear bacterial infection in both the ECS and lumen samples (see 
Appendices- Figure 69). However, floating impurities could still be seen in all the 
samples, and although there was slight motility, it was still unclear whether this was due 
to Brownian motion or due to a microbial infection. Newly assembled modules were 
sterilised by autoclaving using the same methodology as in the previous experiment and 
incubated with medium overnight. The medium was then removed and incubated in a 
48-well plate as before. The medium was also plated out onto nutrient agar plates using 
aseptic technique, and both plates were incubated for 7 days. After 7 days, no colonies 
could be observed on the sample plates from the ECS or lumen, although the floating 
impurities were still visible under the microscope (Figure 46). The positive control in the 
48-well plates showed clear microbial contamination, and the agar plates (inoculated 
with E.coli K-12) showed a lawn of bacterial growth. The floating impurities were 
therefore thought to be debris from the resin, and the methodology for sterilisation by 
autoclaving was considered efficient and employed further.   
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Figure 46: Medium samples from modules sterilised by water permeation and autoclaving. Samples were plated in TCP plates and viewed 
under the microscope at 40x magnification, and on nutrient agar plates and imaged after 7 days incubation. Smear marks can be seen on the 
positive control showing bacterial lawn, and cannot be seen in any of the other samples. Scale bars = 20µm 
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5.4.4. Module integrity assessment 
For the utilisation of the module as a bioreactor to model substrate transport, the 
integrity of the fibre itself alongside the epoxy resin seal was assessed (Figure 47). The 
pressure drop within the fibres did not vary significantly over the 2 hours indicating good 
fibre integrity before autoclaving. After autoclaving the modules an increase in the 
pressure drop was observed at both 0 and 24 hour time points, although the increase 
was not significantly different to the pressure drops seen before autoclaving at the 
respective time points. This increase could have been due to a change in either fibre 
surface causing an increase in the friction factor, or a decrease in the internal diameter 
of the fibre. However, despite the change in pressure drop, the integrity of the modules 
after sterilisation was maintained. This was further confirmed by the LY permeation 
percentages, which showed no significant difference in permeation before or after 
autoclaving.  
Although it was possible to assess the module integrity for the intact modules using 
batch 2 fibres, the variation of the fibres throughout the batch was large with many 
modules failing. This was either due to fibre breakage or leaks within the fibre appearing 
after fluid flow, observed by a drop in pressure through the fibre.  
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Figure 47: The pressure drop across modules incorporating batch 2 fibres at 0 and 24 
hours after flow at 10mL/min. The LY permeation from within the fibre through to the 
ECS is shown as data labels. No significant difference between the pressure drop before 
and after autoclaving at the respective time points, and between LY permeation was 
demonstrated.  (Mean value ± SEM, n=3) 
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5.4.5. Long term cell viability on fibres in static conditions 
Based on results obtained from the short term attachment and viability studies on the 
polymer membranes (see Section 4.4.7.2.), RPTECs were cultivated in static conditions 
on each batch of PSF+PVP fibres produced to assess long term performance. The Presto 
Blue reagent was added directly to the wells at a 1:10 dilution according to 
manufacturer’s protocols and previous protocols, and due to the secretion of factors by 
the RPTECs required for cell maintenance on the growth substrate. However, this 
methodology resulted in a large amount of fluorescence on day 2 due to the unattached, 
but still viable cells alongside the attached cells on the fibres in each well as shown in 
Figure 48. All batches showed a similar trend in growth and metabolic activity according 
to the fluorescence, which increased from day 4 to day 6, and declined at day 8. Both 
the fluorescence values and the equated cell numbers were significantly different on 
each fibre batch on each day with the exception of day 2 (p ≤ 0.05). This is again thought 
to be due to the number of metabolically active unattached cells present within the well. 
All fluorescence values were also significantly higher than the negative control, 
indicating the presence of metabolically active cells. 
To investigate morphology of cells on the fibres, the cells were stained with a live/dead 
staining kit. Batch 1 fibres showed a good coverage of cells along the fibre with the least 
amount of dead cells. However, the cells were elongated and did not appear to form a 
connected monolayer (Figure 49a-b). Cells cultured on batch 3 fibres performed the 
poorest, with a vast amount of the fibre showing no cell attachment. The fibres also 
showed the highest number of dead cells out of the three batches (Figure 49e-f). This 
could be due to the degredation or disscociation of PVP within the dope solution over 
time, resulting in a poor cell culture surface after the production of hollow fibres. Cells 
seeded on the batch 2 fibres performed the best, with a confluent monolayer achieved 
at day 9. Cells also exhibited dome like formations (Figure 49c), indicative of polarised 
transporting epithelium.  
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Figure 48: The Presto blue reduction by RPTECs on each fibre batch (a) and the cell 
number on each fibre batch (b) over 8 days in culture (Mean value ±SEM, n=3). * 
indicates a significant difference between all batches. All fibre batches on each day show 
a significant increase in RFU compared to the negative control, p ≤ 0.05 (ANOVA with 
Tukey post hoc analysis) 
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Figure 49: Visualisation of viable cells (green) and non-viable cells (red) on the exterior 
of batch 1 (a)(b), batch 2 (c)(d) and batch 3 (e)(f) after 9 days of RPTEC culture. Scale bar 
= 10µm  
(a) (b) 
(c) (d) 
(e) (f) 
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5.4.6. Cell performance in the hollow fibre bioreactors 
Throughout the culture period the modules maintained cell attachment and viability as 
demonstrated by the Presto Blue analysis (Figure 50). The highest number of cells was 
recorded at day 2 after the static culture period, but depleted over the remainder of the 
culture period under flow conditions. However, after the initial significant depletion, the 
cell number remained constant (no statistical significant decrease in cells between the 
remaining days). The predicted cell numbers over days 4-8 were within the range of 5 x 
103- 8 x 103, a mere 0.5%- 0.8% of initial cell seeding. The low cell attachment and 
metabolic activity within the bioreactors was thought to be due to the leakage of the 
fibres as tears were detected along the fibre after initial seeding, leading to cell 
migration into the ECS. This prediction however was not confirmed by nutrient and 
metabolite analysis (Figure 50b-d). Glucose consumption and lactate production was 
shown to be higher within the lumen circuit indicating the presence of cells compared to 
the ECS. Characteristic peaks and troughs were seen every 2 days in lactate production 
in the lumen due to the complete medium exchange, whereas ECS lactate amounts were 
constant indicating little metabolite transfer through to the ECS. The glucose 
consumption and lactate production also corresponded with the cell numbers indicated 
from the Presto Blue analysis, depleting over the time in culture. The yield of lactate 
from glucose was ~0.4 mol/mol, below the maxiumum value of lactate production from 
glucose (~2 mole) [307]. As it is assumed that the culture conditions did not limit the 
atmospheric oxygen, this indicated that cells were utilising glucose through the citric 
acid cycle via aerobic respiration. Ammonium production was similar within the lumen 
and ECS indicating a low rate of ammniogenesis, which may have been due to the 
glutamine concentrations within the medium. However, glutamine concentrations 
within the samples could not be reliably determined.  
Although cell numbers in the bioreactors were low and cell migration due to 
compromised fibre integrity was suspected but disproved, modules with intact fibres 
produced improved results. Presto Blue reduction was higher at all days in culture with a 
decrease from day 2 on days 4 and 6, but an increase back up to the fluorescence 
exhibited at day 2 on day 8 (Appendices- Figure 70). The nutrient and metabolite data 
showed a lower amount of glucose and higher amount of lactate within the lumen 
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circuit, indicating the presence of cells, although the trends did not correlate with the 
cell numbers indicated by the Presto Blue results as with the previous data. These 
results are promising, and may have resulted in higher cell numbers with a longer period 
of culture. However, they could not be reproduced due to the batch variation of the 
fibres within the batch.     
Page | 191  
 
Assembly and assessment of the bioartificial kidney device  Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: (a) The Presto blue reduction by RPTECs in single hollow fibre bioreactors under flow conditions (Mean value ±SEM, n=3). * indicates 
statistically significant difference to rest of the days in culture. All samples on each day show a significant increase in RFU compared to the 
negative control (NC), p ≤ 0.05 (ANOVA with Tukey post hoc analysis), (b) the glucose, (c) lactate and (d) ammonium spent medium analysis 
over 7 days culture under flow conditions (9 days overall). The red dashed line indicates the starting concentration of glucose in the medium 
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5.5. Chapter discussion and conclusion 
5.5.1. Discussion 
This chapter focuses on the generation of a BAK device incorporating tailored PSF+PVP 
hollow fibres as a renal culture substrate for characterised hPTCs. The assessment of 
long term RPTEC growth on the exterior of the different batches of fibres generated 
interesting results. Although all 3 batches of fibre were produced from the same dope 
solution, they yielded distinctly different results in cell proliferation, morphology and 
metabolic activity, with the greatest difference between batch 2 and 3 fibres. This 
finding questions reports in literature stating that PSF+PVP is not a good culture 
substrate for renal cell culture [181]. Furthermore, the variation between batches of 
fibres produced from the same dope solution identifies the need for thorough 
characterisation of polymer membranes when using additives. Aspects such as the bore 
solution and gelation bath parameters, the purity of the dope solution and degradation 
of the additive should be thoroughly investigated to ensure consistency between results. 
The use of epoxy resin as a sealant after the incorporation of the fibres into the glass 
casings has also identified some unexpected aspects that had not been reported 
previously. Small fragments were observed in culture that was not identified in previous 
assessments of sterilisation on flat sheet membranes. This calls into question the 
suitability of epoxy resin as a sealant, which has been used previously [238], and the 
long-term effects of these fragments on cells within the bioreactor. 
After incorporation within the HFB, physical characterisation of the fibres is incomplete 
alongside non-reproducible cell growth and proliferation. This is due to the suspected 
effects of fibre tearing within the cases. The use of the spinneret method of hollow fibre 
production and the effects of sterilisation on the fibre integrity should therefore be 
investigated. The spinneret method produced fibres with varying wall thicknesses in 
each batch, and as such, physical characterisation of the fibres could not be completed. 
The sterilisation effects have also not been completely ascertained, and may produce 
structural changes as has been shown in literature for other scaffolds [237], which may 
be detrimental. As a result of a lack of fibre integrity, parameters such as L(p) and TMP 
could not be ascertained and as such, the effects of these parameters on RPTECs within 
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the bioreactor could not be reported, as done by Aebischer et al [10]. Cell growth, 
proliferation and metabolic activity could not also be reproducibly reported leading to 
the incomplete assessment of the device as a whole. However, some of the findings 
from this chapter are essential in the further development BAK devices as a whole.  
5.5.2. Conclusion   
Bioreactors have been widely utilised throughout the tissue engineering field for the 
cultivation of a variety of cell types. For the generation of BAK devices, HFBs have been 
routinely used, as they are able to mimic the native architecture of the PT. The assembly 
of the device includes a number of design aspects, and as such, various parameters such 
as fibre generation and properties, choice of sealant and the method and effect of 
sterilisation have been identified as requiring further investigation from the findings in 
this chapter. Of notable importance is the difference in cell proliferation and metabolic 
activity between the fibre batches, drawing importance on the fact that although a key 
parameter was maintained (the same dope solution), there were vastly different results 
achieved. Cells however were not able to be reproducibly cultivated successfully within 
the device due to the time constraints of the project. There are many improvements, 
which can be made on the device as a whole in the generation of an optimised BAK 
device as an in vitro model for pharmaceutical research, which will be detailed in 
Chapter 6.  
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6.1. Summary  
The generation of reliable in vitro models is paramount in the current climate, where the 
demand for affordable, efficacious drugs is increasing with an expanding and aging 
population. The particular emphasis on pre-clinical model development arises from the 
time and monetary investments in bringing a new drug to market, with only 1 in 6 drugs 
that enter clinical development in phase I progressing through to FDA approval [308]. 
Current methods of pre-clinical testing utilising cellular models or proteins do not 
accurately represent in vivo conditions, thereby allowing the progression of unsuitable 
CDs through to the later stages of testing. With IVIVEs inaccurately reported, the lack of 
reliable and representable models is a major contributing factor to the failure rate of 
drug approval. The DDI potential of drugs is of particular concern in the case of renal 
diseases, as the kidney is the secondary site of drug metabolism and excretion within 
the body. Patients with impaired kidney function such as CKD are either subject to 
lifelong RRTs due to the shortage of organs available for transplantation, or subject to 
lifelong courses of immunosuppressants after transplantation. This reduction in patient 
quality of life alongside the cost of dialysis and drug therapies highlights the need for the 
generation of renal models indicative of the in vivo environment. With these factors in 
mind, the overall vision of this doctoral thesis was to develop a bioartificial kidney 
device utilising primary proximal tubule cells as an in vitro model to assess the DDI 
potentials of CDs. To achieve this four aims encompassing the pharmacological, 
biological, chemical and engineering aspects of the project were identified and 
addressed.  
Due to its application the need for robust fluorescence assays for HTS were identified to 
characterise the functionality of the drug transporters of interest. The advantages 
offered using fluorophores over radioligands currently utilised in HTS assays include 
being more cost effective, safe and easier to handle. Polarised monolayers of cells were 
initially desired to characterise the functionality of P-gp, as the arrangement of cells with 
specialised barrier functions are more indicative of native epithelial cells. P-gp was 
chosen as the transporter of interest as it is an efflux transporter with a wide range of 
substrate specificities. Initial assay development focussed on the transport of Rho123 
through monolayers of MDCKII (wild type) cells. Although the active transport of Rho123 
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was detected, the results could not be reproduced. This was due to high LY percentage 
permeation through the monolayers during the assay of the second run indicating 
monolayer damage. The cause for this damage across all concentrations was unknown in 
the second run, however, in both runs LY permeation increased after the assay. In run 1, 
this exceeded the 1% threshold in the B-A direction at the higher (50µM-200µM) 
concentrations tested, indicating the potential toxicity of Rho123. When scaled down to 
incorporate Rho123 transport through MDCK-MDR1 cells alongside MDCKII cells, active 
transport was detected at the lower (1µM and 2µM) concentrations. Although the LY 
permeation was above the threshold percentage, the assay was run again at a lower 
concentration range to decrease the likelihood of monolayer damage due to Rho123. 
Monolayer integrity was acceptable at the 10nm-100nm concentration range; however, 
no active transport was demonstrated through either cell line. It was therefore 
concluded that the Rho123 assay for the assessment of the functionality of P-gp on 
polarised monolayers of cells was unsuitable.  
As a lack of intact polarised cell monolayers were achieved on transwell inserts 
alternative methods of transporter characterisation were investigated. These utilised 
non-polarised monolayers of cells grown on flat well plates. Calcein-AM was established 
as a probe substrate for the P-gp efflux assay as the molecule becomes a P-gp substrate 
after it has been cleaved into its fluorescent form inside the cell. In the presence of 
inhibitors the fluorescence increased indicating P-gp functionality on MDCK-MDR1 cells. 
The cross specificity of Calcein-AM for other efflux transporters was also investigated by 
applying the assay to MDCK-BCRP cells in the presence and absence of BCRP and P-gp 
inhibitors. The resulting lack in fluorescence from the uninhibited sample set confirmed 
that Calcein-AM could be applied as a selective P-gp substrate in multi-transporter 
systems to assess P-gp functionality.    
For the assessment of the efflux transporter BCRP Hoechst 33342 was selected as the 
fluorescent probe in the same assay design used for P-gp characterisation. A range of 
concentrations were applied to MDCK-BCRP cells to ascertain the most suitable 
concentration. 20µM of Hoechst 33342 provided the highest fold increase in 
fluorescence from the uninhibited sample in the presence of Ko143 with the lowest 
amount of error. Hoechst 33342 was also found to be a specific substrate for BCRP in 
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cells overexpressing P-gp as there was no significant increase in fluorescence in the 
presence of P-gp inhibitors from the uninhibited sample. Ko143 was found to be a 
potent inhibitor of BCRP, whereas Novobiocin was less effective at the concentrations 
used. This could be due to Novobiocin exerting the inhibitory effect on a part of the 
transporter not responsible for Hoechst 33342 efflux. Regardless of the Novobiocin 
ineffectiveness, Hoechst 33342 was confirmed as a suitable probe substrate for BCRP in 
the presence of other efflux transporters.  
OCT2 was selected as the uptake transporter of significance to be characterised on HEK-
OCT2 cells. ASP+ uptake was assessed at a range of concentrations in the presence and 
absence of the OCT2 inhibitors Imipramine and Ipratropium. Due to the nature of the 
transporter the assay design was altered and required lysing of the cells to measure the 
amount of ASP+ taken up within the cells. This lead to a high amount of variability in the 
uninhibited sample set, however, a significant decrease in fluorescence was detected in 
the presence of both Imipramine and Ipratropium at the 20µM concentration. As ASP+ is 
a fluorescent molecule the uptake amount was able to be quantified which was an 
advantage over the efflux assay design. ASP+ is also an OCT2 specific substrate and can 
therefore be applied in cells expressing multiple uptake transporters without the need 
of cross specificity analysis.  
Once the assays had been developed to assess the functionality of specified transporters 
they were then applied in RPTECs alongside the genetic and surface transporter 
expression analysis. Due to the cost of the cells per vial the degree of transporter loss 
was characterised over a range of doublings. This was to enable cell banking whilst 
retaining transporter expression and functionality similar to the initial doubling. Cells 
seeded at Pd=5 demonstrated the functionality of BCRP and OCT2, the surface 
expression of P-gp, BCRP, OCT2, MRP2, OAT3 and MATE1 and the genetic expression of 
BCRP and OCT2 similar to Pd=0 over the other doublings tested. The functionality results 
and genetic expression data for P-gp showed an increase at the later doubling (Pd=9) 
from the initial decrease, indicating an upregulation in the transporter. This may be 
demonstrative of cell adaptation to the in vitro environment, although the surface 
expression appeared to decrease through the doublings. However, overall Pd=5 proved 
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to be the most suitable doubling to seed at whilst allowing the most cost effective 
method of generating sufficient cell numbers for incorporating into the bioreactor. 
Due to the potentially porous nature of the generated fibres, RPTEC culture on porous 
surfaces with a range of coatings was investigated. Although utilised in literature for 
renal cell growth [168] PCT transwell inserts did not provide a suitable surface for RPTEC 
culture, with consistently high LY permeation throughout the culture period. The 
monolayer integrity was not improved when cultured on the various coated surfaces as 
LY permeation remained above the adjusted 2% threshold. Furthermore transwell 
inserts coated with Matrigel, which showed the best maintenance of the cell monolayer 
over the culture period, was found to block the membrane pores. This deemed the 
coating unsuitable as it may have impaired the transport of substrates through the 
membrane, impeding the use of the developed assays and further testing within the 
final device.  
As surface coatings could not be applied to the membranes in the final device, the 
generation of membranes specific to renal cell growth was investigated. Properties 
favourable to renal cell growth include hydrophilic, negatively charged surfaces. 
Therefore, carboxylic acids were incorporated onto the PSF backbone alongside PVP 
which is widely used to increase the biocompatibility of surfaces. The generated flat 
sheet membranes using MA and GA as an additive did not show incorporation of the 
acids onto the surface and an increase in hydrophobicity from the pure PSF membranes. 
Although the surface roughness was similar for all membrane blends, the consequent 
RPTEC culture demonstrated a decrease in the metabolic activity of cells over a short 
term culture period on these membranes. The inclusion of PVP onto the PSF backbone 
increased the hydrophilicity of the surface and demonstrated renal cell attachment and 
metabolic activity similar to the TCP control. The membranes were also able to be 
effectively sterilised by autoclaving whilst retaining their structural integrity, proving 
valuable for both the cell culture application and the assembly process. 
Hollow fibres were produced using the NIPS method utilised in the flat sheet membrane 
generation. 2 continuous batches were initially produced, altering the pressure and 
water flow rates to adjust the wall thicknesses. Due to the fragility of these fibres, a 
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third batch with thicker walls was later produced. Although the fibres were easier to 
handle they were less porous and permeable to water than the previous batches. Long 
term growth of RPTECs on the exterior of the fibres was also drastically impaired, 
concurrent with the long term viability of renal cells on membranes incorporating PVP in 
literature [181]. However the earlier batches of fibres demonstrated a vast 
improvement in cell growth and metabolic activity, with cells cultured on batch 2 fibres 
performing the best with cell morphology indicating polarised transporting epithelium 
formation. Upon further investigation this was not due to the surface topography of the 
fibres, which were similar across all batches on the interior and exterior sides, and 
therefore may be due to the degradation of the PVP in the dope solution over time.  
Batch 2 fibres were then incorporated into single fibre glass casing to produce modules 
for cell seeding. Sterilisation by autoclaving was effective, although water was required 
to permeate the fibre to ensure the complete sterilisation of the fibre and casing. 
Although the fibres were fragile they demonstrated the ability to remain intact under 
high flow rates over 24 hours after sterilisation. However, variability in the fibre integrity 
throughout the batch was discovered and many modules failed due to unseen tears 
within the fibres. The compromised fibres consequently demonstrated poor cell 
performance over 7 days under flow conditions when seeded with RPTECs. Calculated 
cell numbers dropped to 0.5% of the initial seeding density, which was reflected in the 
metabolic activity and nutrient and metabolite analysis over the culture period. 
Subsequent analysis techniques such as imaging and PCR could not be undertaken due 
to the low cell numbers. However, in intact fibres the metabolic activity pattern 
indicated a rise in cell numbers after an initial drop after applying flow conditions. This is 
promising and may have led to an increase in cell numbers to form an acceptable 
monolayer over an extended culture period.  
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6.2. Discussion 
The device generated from this project satisfied a number of criteria that are required in 
a reliable in vitro model for pharmaceutical research. The device incorporated primary 
renal cells, which had been characterised in terms of drug transporter expression and 
functionality. The methods of drug transporter functionality were developed as 
fluorescence assays to reduce the monetary, safety and disposal concerns currently 
encountered from the use of radioligands. The porous polymer membrane had been 
tailored as a renal culture substrate without the use of protein coatings and 
demonstrated the proliferation of cells and the formation of a tight monolayer of cells in 
static culture. For the application of flow, shear stresses similar to the physiological 
environment of the PT [19] were applied to encourage the formation of an improved 
functional monolayer of cells within the device. The device design was also generated to 
mimic the native architecture of the PT to a degree, allowing the formation of a tubule 
of cells with the lumen representing the ultrafiltrate, separated by the membrane 
support from the ECS representing the vascular supply. 
Although the device demonstrated progression in various aspects such as assay 
development, drug transporter capabilities of primary cells over time in in vitro culture 
and polymer membrane development as a substrate for renal cell culture; the 
functionality of the device as a whole is yet to be improved compared to the models that 
currently exist. hPTC monolayer formation and cell functionality is yet to be 
demonstrated within the device, as reported in many other devices such as the RAD [11], 
Kidney on a chip [13] and BRECS [15]. The degree of similarity between the generated 
device and the existing models also varies significantly. The generated device and the 
RAD share a similar structure to the PT, generating a tubule of cells with a lumen and an 
ECS, whereas the Kidney on a chip device forms a flat monolayer of cells to separate the 
apical and basolateral compartments of the device. In this way the transport of 
substances through the monolayer can still be ascertained. However, there is no flow in 
the basolateral compartment. The BRECS varies the most in device design, owing to the 
clinical endpoint of the device. Although this allows the generation of a large cell 
population within the device, transport capabilities are not assessed, and the generation 
of small proteins and hormones is ascertained by the a selective filter. The footprint of 
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the devices is also an important aspect to consider when developing models for 
pharmaceutical research. The generated device has a relatively large footprint owing to 
the requirement of 2 pumps to provide flow to the lumen and ECS circuits, whereas the 
requirement of the Kidney on a chip device is reduced. The size of the Kidney on a chip 
device is also drastically reduced compared to the generated device, allowing multiple 
devices to be utilised. The generated device, whilst allowing multiple modules to be run 
at the same time, is more difficult to handle due to its increased size and setup. Another 
important design aspect that is addressed in the Kidney on a chip system is the use of 
transparent components in order to observe cells directly within the device. Due to the 
use of PSF+PVP membranes the resulting hollow fibres were opaque, and cells were 
monitored indirectly via metabolite analysis and Presto blue reduction. One of the final 
criteria which has not been addressed in this device is the complete characterisation of 
fluid flow through and across the before and after cell seeding. This was addressed in 
the HFB generated by Aebischer et al [9][10][279], detailing the effect of fluid flow 
through the fibre in terms of shear stress effects on cells, and through the membrane 
wall in terms of TMP effects on cells. 
These criteria, once addressed will aid in the generation of an optimised in vitro model 
of the proximal tubule for use in pharmaceutical research. Other aspects to be 
addressed to achieve this aim are detailed in Section 6.4. 
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6.3. Conclusions 
This doctoral thesis addresses the need for more reliable in vitro models within the 
pharmaceutical industry by developing a bioartificial kidney device incorporating 
primary human renal cells. The approach to this project identified four main elements, 
summarised in Section 1.2., which have been investigated as thoroughly as possible.  
The first aim of the project was to develop a panel of fluorescence assays to replace the 
current assays using radioligands to assess renal drug transporter functionality. Although 
functionality assays using fluorescent substrates have been developed, there is currently 
no complete panel available. Assays assessing the functionality of 3 renal transporters: 
P-gp, BCRP and OCT2 were developed in cell lines overexpressing the transporter in 
question. The cross specificity of substrates between the 2 efflux transporters was also 
addressed to ensure the functionality for the individual transporter could be assessed in 
cell systems expressing multiple transporters. However, these assays were developed in 
non-polarised monolayers of cells, as intact cell monolayers could not be achieved 
through the bidirectional transport assay developed for the assessment of P-gp.  
The second aim of the project was to determine the transporter capabilities of primary 
human renal proximal tubule cells over time in in vitro culture. As well as defining the 
transporter characteristics over time in vitro, which has not been reported in literature 
to date, the expansion of cells was also required in order to generate the numbers of 
cells required for the seeding of the device. The functionality assays developed 
previously were employed alongside genetic expression analysis and surface 
visualisation to determine the degree of transporter expression and function loss. Pd=5 
demonstrated sufficient transporter functionality and expression compared to the 
starting doubling, although later doublings indicated the upregulation and increased 
function of P-gp. OCT2 functionality however could not be reliably determined due to 
the assay format resulting in the loss of cells.  
The third aim of the project was develop a suitable substrate for renal cell culture. 
Membrane tailoring arose from the finding that porous commercial membranes did not 
generate acceptable monolayers of cells, even with the use of protein coatings. 
Therefore polymer blends based on a PSF backbone were produced and physically 
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characterised. Although reported as an unsuitable renal cell culture substrate, PSF+PVP 
demonstrated the best results, in terms of increased hydrophilicty, alteration of surface 
chemistry and short-term renal cell metabolic activity. The membranes were also shown 
to be sterilised effectively with no apparent structural changes. The success of the 
PSF+PVP blend allowed the progression into hollow fibre production and the 
achievement of the next project aim. 
The fourth project aim was to incorporate hollow fibres into glass casings to generate 
single HFBs for the culture and assessment of RPTECs. Devices were generated and cells 
were successfully seeded within the device, however reproducible cell expansion did not 
occur and the resulting analysis of transporter expression and functionality could not be 
done. The investigation into long-term static culture on the exterior of the hollow fibres 
did present some interesting results, prompting the need for further research into the 
variation between fibre batches and the status of PVP in the dope solution over time.   
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6.4. Further Work     
This work has demonstrated proof of concept of the assembly of a bioartificial kidney 
device incorporating primary human renal cells with characterised transporter 
expression and functionality for use in DMPK research. However, to be a fully functional 
validated in vitro model a number of challenges must be addressed. 
Developing functionality assays for the full panel of transporters desired for assessment 
(OAT3, MRP2 and MATE1) alongside improving the existing method for uptake (OCT2) 
transporter analysis would be required. Fluorophores and specific inhibitors for the 
remaining transporters would need to be identified and applied in cell lines 
overexpressing the transporters to assess both the viability of the compounds and the 
cross specificity of the substrates. The continued development of assays on polarised 
monolayers would also be advantageous to understand the transport of substrates 
through cell monolayers representative of the native renal epithelium. This would 
initially require the culture of intact cell line monolayers on transwell inserts for assay 
development, before the application of the transport assays on RPTEC monolayers. To 
achieve this RPTEC culture could be tested out on a variety of membranes over a long 
culture period to ascertain the optimal conditions for monolayer integrity. Fluorophores 
utilised in the assays detailed in this thesis may need to be changed in the alteration of 
the assay design to inherently fluorescent molecules. This would allow the detection of 
substrate in the transport buffer and allow standard curves to be generated.  
Alongside assay development and transporter functionality, further characterisation of 
RPTECs seeded at Pd=5 compared to the initial doubling would be beneficial. The genetic 
expression of the full panel of transporters would indicate the changes in expression 
over time in vitro. Alternative cell sources could also be characterised to investigate 
whether a more cost effective source of cells with similar or improved transporter 
expression and functionality is available. The presence of tight junction complexes 
would also need to be ascertained by to ensure the cells are capable of forming 
polarised monolayers in vitro.       
Further development of the membrane materials for RPTEC culture is required to 
characterise the dope solution, assessing the rate of degradation of the PVP and to 
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control the porosity and skin layer formation during production. The removal of the 
nitrogen contaminations found in this work by degassing the dope solution under a 
vacuum also may prove valuable in terms of physical properties and renal cell 
performance. Other blends incorporating acrylic based monomers or phospholipid 
polymers could be trialled as reports in literature indicate they are an improved 
substrate for renal cells [181][193]. The development of membranes with good optical 
properties will also be beneficial to observe cells on the membranes and eventually 
within the fibres. However, this will require the formulation of new polymer based 
blends as PSF based blends are opaque. The long term viability of cells on the 
membranes and the ability for cells to form confluent monolayers would also need to be 
assessed alongside the other physical characterisation techniques used in this thesis.  
The method of fibre production is a key challenge to address as much of the resulting 
data collected was impaired due to a lack of fibre integrity. The production process 
would need to be fully characterised, including determining the pressures and water 
flow rates with the corresponding wall thicknesses, and ensuring a consistent feed of 
homogenised polymer into the gelation bath to improve the uniformity of the wall 
thickness. Introducing an air gap into fibre production before entering the gelation bath 
may also be beneficial to increase the porosity of the fibre exterior [309] thereby 
improving transport through the membrane. Transport of small molecules through the 
lumen layer would also need to be established, with the porosity of the skin layer 
altered accordingly by introducing a non-solvent/water mix as the bore fluid. This is a 
key aspect in the device design as water flux was found to be quite low in the fibres 
generated and is required for determining the transport of compounds through the cell-
fibre layer.  
Modelling is also an important tool to utilise in further development of the device. By 
applying mass transfer models described in literature [290][292] alongside the 
computational analysis of aspects such as fluid flow through the fibre, an optimised BAK 
device can be generated for renal cell proliferation.  
To produce a model capable of reproducible results, the individual assembly of the 
device would need to be kept consistent. This would include the method used to seal 
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the fibres into the module, the position of the fibre within the module and the 
environment within the casing. Using adhesives which do not produce residues, as seen 
in this work would be beneficial as the effect of the fragments on the cells is unknown 
and could exert damaging effects over the culture period. Producing disposable modules 
would reduce the time spent on cleaning the casings and ensure all residues are 
removed from the module before each run. However, the module would need to be able 
to withstand autoclaving as other methods of sterilisation such as gamma irradiation are 
not as cost effective.         
The device design would also need to be optimised to allow easy incorporation into 
current methods employed in DMPK testing. In this thesis, syringes pumps with 
maximum syringe volumes of 20mL were utilised to allow more than 2 modules to be 
run at the same time. Syringe pumps were utilised as they were the best option at the 
time of design to provide both a low flow rate and a smooth action of flow within the 
device. However, to apply the desired flow rate of 50µl/min, the syringe had to be 
replaced and refilled from the medium reservoir every 6 hours. This is not practical for 
use in industry; however, a number of options are available to counter this problem. The 
device could be scaled down to allow a smaller flow rate to be applied to exert the same 
shear stress on the cells within the fibres. However, this would require smaller modules 
and fibres to be produced, which would prove more difficult to assemble and 
adequately sterilise. A more effective scaled down design would resemble a kidney-on-
a-chip type layout, of which there are currently many being developed. Another option 
is to incorporate a recirculatory pump within the device instead of a syringe pump to 
allow the constant exchange of medium throughout the culture period. Peristaltic 
pumps which provide the low flow rates required for this device are available, although 
the medium flow is pulsatile which is less comparable to the flow within the proximal 
tubule. However, the capacity for some peristaltic pumps range between 4 and 32 
channels (205S/CA; Watson Marlowe. UK), allowing the multiple running of modules at 
the same time. This is therefore a more desirable option using the same module setup 
described within this thesis.       
To make the bioreactor suitable for application in DMPK testing, the culture of cells into 
a polarised monolayer would have to demonstrated and assessed. This would require 
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the development of permeability assays similar to the LY permeation assays utilised in 
the assay development section of this work. Other possible fluorescent molecules for 
permeation studies include FITC-inulin which does not permeate an intact cell 
monolayer and is widely used in literature [168][310][311]. Wider studies into the 
monolayer formation within the device also need to be applied to ascertain the optimal 
conditions for renal cell growth. These include the optimal flow rate to apply within the 
device by looking at cell removal from the lumen at different flow rates, the optimal 
culture period for cell culture to produce a confluent polarised cell monolayer, and the 
effect of co-current versus counter current flow of medium in the ECS compared to the 
lumen. As the device will be utilised for DMPK studies the monolayer does not need to 
be maintained for a prolonged period of time, however, alternative applications of this 
device could be for use in long term toxicity and clearance studies. For these 
applications it would be necessary to maintain polarised cell monolayers for weeks to 
allow long term testing. 
Finally, cells will need to be characterised within the device utilising assays developed in 
this thesis alongside other assays described in this further work section. The device will 
require validation to ensure consistency and reproducibility of results before being 
incorporated into the industrial setting. The enhanced expression and functionality of 
transporters within the device will provide an in vitro model more indicative of the 
physiological conditions within the proximal tubule. This will enable IVIVE more 
predictive of the in vivo situation, therefore allowing time and money to be reduced in 
both the DMPK and wider development of NCEs in the future.      
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1. List of Equipment 
- Agilent 2100 bioanalyzer; Agilent Technologies, UK 
- Contact angle system; Dataphysics Instruments, Germany 
- CM-0045 CO2 meter; CO2 Meter Inc, USA 
- Delta 20BM spin coater; BLE Laboratory Equipment, Germany  
- Emitech SC7640 Sputter Coater; Quorum Technologies, UK 
- Eppendorf 5804 centrifuge; Eppendorf, UK 
- FEGSEM; Carl Zeiss, Germany 
- Fluostar Omega; BMG Labtech, Germany  
- Galaxy 170r Incubator; New Brunswick Scientific, UK  
- Grant 24L unstirred water bath; Thermo Scientific, UK 
- Heraeus HERAcell 150 CO2 Incubator; Thermo Scientific, UK 
- Herasafe KS Class II Biosafety Cabinet; Thermo Scientific, UK 
- K-AlphaTM X-ray photon spectrometer system, Thermo Scientific, UK 
- Magnetic Stirrer 11-102-17S; Thermo Scientific, UK 
- MilliQ ultrafiltration unit, Millipore, UK 
- Nanodrop 2000c, Thermo Scientific, UK 
- Nikon Eclipse Ti Fluorescence Microscope; Nikon Instruments, UK   
- Nikon TS-100 Inverted Microscope; Nikon Instruments, UK  
- NucleoCounter NC-100 mammalian cell counter; Chemometec, Denmark 
- NucleoCounter NC-3000 mammalian cell counter; Chemometec, Denmark 
- PHD Ultra syringe pump; Harvard Apparatus, USA 
- Polarstar Omega, BMG Labtech, Germany 
- REMS Autosampler, World Precision Instruments, USA 
- Sanyo MIR-S100C Flask Shaker Platform; Sanyo Biomedical, UK 
- StepOne plus RT-PCR system; Applied Technologies, UK 
- Systec VX-95 autoclave, Systec, Germany 
- Veeco Explorer atomic force microscope, Veeco Instruments, USA 
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2. List of Equations 
2.1. Equation 1: Cell Counting and viability 
 
(1) Cx(v)͞ = Cx(c) / 4 
(2) Cx(v)͞/mL = Cx(v)͞  * df 
(3) Cx(v) = Cx(v)͞/mL * V(0) 
(4) V(f) = Cx(v) / SD 
 
Where: Cx(v)͞ is the average viable cells, Cx(c) is the cell count on the haemocytometer, 
Cx(v)͞/mL is the average viable cells per mL, df is the dilution factor of trypan blue to 
sample, Cx(v) is the total viable cells, V(0) is the cell suspension volume, V(f) is the 
resuspension volume and SD is seeding density.   
2.2. Equation 2: Population Doublings 
 
Population doubling = 3.32 * (log Cx(t) – log Cx(0)) + x 
 
Where Cx(t) is the cell yield, Cx(0) is the initial cell number and x is the previous number 
of cell doublings.  
2.3. Equation 3: Transepithelial electrical resistance (TEER Ω/cm2) 
 
TEER= (TEER (s)͞ – TEER (b �)) / SA 
 
Where: TEER(s)͞ is the average TEER measurement of the sample well, TEER(b �) is the 
average TEER measurement of the blank well and SA is the surface area of the transwell 
insert. 
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2.4. Equation 4: Apparent Permeability (Papp x 106/ cm2) 
 
Papp = (dQ/dt) * V / A * C0 
Where: dQ/dt is the rate of drug transport (nmol L-1/min), V is the volume of the 
receiver compartment (mL), A is the surface area of the membrane (cm3) and C0 is the 
initial donor concentration (nmol/L) 
2.5. Equation 5: Efflux Ratio  
 
Efflux ratio = Papp (B-->A) / Papp (A-->B) 
Where: Papp (B-->A) is the apparent permeability in the basolateral to apical direction 
and Papp (A-->B) is the apparent permeability in the apical to basolateral direction. 
2.6. Equation 6: Fibre porosity (%) 
 
 ε = (((Ww – Wd) / ρw) / ((Ww – Wd) / ρw) + ρp) * 100% 
Where: Ww is the mass of the wet membrane (g), Wd is the mass of the dry membrane 
(g), ρw is the density of water (1.0 g/cm3) and ρp is the density of the membrane (g/cm3). 
2.7. Equation 7: Volumetric water flux (m3/m2·s) 
 
J = Vp / tA 
Where: Vp is the volume of permeate collected, t is time (h) and A is membrane surface 
area (m2). 
2.8. Equation 8: Hydraulic permeability (Pa m3/m2·s) 
 
Lp = J / ΔP 
Where: J is the volumetric water flux (m3/m2·s) and ΔP is the transmembrane pressure 
(Pa) 
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3. Development of MDCKII cell growth in transwells  
To ascertain culture conditions for MDCKII growth on the porous transwell inserts due to 
poor visibility through the membrane insert, cells were seeded at a range of cell 
densities and cultured over a period of 7 days on 12 well transwell inserts (0.4µm, 
1.12cm² insert area). LY permeation percentages were obtained daily from day 3 
onwards. The seeding densities: 1 x 105, 5 x 105, 1 x 106, 2 x 106 and 5 x 106 were 
calculated at cells per well, and medium was changed on day 2 after seeding. It was 
noted that the wells seeded at 2 x 106 and 5 x 106 contained detached cells in the 
medium indicative of an excess of cells, at seeding on the day 2 medium change.   
 
Figure 51: LY permeation over 7 days in monolayers of MDCKII seeded at a range of 
seeding densities (n=1) 
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4. Rhodamine 123 transport in MDCK-MDR1 and MDCKII cells  
TEERs were measured before the Rho123 assays as an indication of monolayer integrity 
by using an automated TEER reader (REMS Autosampler, WPI, USA). Briefly, electrodes 
were placed in the insert and well of the transwell plate, and the resistance of the 
monolayer was measured. The values were then divided by the insert area (0.11cm2) to 
determine the TEERs. TEERs of above 500Ω/cm² were deemed as viable and used in the 
Rho123 assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: TEER values at a range of concentrations of Rho123 between 1µM and 100µM 
before the bidirectional transport assay in (a) MDCKII and (b) MDCK-MDR1 cell 
monolayers (Mean value ± SEM, n=3) 
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Figure 53: TEER values at a range of concentrations of Rho123 between 10nM and 
2000nM before the bidirectional transport assay in (a) MDCKII and (b) MDCK-MDR1 cell 
monolayers (Mean value ± SEM, n=3) 
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5. Calcein-AM efflux in the presence of P-gp inhibitors in MDC-MDR1 cells 
MDCK-MDR1 cells were incubated with Calcein-AM in the presence and absence of the 
P-gp inhibitors Quinidine, Verapamil (Figure 54a) and Ketoconazole (Figure 54b). The 
fluorescence over the 71 cycles are shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54: Calcein-AM fluorescence in MDCK-MDR1 cells in the presence and absence of 
the P-gp inhibitors Quinidine, Verapamil (a) and Ketoconazole (b) over 71 cycles 
(approximately 60 minutes) (Mean value ± SD, n=9) 
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6. Calcein-AM degradation and its effect on fluorescence  
As with other substrates, Calcein-AM was diluted from its desiccated form in DMSO to a 
stock concentration, and then diluted in transport buffer for the assay. The 
recommended storage conditions are for 2 weeks at -5°C to -30°C (Life Technologies 
product manual). However, following the use of Calcein-AM diluted in DMSO within the 
specified period in a repeat of the above assay, there was evidence that this period 
might not be sufficient to prevent Calcein-AM degradation.  
During the cycles, the Calcein-AM fluorescence is did not change in the absence of an 
inhibitor, and started off at cycle 1 at a relatively high reading of 406 RFU. Compared to 
the previous 2 experiments, this starting value was approximately 4 times higher. This 
was also seen in the presence of 2 inhibitors Verapamil and Ketoconazole at 
approximately the same RFU values throughout the cycles. This suggests the 
degradation of the Calcein-AM forms a complex which is fluorescent, but is either not 
affected by esterases within the cells, or cannot be transported through to the cells. In 
the presence of Quinidine, the fluorescence values were noticeably higher than any 
other state. However the same steady levels in fluorescence throughout the cycles, at 
approximately 1000 RFU, indicated this is an artefact from the Quinidine and Calcein-AM 
rather than any effects from the cell. This raises the question of the suitability of the 
inhibitors to their corresponding transporter in the presence of specific fluorophores, 
and whether the substrate and inhibitors form fluorescent complexes independent of 
the cell (Figure 55).  
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Figure 55: Calcein-AM fluorescence in MDCK-MDR1 cells in the presence and absence of 
the P-gp inhibitors Ketoconazole, Verapamil and Quinidine over 71 cycles 
(approximately 60 minutes) (Mean value ± SD, n=9) 
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7. Hoechst 33342 concentration assessment for efflux assay  
MDCK-BCRP cells were incubated with varying concentrations of Hoechst 33342 in the 
presence and absence of the BCRP inhibitors Novobiocin and Ko143 (Figure 56). 20µM 
H33342 demonstrated the highest fluorescence in the presence of inhibitors and was 
repeated (Figure 57). The fluorescence over the 71 cycles are shown below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Fluorescence of Hoechst 33342 at (a) 1µM and (b) 5µM in MDCK-BCRP cells in 
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the presence and absence of the BCRP inhibitors Novobiocin and Ko143 throughout 71 
cycles (approximately 60 minutes) (Mean value ± SD, n=8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56 continued: Fluorescence of Hoechst 33342 at (c) 10µM and (d) 20µM in 
MDCK-BCRP cells in the presence and absence of the BCRP inhibitors Novobiocin and 
Ko143 throughout 71 cycles (approximately 60 minutes) (Mean value ± SD, n=8) 
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Figure 57: Fluorescence of Hoechst 33342 at 20µM in MDCK-BCRP cells in the presence 
and absence of the BCRP inhibitors Novobiocin and Ko143 throughout 71 cycles 
(approximately 60 minutes) (Mean value ± SD, n=18) 
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8. RPTEC growth profile  
The culture of RPTECs to produce a growth curve was done over a 16 day period. RPTEC 
cell counts were performed over various time points to establish the cumulative 
population doubling over time. The equation was then used to calculate the doublings of 
cells cultured for 0 (Pd=0), 7 (Pd=5), 14 (Pd=7) and 24 (Pd=9) days for experimental use. 
Initially cells up to the guaranteed doubling by the manufacturer (Pd=15) were going to 
be used, however the length of time and consumables needed for cell culture was too 
large.  
 
 
 
 
 
 
 
 
 
 
Figure 58: Growth curve of RPTECs over 16 days (Mean value ± SEM, n=3) 
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9. RNA integrity assessment 
RNA stock solutions were run on the Agilent 2100 bioanalyzer to assess RNA integrity. All 
sample and ladder electropherograms displayed the typical peaks exhibited in 
eukaryotic cells i.e. a marker peak (2 small peaks) and two ribosomal peaks (18S and 28S) 
(Figure 59).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Electropherograms showing successful RNA runs in terms of integrity (a-c) 0, 
(d-f) 5, (g-i) 7, (j-l) 9 doublings with the reference ladder (m) 
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10.  Calcein-AM efflux assay in RPTECs at various population doublings  
Calcein-AM was incubated with RPTECs seeded at doublings 0, 5, 7 and 9 in the presence 
and absence of Verapamil and Ketoconazole to assess P-gp functionality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Calcein-AM fluorescence in RPTECs seeded at (a) 0 and (b) 5 doublings in the 
presence and absence of the P-gp inhibitors Verapamil and Ketoconazole over 71 cycles 
(approximately 60 minutes) (Mean value ± SD, n=36) 
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Figure 60 (continued): Calcein-AM fluorescence in RPTECs seeded at (c) 7 and (d) 9 
doublings in the presence and absence of the P-gp inhibitors Verapamil and 
Ketoconazole over 71 cycles (approximately 60 minutes) (Mean value ± SD, n=36) 
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11.  Hoechst 33342 efflux assay in RPTECs at various population doublings  
Hoechst 33342 was incubated with RPTECs seeded at doublings 0, 5, 7 and 9 in the 
presence and absence of Novobiocin and Ko143 to assess BCRP functionality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61: Hoechst 33342 fluorescence in RPTECs seeded at (a) 0 and (b) 5 doublings in 
the presence and absence of the BCRP inhibitors Novobiocin and Ko143 over 71 cycles 
(approximately 60 minutes) (Mean value ± SD, n=36) 
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Figure 61 (continued): Hoechst 33342 fluorescence in RPTECs seeded at (c) 7 and (d) 9 
doublings in the presence and absence of the BCRP inhibitors Novobiocin and Ko143 
over 71 cycles (approximately 60 minutes) (Mean value ± SD, n=36) 
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12.  RPTEC culture in transwell plates 
RPTEC culture was initially attempted in static plates on polycarbonate transwell inserts 
as performed in literature [168] at a seeding density of 3.13 x 105 cells/cm2 (Figure 62). 
LY permeation was assessed on days 4, 6 and 8, with a higher percentage of LY 
permeating than the initial threshold (≤ 1%). On day 6 LY permeation was within the 
raised threshold (2-3%). RPTEC culture was then trialled at a higher seeding density (4.46 
x 105 cells/cm2) with cells incubated for 1 day in static conditions before culture on a 
shaker platform at 90rpm. LY permeation was assessed on days 2, 4 and 6. The LY 
percentage permeation on days 2 and 4 were both within the higher threshold, with day 
4 displaying the lowest percentage (2.28%). 
 
 
 
 
 
 
 
 
 
 
Figure 62: LY percentage permeation through RPTEC monolayers cultured in static and 
agitated conditions over 8 days against a no cell control. (Mean value ± SEM, n=4)   
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13.  Presto Blue assay calibration curves 
The Presto Blue assay was used to assess the metabolic activity of RPTECs on fibres in 
static and flow conditions over time (described in Section 4.4.7.2. and 5.4.6. 
respectively). Calibration curves were generated to equate fluorescence with the 
number of metabolically active cells present. Cells were seeded in a 48 well plate at 
varying cell densities for the membrane and fibre curves respectively. The cells were left 
to attach for four hours before carrying out the assay, where medium was aspirated 
from each well and replaced with the Presto Blue reagent at a 1:10 dilution. Cells were 
incubated for 40 minutes at 37˚C before sampling three times and reading on the 
microplate reader. Cells were then removed from the wells and counted. The cell 
numbers were plotted against RFU of the samples (Figure 63).  
 
 
 
 
 
 
 
 
 
 
 
Figure 63: Presto blue calibration curve with recovered cells from the well against 
fluorescence intensity (RFU). (Mean value ± SEM, n=3) 
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14.  Membrane sterilisation 
Membrane sterilisation was investigated by measuring the OD of incubated nutrient 
broth (Figure 64) and performing spread plates (Figure 65). Membrane discs were 
incubated for 48 hours in nutrient broth before analysis. 
The OD was measured at both 600nm and 660nm to investigate both bacterial and 
fungal growth. Fresh broth incubated for 48 hours was used as the blank for all samples. 
All samples displayed ODs similar to the blank, with only two samples showing a slight 
increase in ODs at 660nm (autoclaved PSF and IMS sterilised PSF+PVP). However, when 
comparing this to the positive E.coli K-12 control incubated for 24 hours and the spread 
plates, the increase indicates machine error. The spread plates were all clear except for 
antibiotic sterilised PSF and autoclaved PSF+GA. However as only 1 colony was present 
on each of the plates, whereas the positive control had too many colonies to count, the 
contamination was assumed to be due to operator technique.      
 
 
 
 
 
 
 
 
 
 
Figure 64: The optical density at 600nm (a) and 660nm (b) of nutrient broth incubated 
for 48 hours with sterilised membranes: PSF, PSF+PVP, PSF+MA and PSF+GA against a 
positive E.coli control  
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Figure 65: Images of spread plates incubated with nutrient broth from PSF, PSF+PVP, 
PSF+MA and PSF+GA membranes after sterilisation with IMS, antibiotics and autoclaving 
with a positive and negative control plate. Red circles indicate the presence of a 
bacterial colony on the plates.    
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15.  Membrane sterilisation images 
Flat sheet membranes were sterilised as described in Section 4.3.7. Membrane cross 
sections were then imaged via SEM. During processing membrane cross sections were 
damaged, although the macrovoid structure can be seen in some images.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: Cross sections of PSF, PSF+PVP, PSF+MA and PSF+GA membranes sterilised 
using 70% IMS (a-c), Antibiotic/ antimycotics (d-f) and autoclaving (g-i). Scale bars = 2µm
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16.  Bioreactor setup  
An incubation chamber was originally designed to house the pumps and modules during 
RPTEC culture in the HFBs. The chamber was assembled with a clear polycarbonate lid 
on top of a baseplate containing holders for the pumps, modules and cables (Figure 67). 
The heater and CO2 meter were attached to the sides of the lid and controlled externally 
by the settings box and laptop respectively.  
Although this setup allowed a simplistic layout of the pumps, modules and bottles, 
various issues arose leading to the use of an incubator for RPTEC culture instead. The 
CO2 concentration could not be controlled by the meter (CM-0045; CO2 meter, USA) as 
the flow rate from the gas cylinder was too high. When a flow meter was applied to the 
system, the flow rate was reduced and the CO2 percentage was controlled for a few 
hours at 5% before increasing to 12%.  Alongside the unstable CO2 concentrations within 
the box the application of heat and/or CO2 caused the suspected leaching of plasticisers 
from the PCT lid or polyvinyl chloride cable tidy which resulted in a ‘burning plastic’ 
smell being emitted overnight. As the effect of this phenomenon on the cells was 
unknown, the chamber was discarded. 
17.  Hydraulic permeability  
The hydraulic permeability for modules containing batch 2 fibres were ascertained once 
but could not be repeated due to fibre breakage (Table 22).  
Table 22: Transmembrane pressure, water flux and hydraulic permeability of modules 
incorporating batch 2 fibres  
Module Transmembrane pressure 
(mbar) 
Water flux (J) 
(m³/m²·s) 
Hydraulic permeability 
(L(p)) 
(109 Pa m3/m2·s) 
1 10.4 1.55 x 10-8 265.5 
2 14.2 2.05 x 10-8 143.8 
3 11 3.42 x 10-8 310.17 
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Figure 67: Image of the incubation chamber assembled initially for RPTEC culture in 
single hollow fibre bioreactors. A= Syringe pumps, B= Module holder, C= Heater and 
control unit), D= CO2 controller, E= CO2 Flow meter. The module is shown in position 
with the ECS (red) and lumen (green) loops highlighted 
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18.  Surface topography of hollow fibres  
AFM was performed on the interior and exterior of the hollow fibres using contact mode 
on a 20µm x 20µm area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: AFM images of the Lumen (top rows) and Exterior (bottom rows) of batch 1, 2 
and 3 fibres 
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19.  Module sterilisation 
Medium incubated in modules sterilised by autoclaving after assembly showed no clear 
signs of infection after 2 days. However, medium incubated in modules sterilised by 70% 
IMS showed typical signs of infection in the lumen and ECS after 2 days.   
 
 
 
 
 
 
 
 
 
 
 
Figure 69: Images of medium from modules sterilised with 70% IMS (lumen (c), ECS (d)) 
and autoclaving (lumen (e), ECS (f)) with negative (a) and positive (b) infection controls
(a) (b)
(c) (d)
(e) (f)
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20.  Cell performance in hollow fibre bioreactors  
One module incorporating batch 2 fibres was intact when seeded with cells. The 
resultant Presto Blue (indicating metabolic activity) and nutrient metabolite data 
indicate a growth and proliferation of cells within the device during culture. The data 
also indicates that a longer culture period may be required to generate a confluent 
monolayer of cells within the fibre.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70: The (a) Presto Blue fluorescence and (b) glucose (c) lactate and (d) 
ammonium concentrations of RPTECs during 8 days of culture under flow conditions 
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